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Abstract 
 
Duchenne Muscular Dystrophy (DMD) is an X-linked disorder, caused by mutations 
in the DMD gene. This gene encodes dystrophin, a structural protein that links the 
sarcomere to the extracellular matrix via a trans-membrane protein complex. In the 
absence of dystrophin the associated glycoprotein complex fails to assemble, leading 
to sarcolemmal instability, impaired ion handling, skeletal muscle wasting and 
fibrosis. Patients become non-ambulant in their teens and seldom live past their third 
decade. Cardiac failure is one of the leading causes of death. The heart initially 
compensates for reduced functional capacity by becoming hypertrophic, but 
eventually becomes fibrotic and develops dilated cardiomyopathy.  
 
Several proposed therapies have now reached clinical trial phase, but there is still no 
cure available for all DMD patients. Some of these therapies target skeletal muscle 
better than the heart. Sample availability restricts research into cardiac mechanisms 
of disease and testing treatments. This thesis presents a model that can potentially 
be used as an in vitro outcome measure for testing DMD therapies. Cardiomyocytes 
isolated from hearts collected from the DMD mouse model (mdx) embryos became 
larger than control mouse embryo-derived cardiomyocytes in response to serum 
starvation in culture. Control and mdx cardiomyocytes were collected at five time-
points of serum starvation and RNA-Seq was performed on the samples to identify 
pathways responsible for this hypertrophic response observed in dystrophic cells. 
 
Several pharmacological compounds as well as a proposed gene therapy method 
were trialled for their ability to reduce the hypertrophic response. Serum starved 
cardiomyocytes from mdx mouse embryos were transduced with adeno-associated 
viruses containing a gene construct expressing a functional internally truncated 
version of dystrophin. The viral rescue therapy and some pharmacological 
compounds significantly reduced the dystrophic hypertrophy caused by serum 
starvation. This model of mdx cardiomyocyte hypertrophy could therefore be used for 
testing therapies in pre-clinical trials. 
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Chapter 1. Introduction 
 
1.1 Mesoderm to Muscle 
Embryogenesis is a remarkable progressive event that entails cell division from 
fertilisation resulting in the formation of three germ layers – ectoderm, endoderm and 
mesoderm – and subsequent development of a foetus. The three germ layers each 
give rise to specific parts of the human body. Skeletal, cardiac and smooth muscle 
are all derived from mesoderm in a progressive manner depending on spatial 
orientation and signalling cascades (Yin et al., 2013; Xin et al., 2013). 
 
1.1.1 Heart Development 
The heart is an essential organ that pumps blood to other tissues in the body and it is 
the first organ to form in vertebrates (Buckingham et al., 2005). Fate-mapping 
analyses in various models such as zebrafish, frogs, chick embryos and mice have 
helped to establish cardiac development. Two distinct mesoderm-derived progenitor 
cell populations form different parts of the heart. The first (or primary) heart field 
(FHF) contributes mostly towards atrial and left ventricular development (Evans et al., 
2010), whilst the second (or secondary) heart field (SHF) forms most of the right 
ventricle and outflow tract, along with the conduction system (Van Vliet et al., 2012). 
The pharyngeal mesoderm, which is the origin of the SHF, also forms head muscles 
(Tzahor & Evans, 2011). At 6.5 days post coitum (E6.5) in mouse embryo 
development cardiac progenitors become a distinct population (Lyons, 1996). The 
cardiac crescent of heart fields forms a contractile heart tube by E8.0, which then 
loops at E8.5 and forms cardiac chambers by E10.5 (Watanabe & Buckingham, 
2010). Septation and valve formation by the E15 stage marks the completion of heart 
development in mouse embryos (Xin et al., 2013). 
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Sonic hedgehog (SHH), retinoic acid (RA) and Wnt/β-catenin signalling are essential 
for initially maintaining the proliferative and undifferentiated state of cardiac 
progenitor cells (Evans et al., 2010). However, SHH and the non-canonical Wnt 
signalling pathway later also drive differentiation in the SHF (Rochais et al., 2009). 
The earliest currently known pre-cardiac progenitor marker is the mesoderm 
posterior 1 homolog Mesp1 (Van Vliet et al., 2012). It is expressed at different times 
in mouse FHF and SHF, with an overlap at E6.75, but not all Mesp1 positive cells 
express the same downstream genes and may therefore require other signalling 
molecules to determine their fate (Lescroart et al., 2014). Mesp1 drives the Islet1 
gene Isl1 expression, which marks proliferating undifferentiated cardiac progenitors 
(Evans et al., 2010) and together with bone morphogenic protein (BMP) induces 
pharyngeal mesoderm commitment to the SHF (Tzahor & Evans, 2011).  
 
GATA4 and Nkx2.5 are central cardiac commitment markers expressed in both heart 
fields (Van Vliet et al., 2012; Xin et al., 2013) and along with BMP and serum 
response factor (SRF) regulate gene expression initialising cardiac beating (Evans et 
al., 2010). Isl1 downregulation and induction of Tbx5 expression are only associated 
with the FHF cells (Sirbu et al., 2008), marking left ventricular determination as well 
as contributing cells towards atrial myocyte formation (Buckingham et al., 2005; Van 
Vliet et al., 2012). RA is upstream of Tbx5 (Sirbu et al., 2008), which together with 
GATA4, Nkx2.5 and Tbx20 (expressed in the right ventricle) regulates the separation 
of the two ventricles by inducing growth of the septum (Takeuchi et al., 2003). Tbx1 
expression in the SHF commits cells to outflow tract development, leading to the 
formation of both the aorta and pulmonary artery (Buckingham et al., 2005); Rochais 
et al., 2009). Some neural crest cells infiltrate the forming heart and contribute to the 
development of the aorta and other big vessels connecting the heart with the rest of 
the vascular system (Watanabe & Buckingham, 2010; Fishman & Chien, 1997). 
Heart field contributions to the developing heart are summarised in figure 1.1. 
  
 3 
 
Figure 1.1. Developmental origin of cells giving rise to heart structure. The 
mammalian heart is a four chamber organ formed from two mesodermal progenitor 
cell populations called the first and second heart field (FHF and SHF). The SHF 
forms the right ventricle, the outflow tract and contributes towards atrial development. 
The FHF forms the left ventricle and also contributes towards atrial development. 
This image was adapted from Xin et al. (2013). 
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1.1.2 Skeletal Muscle Development 
Skeletal muscle development, except in the head (Tzahor & Evans, 2011), is 
dependent on signals that are passed from the neural tube and notochord to paraxial 
mesoderm condensations called somites (figure 1.2 A). These signals trigger the 
ventromedial and dorsal parts of somites to differentiate into the sclerotome and 
dermomyotome, respectively (figure 1.2 B). The dermomyotome bows ventrally at 
both epaxial and hypaxial ends to form the myotome (figure 1.2 C). At sites of limb 
buds hypaxial dermomyotome cells migrate and populate the forming limbs with 
myogenic precursor cells (MPC) (figure 1.2 D) (Bailey et al., 2001). 
 
 
Figure 1.2. Skeletal muscle formation in chick embryos. (A) Epithelial somites are 
formed from the pre-somitic mesoderm. (B) These somites differentiate into the 
dermomyotome and sclerotome. Signal molecules from the neural tube and 
notochord induce myotome differentiation at the dorsomedial lip. (C) Epaxial and 
hypaxial myotome formation at both ends of the dermomyotome. (D) Migration of 
myogenic precursor cells (MPC) to the forelimb bud. This image was adapted from 
Bailey et al. (2001). 
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The neural tube and notochord launch an important cross-talk system that influences 
somite differentiation. SHH from the notochord induces sclerotome formation (Fan et 
al., 1995) whilst Wnt signalling from the neural tube and surface ectoderm initiate 
dermomyotome formation. Combined SHH and Wnt signalling promotes 
dermomyotomal expression of paired box protein Pax3, which is a potent myogenic 
transcription factor acting upstream of myogenic regulatory factor (MRF) genes 
(Maroto et al., 1997). Pax3-positive cells act as pioneers of myotome formation 
establishing the ventral migration at both epaxial and hypaxial ends of the 
dermomyotome (Goulding et al., 1994). 
 
Cells in the myotome exhibit rapid onset of MRF gene expression and subsequent 
myogenesis through four basic helix-loop-helix MRFs: Myf5, Mrf4, MyoD and 
myogenin (Bismuth & Relaix, 2010). Although signalling factor expression hierarchy 
varies in tissues during development and regeneration, most frequently myogenin is 
the terminal MRF to be expressed and can be used as a marker for cells that have 
committed to myotube formation (Parker et al., 2003). Myomaker is a recently 
discovered membrane protein expressed in myoblasts during fusion with myotubes 
and subsequently downregulated, which means that it is one of the final markers of 
myoblast commitment to fusion (Millay et al., 2013). 
 
BMP-4 secretion from the lateral plate mesoderm inhibits myogenesis. Concomitant 
SHH and Wnt signalling activates BMP4 antagonist noggin, which explains why 
hypaxial dermomyotome exhibits delayed myotome formation in comparison to the 
epaxial end (Reshef et al., 1998). However, this delay is a pivotal mechanism in 
myogenesis as it ensures the survival of a small population of Pax3+ MPCs that 
migrate out of the dermomyotome and into forming limb buds eventually giving rise to 
Pax7+ adult skeletal muscle-specific stem cells (Amthor et al., 1998; Gros et al., 
2005) widely known as satellite cells (Mauro, 1961). BMP signalling’s continuing 
significant role in satellite cell population maintenance and differentiation during 
muscle regeneration cycles has also recently been shown (Ono et al., 2011). An 
overview of signalling pathways in myogenesis is depicted in figure 1.3. 
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Figure 1.3. The myogenic lineage signalling pathway. SHH and Wnt crosstalk 
induces Pax3 and noggin synthesis. Pax3 regulates myogenesis through myogenic 
regulator factor (MRF) cross-talk signalling, which is inhibited by bone morphogenic 
protein 4 (BMP4). Noggin, in turn, inhibits BMP4 and therefore indirectly facilitates 
myogenic differentiation. Pax7 – expressed downstream and in parallel with Pax3 – 
maintains the satellite cell population. MyoD marks commitment to myogenesis and 
its expression in satellite cells induces differentiation. Myogenin is the furthest down 
the myogenic pathway out of MRFs and is considered a marker of complete myoblast 
commitment to differentiation and fusion into myotubes. 
 
1.1.3 Satellite Cells and Muscle Regeneration 
In their quiescent state satellite cells are located between the basal lamina and the 
sarcolemma of muscle fibres. They have been characterised as Pax7+ M-cadherin+ 
CD34+, yet MyoD- cells (Zammit et al., 2006). Pax7 expression restricts satellite cells 
from differentiating down the haematopoietic lineage (Seale et al., 2000) and despite 
some success in generating skeletal muscle from the haematopoietic lineage (Corbel 
et al., 2003; Camargo et al., 2003) it has been shown that even whilst CD45+ cells 
are inherent to skeletal muscle, they do not significantly contribute to the satellite cell 
pool, which is directly descended from the central dermomyotome (Sherwood et al., 
2004; Gros et al., 2005). 
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Satellite cells can become activated by weight or shear forces due to trauma or 
exercise. These forces causes nitric oxide (NO) release from the neuronal form of 
NO synthase (nNOS), associated with the focal adhesion dystrophin glycoprotein 
complex (DGC) in muscle fibres (Garbincius & Michele, 2015). The DGC links 
sarcoplasmic F-actin with the extracellular matrix essentially working as a structural 
damage inhibitor increasing sarcolemmal stability (Rando, 2001). During normal 
muscle contraction and relaxation cycles NO fluctuations do not affect satellite cells 
(Wozniak & Anderson, 2007). When fibres are damaged in response to physical 
exercise, or when sarcolemmal stability is compromised, nNOS causes a sharp rise 
in NO levels (Baldelli et al., 2014). An increase in NO also causes satellite cell 
activation through hepatocyte growth factor (HGF) release and its subsequent 
binding to c-Met receptor, which is an early satellite cell activation gene (Le Grand & 
Rudnicki, 2007). Concomitantly the mitogen activated protein kinase (MAPK) 
signalling pathway is activated by microenvironment-secreted FGFs and sphingosin-
1-phosphate (Nagata et al., 2006). All of these events orchestrate an exodus of 
satellite cells from their niche through delamination and cause rapid cell division to 
repair the damaged muscle fibres. 
 
Myf5 signalling plays a pivotal role in muscle differentiation. It is controlled upstream 
by the Pax3/7 pathway and acts on par and upstream – depending on tissue – with 
MyoD (Dumont et al., 2015). As previously described the interaction of MRFs Myf5, 
MyoD and Mrf4 expression in muscle precursor cells represents commitment to 
differentiation and is gradually superseded by myogenin expression, which marks 
terminal differentiation. Subsequently various muscle specific genes are expressed in 
myotubes and myofibres, such as desmin and the DGC constituents marking the end 
of the muscle regeneration cycle (Zammit et al., 2006). 
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1.2 Duchenne Muscular Dystrophy 
Mutations in the genes encoding DGC constituents causing negligible or non-
functional protein expression can destabilise the protein complex and as a result 
compromise sarcolemmal integrity as well as signalling pathways (Sandonà & Betto, 
2009). Consequently, these mutations often cause various forms of muscular 
dystrophies. Duchenne Muscular Dystrophy (DMD) is a recessive X-linked genetic 
disorder. It was first described by Guillaume Duchenne in 1861 and is caused by the 
more than 7,000 determined mutations (Bladen et al., 2015) in the DMD gene 
expressing dystrophin. The extraordinarily large number of mutations recorded can 
be attributed to the length of the DMD gene. These 2.4Mb located at locus Xp21 and 
comprising 79 exons give rise to several isoforms of dystrophin, some of which are 
ubiquitously expressed, some are tissue specific, particularly in skeletal muscle 
(Ferlini et al., 2013). Full-length dystrophin, essential for both skeletal and cardiac 
muscle function, is a 427kDa protein, translated from 14kb mRNA (Scott et al., 2002). 
The incidence of DMD is from around 1/3,600 to 1/6,000 male births (Bushby et al., 
2010a). 
 
Several animal models are available for DMD research and have considerably 
helped to understand pathological mechanisms of the disease and test potential 
therapies. The C57BL/10ScSn-Dmdmdx (mdx) mouse model (Bulfield et al., 1984) and 
the golden retriever muscular dystrophy dog (GRMD) model (Cooper et al., 1988) are 
most widely used, but there are also other model organisms available, such as the 
sapje fish (Bassett & Currie, 2004) and the dystrophic pig (Klymiuk et al., 2013). 
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1.2.1 The Dystrophin-associated Glycoprotein Complex 
Dystrophin protects the sarcolemma of muscle fibres from shear force damage, 
acting in the DGC as a ‘spring’ that links fibre actin cytoskeleton with the extracellular 
matrix and basal lamina (Petrof et al., 1993). Calponin homology domains at 
dystrophin’s N-terminal region interact with sarcomeric F-actin (Stone et al., 2005; 
Cohn, 2005). The middle part dystrophin, also called the rod domain, consists of 
spectrin-like repeats (Duan, 2011). The WW and EF hand domains at the C-terminal 
region accommodate interactions with β-dystroglycan (Chung & Campanelli, 1999). 
The latter is located on the sarcolemma and is linked to the extracellular matrix via 
laminins bound to heavily glycosylated α-dystroglycan (figure 1.4) (Cohn et al., 
2002). 
 
DGC formation is hampered by loss of function or absence of dystrophin and the 
underlying causative mutations have varying effects on expression of dystrophin 
(Birnkrant et al., 2010). DMD patients are diagnosed around the age of five when it 
becomes apparent that their physical abilities are lagging behind compared to their 
peers (Bushby et al., 2010a). Lacking DGC protection, the sarcolemma becomes 
fragile and lipid bilayer lesions visible with electron microscopy (Mokri & Engel, 1975) 
occur, triggering three key proposed pathological pathways, which are also 
hypothesised to interact with each other. 
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Figure 1.4. The dystrophin-associated glycoprotein complex. Dystrophin acts as a 
shock absorber by linking the muscle sarcomere to the extracellular matrix. It is 
bound to sarcomeric F-actin at its N-terminus (NH2) and transmembrane protein β-
dystroglycan at a cysteine-rich domain (Cys) close to its C-terminus (COOH), where 
dystrophin is associated with nNOS. β-dystroglycan is bound to the sarcoglycan 
complex as well as α-dystroglycan on the extracellular side of the sarcolemma. 
Heavy glycosylation of α-dystroglycan is required for laminin binding and association 
with extracellular matrix proteins. In Duchenne muscular dystrophy absence of 
dystrophin also causes mislocalisation of nNOS, sarco- and dystroglycans, leading to 
sarcolemmal fragility. This image has been adapted from Cohn (2005).  
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1.2.2 Skeletal Muscle Pathology 
The first of these pathological pathways is release of signals for satellite cell 
activation. Consequently, the inherent satellite stem cell population proliferates and 
some daughter cells committed to differentiation down the myogenic lineage fuse 
with damaged fibres to repair the sarcolemma (Wang et al., 2014). Other 
differentiating cells can fuse with one another to form and extend de novo myotubes. 
Despite initial success with repairing injured tissue this regeneration cycle is thought 
to be overpowered as the satellite cell population becomes depleted over time due to 
the magnitude of damage (Wallace & Mcnally, 2009). 
 
The second proposed pathway is caused by the rapid rise of sarcoplasmic Ca2+ via 
damage-induced sarcolemmal lesions (Bodensteiner & Engel, 1978) and stretch-
activated channels (Iwata et al., 2003). This triggers an intrinsic dysferlin-mediated 
membrane repair mechanism to be activated, attracting cytoplasmic vesicles and 
transporting them to the sarcolemma (Chiu et al., 2009). However, Ca2+ influx also 
affects mitochondrial function (Vandebrouck et al., 2006), increases reactive oxygen 
species (ROS) production (Whitehead et al., 2006) and activates calcium-dependent 
proteolytic enzymes, which over time cause much more damage to muscle fibres 
(Alderton & Steinhardt, 2000). Lesions in the sarcolemma also cause leaking of 
various proteins, such as creatine kinase (CK). Highly elevated CK in blood serum is 
used as a diagnostic test for several muscle diseases (Ozawa et al., 1999). 
 
The third pathological theory is mediated by free radicals. As previously mentioned, 
NO is imperative for satellite cell recruitment to sites of injury (Yin et al., 2013). With 
impaired DGC formation nNOS is also displaced from the sarcolemma (Kobayashi et 
al., 2008). As a result, NO levels are lower, hindering the process of mopping up free 
radicals that damage muscle fibres and attract inflammatory cells (Messina et al., 
2006) (Whitehead et al., 2006). Additionally, nNOS competes for arginine with 
arginase, which produces pro-fibrotic agents in type M2a macrophages (Wehling-
Henricks et al., 2010). Co-culture of myoblasts and macrophages has shown a delay 
in myoblast differentiation (Merly et al., 1999). Hence, reduced nNOS function can 
also hasten replacement of necrotic fibres with fatty tissue. 
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1.2.3 Cardiac Pathology 
Cardiac failure is one of the primary causes of death in DMD (Romfh & Mcnally, 
2010). Lack of dystrophin destabilises the highly specialised environment of muscle 
fibres, resulting in a range of associated proteins being mislocalised from their niche, 
ultimately compromising signalling pathways as well as structural integrity (Townsend 
et al., 2011). DMD patients mostly develop rapidly progressing dilated cardiac 
myopathy (Williams & Allen, 2007). 
 
Pathology in dystrophic hearts is caused by a disruption in the various signalling 
pathways, illustrated in figure 1.5. Mechanical stress in cardiomyocytes – 
exacerbated by lack of dystrophin – leads to various stimuli capable of instigating 
hypertrophy, such as angiotensin (Ang) release from internal stores (Zou et al., 
2002). Depending on the direction of sarcomere addition as a response to 
hypertrophic signals cardiomyocytes can either undergo concentric (increased width) 
or eccentric (increased length) hypertrophy (Frey et al., 2004; Maillet et al., 2013). 
Cardiac hypertrophy is not necessarily detrimental per se, as in the case of exercise-
induced temporary hypertrophy (Barry et al., 2008), but prolonged exposure to 
permissive stimuli and an underlying compromised signalling environment in 
dystrophic cardiac tissue provoke pathological consequences (Taigen et al., 2000). 
 
Angiotensin-converting enzyme (ACE) generates AngII as a response to mechanical 
stress and its effect is mediated by AngII receptor type 1 (AT1R), activating MAPK 
pathways (Schlüter & Wenzel, 2008). MAPKs are capable of increasing protein 
synthesis (Zou et al., 2002), as well as increasing intracellular reactive oxygen 
species (ROS) levels – causing a nuclear factor kappa B (NFκB) mediated 
hypertrophic response – and triggering apoptosis via c-Jun N-terminal kinase (JNK) 
(Schlüter & Wenzel, 2008). An alternative pathway for MAPK-induced hypertrophy is 
mediated by integrins (ITG) as a result of mechanical stretch (Zou et al., 2002) 
(Kuppuswamy et al., 1997). Both ITG and AngII activation of MAPKs cause cardiac 
hypertrophy directly via interaction with myocyte enhancer factor 2 (MEF2) and 
indirectly by the ROS-NFκB stimulating effect on stretch-activated Ca2+ channels on 
the cell membrane and by reducing calcineurin autoinhibition, leading to the 
potentiation of MAPK effect on MEF2 (Schlüter & Wenzel, 2008; Gaspar-Pereira et 
al., 2012).   
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Lack of dystrophin also causes nNOS mislocalisation in cardiac tissue (Garbincius & 
Michele, 2015), which leads to lower NO levels and compromises ROS clearance 
(Booz, 2005). NO activates soluble guanylyl cyclase (GC) receptors, which produce 
cyclic guanosine monophosphate (cGMP) (Zois et al., 2014). cGMP sequentially 
regulates hypertrophy by improving the function of cGMP-dependent protein kinase 
G (PKG), which in turn inhibits voltage-gated L-type calcium channels (CaV1) (Barry 
et al., 2008). PKG also inhibits Na+/H+ exchanger 1 (NHE) function (Frey et al., 
2004), consequently aiding Na+/Ca2+ exchanger (NCX) function (Bkaily et al., 2015).  
 
Ultimately both of these actions of cGMP lower intracellular Ca2+ concentration 
([Ca2+]i). Reduced NO therefore leads to an increase in Ca2+, which feeds back to 
increased hypertrophy as a result of augmented calcineurin activity and subsequent 
nuclear factor of activated T-cells (NFAT) mediated gene activation (Enwere et al., 
2014; Liu et al., 2012). On the other hand, β-adrenergic receptor (βAR) activation can 
lead to calcineurin-dependent apoptotic commitment by dephosphorylation of the Bcl-
2 associated death promoter (BAD) (Wang et al., 1999; Saito et al., 2000). For this 
reason, despite the option of inhibiting calcineurin’s pro-hypertrophic activity with 
Cyclosporine A, it is important to maintain some NFAT and calcineurin activity to 
permit apoptosis of cardiomyocytes (Zou et al., 2002; Frey et al., 2004). 
 
Intracellular Ca2+ activates ryanodine receptors (RyR) on the sarcoplasmic reticulum 
(SR) causing a positive feedback loop, releasing more Ca2+ from SR stores, 
consequently exacerbating the pathological environment, especially in mdx mice, 
where expression of RyRs is upregulated (Williams & Allen, 2007; Yamaguchi et al., 
2011). Intracellular Ca2+ additionally activates calmodulin-dependent kinases 
(CaMK), leading to MEF2 induced cardiac hypertrophy (Frey et al., 2004; Konno et 
al., 2010), mentioned before. CaMK may have this effect by modulating the MEF2 
activation domain resulting in the potentiation of its activation by MAPK (Lu et al., 
2000). Cardiac SR luminal Ca2+-ATPase (SERCA) is one of the major proteins 
responsible for mopping up intracellular Ca2+, storing it in the SR. SERCA is inhibited 
by dephosphorylated phospholamban (PLN) (Haghighi et al., 2014). β-AR activation 
leads to PLN phosphorylation and a consequent increase in SERCA activity 
(MacLennan & Kranias, 2003). However, blocking β-ARs and the concomitant PLN 
inhibition is counteracted by increased SERCA expression (Barry et al., 2008). 
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A pathway attenuating hypertrophic response in cardiomyocytes is GATA4-mediated 
expression and release of atrial and brain natriuretic peptides (ANP and BNP), which 
form a negative feedback loop for various cellular signals (Gardner et al., 2007). 
Natriuretic peptides are activated by furin cleavage (Ichiki et al., 2013) and their 
response is mediated by natriuretic peptide receptors (NPR). NPRA and NPRB are 
GCs, generating anti-hypertrophic cGMP and also inhibiting the MAPK pathway (Zois 
et al., 2014; Schlüter & Wenzel, 2008). 
 
Corticosteroids are prescribed to DMD patients in order to combat their muscle 
phenotype (Bushby et al., 2009). Glucocorticoid receptors (GCR) reside in the 
cytoplasm in their inactivated state, but once bound by corticosteroids they 
translocate to the nucleus where they inhibit NFκB function (Rao et al., 2011). 
Consequently, corticosteroids have an anti-hypertrophic as well as an anti-apoptotic 
effect on cardiomyocytes (Ren et al., 2012). A signalling system regulated by the 
tumour necrosis factor-like weak inducer of apoptosis (TWEAK) and its receptor 
Fn14 has been discovered to be playing a role in skeletal muscle wasting (Bhatnagar 
& Kumar, 2012), and cardiac hypertrophy (Ren & Sui, 2012).  This TWEAK-Fn14 
signalling system is capable of activating NFκB signalling (Enwere et al., 2014) and 
therefore could also be inhibited by steroids.  
 
P2X purinoreceptor 7 (P2RX7) is upregulated in mdx mouse myoblasts (Young et al., 
2012). As a response to extracellular adenosine triphosphate (ATP), P2X7Rs open a 
pore permeable to Ca2+ and consequently cause a rise in [Ca2+]i (Sinadinos et al., 
2015), which plays a big role in disease progression. Although purinergic receptors 
are primarily associated with an augmented immunological response in DMD (Jiang 
et al., 2005; Young et al., 2015), it has also been shown that P2RX7 is expressed in 
caveolin-1 deficient mouse atrial cardiomyocytes (Barth et al., 2010). Considering the 
drastic P2RX7 upregulation observed in mdx myoblasts it may also be the case for 
cardiomyocytes. Involvement of this pathway in DMD cardiac tissue pathology needs 
to be elucidated. 
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A group of markers for pathological cardiac hypertrophy have been identified and 
named the foetal gene program (FGP) (Taegtmeyer et al., 2010). In addition to the 
aforementioned onset of ANP and BNP expression, a switch in the adult heart 
myosin heavy chain (MHC) composition, whereby MHCα expression is gradually 
replaced by MHCβ expression, is characteristic for FGP activation (Rajabi et al., 
2007). Similarly a shift from cardiac α-actin expression to skeletal α-actin preference 
in cardiomyocytes is also an indicator of FGP initiation (Rajabi et al., 2007; 
Taegtmeyer et al., 2010). All of these are markers of hypertrophy that deserve to be 
investigated for potential effector treatment targets. 
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Figure 1.5. Pathological pathways in mdx cardiomyocytes. Mechanical stretch 
causes activation of signalling cascades leading to activation of several cross-talking 
pathways. Purinergic receptors (P2RX7) and voltage-gated (CaV1) channels cause 
Ca2+ influx to the sarcoplasm. β-adrenergic receptors (βAR) can inhibit 
phospholamban (PLN) inactivation of sarcoplasmic reticulum luminal Ca2+ ATPase 
(SERCA), which together with ryanodine receptors (RyR) regulates sarcoplasmic 
reticulum (SR) Ca2+ storage. Elevated intracellular Ca2+ leads to calmodulin-
dependent kinase (CaMK) and calcineurin activation, both leading to a hypertrophic 
response via myocyte enhancer factor 2 (MEF2) and nuclear factor of activated T-
cells (NFAT) activation, respectively. Calcineurin can cause the onset of apoptosis 
via the Bcl2-associated death promoter (BAD). Integrin (ITG) and angiotensin type 1 
receptor (AT1R) activation can trigger mitogen activated protein kinase (MAPK) 
signalling, which in turn leads to cardiac hypertrophy via MEF2 and apoptosis via c-
Jun N-terminal kinase (JNK) activation. Both the MAPK pathway and CaV1 can be 
inhibited by natriuretic peptide receptors (NPR) A and B. Neuronal nitric oxide 
synthase (nNOS) can also mediate the same CaV1 inactivation pathway through 
nitric oxide (NO) activated cyclic guanosine monophosphate (cGMP) production and 
subsequent protein kinase G (PKG) activation, which in turn inhibits CaV1 function. 
NO also aids reactive oxygen species (ROS) clearance. The latter is responsible for 
triggering nuclear factor kappa B (NFκB) mediated cardiac hypertrophy. 
Corticosteroid treatment can activate glucocorticoid receptors (GCR) that translocate 
to the nucleus and inhibit NFκB signalling. Phosphodiesterase 5 (PDE5) breaks 
down cGMP and is therefore also a therapeutic target in DMD. 
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1.3 Clinical Aspects and Management of DMD 
Expanding fibrotic infiltration in Duchenne patients causes progressive muscle 
weakness and wasting primarily in large muscles of the upper and lower limbs 
leading to loss of ambulation by early teens (Yiu & Kornberg, 2015). Lack of 
dystrophin also affects cardiac tissue with large-scale fibrosis leading to ventricular 
hypertrophy to compensate loss of function. Subsequent wall thinning, however, 
results in dilated cardiomyopathy (Romfh & Mcnally, 2010). Deterioration of 
intercostal muscles and the diaphragm often forces patients to require nocturnal 
ventilation to compensate reduced lung function. Respiratory and cardiac failure are 
the primary causes of mortality in the patient cohort (Wehling-Henricks et al., 2010). 
Extensive aplasia also involves paraspinal muscles, affecting posture, resulting in the 
development of scoliosis, especially once patients are wheelchair-bound. Surgical 
correction of the spine needs to be performed before pulmonary and cardiac function 
is compromised and carefully performed by experienced specialists due to an 
increased anaesthetic risk (Alman et al., 2004). As an anomaly some laryngeal and 
extra-ocular muscles are spared in DMD (Sussman, 2002; Smythe, 2009). These 
sparing phenomena are under strong scientific scrutiny as they could elucidate 
further intricacies of muscle regeneration as well as potential rescue therapies. 
Interestingly laryngeal and extra-ocular muscles are not derived from the 
dermomyotome, but from the pharyngeal mesoderm instead, which is the same 
source as the FHF (Tzahor & Evans, 2011). 
 
One potential explanation for their sparing could be that extra-ocular as well as 
specific laryngeal muscles are mostly composed of slow-twitch fibres, which are less 
severely damaged by routine contractions (Smythe, 2009). Furthermore, it has been 
shown that fast-twitch fibres can be rescued to some extent in mdx mice using β-
adrenergic agonists (Gehrig et al., 2010). This suggests there may also be a 
therapeutic effect in humans, but so far on the contrary β-blockers have been 
identified to have more effect on alleviating cardiac symptoms in DMD patients 
(Jefferies et al., 2005). Corticosteroids are the only currently available treatment 
prescribed for decelerating disease progression (Strober, 2006). There are several 
side-effects associated with steroid treatment including weight gain, coupled with 
height restriction, delayed puberty and reduced bone mineral content. Recent 
meetings of specialists have, however, concluded that despite the side-effects the 
overall benefits in terms of prolonging ambulation, improving skeletal and pulmonary 
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muscle function as well as delaying scoliosis significantly outweigh the 
disadvantages, which can be tackled with further alternative medication (Bianchi et 
al., 2011).  
 
Dietary supplements for increasing muscle strength - creatine monohydrate 
(Tarnopolsky & Martin, 1999) - and reduction of fibre necrosis via upregulation of 
nNOS with L-arginine (Voisin et al., 2005), combined with reduced fat and sugar 
uptake have also been investigated as potential options to improve muscle function 
and control steroid-associated risks. In fact, L-arginine transporter function and 
expression were found to be considerably elevated in dystrophic mouse hearts, 
providing L-arginine as an alternative to reduced NO levels for GC activation and 
cardioprotection (Ramachandran et al., 2012). Furthermore, phosphodiesterase type 
5 (PDE5) breaks down cGMP, dampening its signalling potential and the downstream 
cardioprotective effect (Kobayashi et al., 2008). Sildenafil, an inhibitor of PDE5 was 
therefore explored as a potential DMD therapeutic in a clinical trial, but unfortunately 
did not show cardiac improvement and the trial was terminated before completion 
(Leung et al., 2014). 
 
It has been suggested that a small decrease in muscle strength can cause a much 
greater reduction in function (Beenakker et al., 2005). Therefore, even a modest 
delay in disease progression can significantly benefit the patient’s quality of life. 
Patient care and standardisation of disease management have recently been 
targeted as important factors for improving patient well-being as well as a starting 
point for recruiting patients in clinical trials for novel rescue therapies (Bushby et al., 
2009; Mayhew et al., 2011). 
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1.4 Proposed Therapies for DMD 
Several rescue therapies for DMD are currently in clinical trials, but some target 
skeletal muscle more efficiently than cardiac tissue (Betts et al., 2015). Recovery in 
skeletal muscle may escalate the cardiac phenotype as a result of increased activity 
in patients and therefore it is essential to target cardiac muscle in therapeutic 
approaches (Duan, 2006). 
 
Due to the large number of varying mutations in the DMD gene patients with 
mutations in dystrophin exhibit a spectrum of disease severity. Some mutations – 
such as in-frame deletions – in the DMD gene cause a milder phenotype, termed 
Becker Muscular Dystrophy (BMD). These patients mostly become symptomatic in 
adulthood and general progression of the disease is significantly slower as a result of 
partial salvation of dystrophin function (Bushby et al., 1991). Some of these patients 
with large open reading frame deletions only present with mild symptoms in late 
adulthood (Ferreiro et al., 2009). These cases have inspired the rationale behind 
some rescue therapies for DMD. 
 
1.4.1 Gene Delivery Therapy 
One option to alleviate symptoms in DMD patients is to use Becker patient genetic 
data for developing smaller forms of the DMD gene expressing functional variants of 
the dystrophin protein. Several groups have created mini- and micro-Dystrophin 
(often referred to as mDys and µDys) constructs (figure 1.6) to restore functional 
dystrophin expression in affected tissues (Moisset et al., 1998; Fabb et al., 2002). 
However, screening these variants for efficacy has been a time-consuming process 
that often requires costly in vivo testing in animal models as well as specialist 
knowledge and licenses for viral production and transduction (Wang et al., 2007). 
Time- and cost-efficient in vitro methods have been developed for faster screening of 
dystrophin variants through means of CK release measurements as a result of 
exposing cells to hypo-osmotic stress (Jørgensen et al., 2009). Although beneficial 
for determining efficacy in dystrophic mouse myoblasts, this method does not 
elucidate any systemic response complications that may arise (Wang et al., 2007), 
nor has it been tested in cardiomyocytes. 
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Figure 1.6. Engineering dystrophin constructs for gene therapy. Viral vectors have a 
restricted packaging capacity and most prospective therapeutic vectors cannot fit the 
full-length dystrophin gene. For this purpose, based on Becker muscular dystrophy 
patient mutations, smaller mini- and micro-dystrophin constructs have been 
developed to allow packaging and delivery with viral vectors. This image was 
adapted from Fabb et al. (2002), the depicted µDys construct is reported in 
Jørgensen et al. (2009).  
 
Differentiation of fibroblasts into myogenic cells for diagnostic and in vitro 
experimental purposes has successfully been achieved by adenoviral transduction of 
MyoD (Roest et al., 1996). This method has also been proposed as an ex vivo 
therapeutic approach to compensate the diminishing satellite cell population in DMD 
(Lattanzi et al., 1998). Whilst using adenoviruses allows effective transduction of 
various genetic material it is not the safest approach, despite overriding the immune 
system by ex vivo transduction and screening for viral incorporation before 
transplantation. 
 
New generations of lentiviruses and adeno-associated viruses (AAV) may be a 
solution, but their capsid size restricts the genetic material they can fit. Using mini-
Dys and µDys constructs, developed on the basis of less pathogenic mutations in 
BMD patients, offers an invaluable tool for viral rescue therapies for DMD (Trollet et 
al., 2009; Falzarano et al., 2015). Out of these two viral vectors AAVs have been 
determined to be significantly safer, because they are not pathogenic in humans and 
result in markedly extended transgene expression (Zincarelli et al., 2008). 
Furthermore, AAV insertion sites are episomal over 99% of the time (Kay, 2011) and 
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show varying tissue tropism in different serotypes, which can be further modified by 
capsid mutagenesis (Yu et al., 2009; Michelfelder et al., 2011). 
 
AAVs have a single-stranded genome and can package around 4.7kb of genetic 
material when their own replication genes (rep and cap) have been removed. This 
free space is flanked by inverted terminal loops at either end of the DNA strand 
(Hastie & Samulski, 2015). The conversion of single-stranded genetic material is 
often the rate-determining step in AAV transduction and although self-complementary 
vectors have been produced, for the purposes of DMD treatment maximal space is 
required to reintroduce dystrophin in a most functional form as possible (Tang et al., 
2010). In addition to packaging capacity, another draw-back of AAVs is the lack of 
muscle-specific gene delivery. Expression of the DMD gene specifically in skeletal 
and cardiac muscle is essential as development of an immune response is higher 
when dystrophin is introduced elsewhere in the body (Hartigan-O'Connor et al., 
2001). Myosin heavy- and light chain promoters are currently most promising for 
delivery to both heart and skeletal muscle and avoiding non-specific delivery (Salva 
et al., 2007; Schinkel et al., 2012). 
 
Previous studies employing viral vectors have shown that even whilst a smaller 
construct of dystrophin driven by a muscle-specific promoter ameliorates the 
phenotype in fast-twitch fibres in mdx mice, it is ineffective in restoring diaphragm 
and cardiac tissue function (Dunant et al., 2003). It may be hypothesised that by 
restoring fast-twitch fibre function in humans, ambulation is also prolonged, hindering 
degeneration of the diaphragm through a reduced probability of developing scoliosis. 
However, this is nevertheless only a delay in phenotypic development. Augmented 
cardiac deterioration has been observed in mdx mice where only skeletal muscle 
function is therapeutically rescued (Townsend et al., 2008). This study correlates with 
pathology observed in defective dystrophin-induced X-linked dilated cardiomyopathy 
patients, where dystrophin is definitively only lost in the myocardium (Cohen, 2004). 
Hence, it is pivotal to reiterate that both skeletal and cardiac muscle must be targeted 
when developing therapies for DMD. Promising results have been reported with 
highly cardiac-specific transduction in δ-sarcoglycan knockout mice (Goehringer et 
al., 2009), which have a more prominent cardiac phenotype. Delivery of µDys with 
AAVs to mdx mouse heart, effective construct expression and functional restoration 
has also been published (Schinkel et al., 2012). These results are encouraging for 
 23 
being used in combination with other rescue therapies to successfully target both 
skeletal and cardiac muscle.  
 
AAVs exhibit varying tissue specificity, which can be augmented with capsid and 
promoter engineering (Nance & Duan, 2015). Hence, AAVs may be most suitable for 
gene therapy, potentially ensuring a balanced recovery in both skeletal and cardiac 
muscle (Duan, 2006). The recent approval from the European Medicines Agency for 
the use of an AAV-based therapy against lipoprotein lipase deficiency also improves 
the outlook for approval of other applications of AAVs in clinical trials (Ylä-Herttuala, 
2012). However, utilising AAV vectors for DMD treatment will need to overcome a 
reporting of an immune response towards the introduced construct in clinical trials 
(Mendell et al., 2012). 
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1.4.2 Antisense Oligonucleotides 
Another BMD-inspired method employs antisense oligonucleotides (AON) to 
artificially induce alternative splicing, removing out-of-frame exons and consequently 
restoring the dystrophin gene’s reading frame (figure 1.7) with the overall size of the 
protein being smaller compared to wild-type. AONs have been shown to be 
successful at restoring dystrophin expression, and most importantly restore 
localisation of the DGC constituents to the sarcolemma in mdx mice (Gebski et al., 
2003; Vitiello et al., 2008). There are ongoing multi-centre clinical trials with 
phosphorodiamidate morpholino oligomer (PMO) (Kinali et al., 2009; Cirak et al., 
2011) as well as Prosensa’s (now acquired by GlaxoSmithKlein) 2’-O-methyl 
phosphorothioate oligoribonucleotide (2OMePS), which are both designed to skip 
exon 51 in dystrophin mRNA to restore the reading frame and thus allow a shorter 
variant of the protein to be expressed (Goemans et al., 2011). Preliminary clinical 
data for the 2OMePS (Voit et al., 2014) and PMO (Mendell et al., 2013) compounds 
showed some improvement in DMD patients but require further and larger cohort 
studies. 
 
 
Figure 1.7 Exon skipping as a therapeutic option to restore dystrophin expression. In 
this illustrated example, a large deletion of the DMD gene exons 45-50 results in an 
acceptor codon (one nucleotide missing from a codon) both at the end of exon 44 
and the start of exon 51, leading to reading frame disruption. When exon 51 is 
skipped with antisense oligonucleotides then exon 52 donates an overhanging 
nucleotide to the acceptor codon at the end of exon 44 and the reading frame is 
restored. This leads to internally truncated, but functional, dystrophin expression. The 
image is adapted from Aartsma-Rus & van Ommen (2009). 
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Unfortunately, exon 51 skipping by these compounds can only restore dystrophin 
expression in roughly 13% of DMD patients (Aartsma-Rus & van Ommen, 2009) and 
this is the biggest group of patients that could be treated with one compound. 
Overall, exon skipping may eventually help up to 83% of all DMD patients, requiring 
development of several compounds specific for mutations that only a small number of 
patients have (Bushby et al., 2009). In essence, exon skipping therapy is moving 
closer to personalised medicine and consequently there will be evident implications 
on the price of these drugs. It must also be noted that disparities between cardiac 
and skeletal muscle rescue have been observed in the efficacy of PMOs with higher 
dystrophin expression in skeletal muscle (Wu et al., 2010; Betts et al., 2015). For 
these reasons, improved compounds are now emerging and being investigated in 
animal models for exon skipping, such as tricyclo-DNA oligomers (Goyenvalle et al., 
2015) and peptide-conjugated PMOs (Wu et al., 2014). 
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1.4.3 Stop Codon Read-through 
Calcium channel blocking has also been noted as a potential rescue therapy for 
DMD. It has been observed that transient receptor potential canonical (TRPC) 
channel 3 induction can result in muscular dystrophy development in mice (Millay et 
al., 2009). Streptomycin has been shown to be able to block these stretch-activated 
channels and accordingly reduce internal calcium levels in guinea pigs (Gannier et 
al., 1994). This effect was investigated in mdx mice, which were treated in utero and 
until adulthood. The study concluded that initial improvements in mice were 
overshadowed by rapid progression of the disease in late adulthood with no effect on 
the diaphragm or cardiac tissue and, in fact, significant worsening of pathology in the 
heart (Jørgensen et al., 2011). It was hypothesised that one of the reasons for an 
initial improvement in 6 week old pups may have been due to streptomycin’s 
potential of reading through premature stop codons (Welch et al., 2007). However, 
results for that time-point showed that there was no dystrophin expression in TA 
muscle. Elucidation of calcium channel blocking as a potential rescue therapy will 
need to be further investigated. 
 
Atalauren is a drug also capable of premature stop codon read-through (Hamed, 
2006). It was used for clinical trials as a therapeutic agent for cystic fibrosis 
(Wilschanski et al., 2011), but regrettably Ataluren clinical trials with nonsense 
mutation DMD patients were initially discontinued as no significant improvement was 
seen in the primary outcome measure, despite a slight improvement in the low-dose 
cohort (Muntoni & Wood, 2011). Further clinical studies have since been completed 
(Bushby et al., 2014), and it is now conditionally approved by the European 
Medicines Agency for use in DMD patients under the trade-name Translarna (Haas 
et al., 2015). However, this drug would only be applicable to about 15% of DMD 
patients (Bushby et al., 2009), which highlights the need for developing a universal 
therapy for DMD that would equally restore dystrophin expression in both cardiac and 
skeletal muscle. 
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1.4.4 Cell Therapy 
Myoblasts can be isolated from muscle tissue at a high purity (Blanco-Bose et al., 
2001), but have a restricted capacity for proliferation. Satellite cells are found at a 
relatively low abundance of 2-5% in situ (Figeac et al., 2007), readily differentiate into 
myoblasts ex vivo and, hence, also become senescent after activation and onset of 
MyoD expression when cultured (Hawke & Garry, 2001).  
 
Technical advances have improved satellite cell yields from muscle tissue samples 
on the basis of transcription factor (Pax3, Pax7) and cell surface marker (CD34, 
SM/C-2.6) expression (Fukada et al., 2004; Montarras et al., 2005). Although 
myoblasts and satellite cells can routinely be used for in vitro experiments and have 
successfully been used to repopulate muscle in mouse models, these isolation 
methods will unfortunately not be able to produce sufficient quantities of cells for 
therapeutic purposes (Pleasure, 2011). Erythropoietin signalling has been shown to 
delay myogenin expression in vivo, thus inducing transplanted myoblast proliferation 
and incorporation to muscle fibres in mdx mice (Jia et al., 2009). This suggests cells 
that express erythropoietin may have more success in repopulating damaged 
tissues. 
 
Muscle side population cells have been investigated as a potential resource for 
transplantation. These cells express haematopoietic stem cell markers Sca-1 and to 
a lesser extent CD45, they do not become activated or differentiate down the 
myogenic lineage in vitro, but have been shown to differentiate into myocytes and 
satellite cells when used for transplantation in mice (Asakura et al., 2002). However, 
recent results indicated that muscle side population cells derived from dystrophic 
mouse muscle fail to go down the myogenic lineage and instead become adipogenic 
(Penton et al., 2013). 
 
Pericytes, derived from microvasculature in muscle tissue, are another type of 
precursor cells that have been scrutinised and tested as a source of cells for 
myogenic regeneration. These cells express proteoglycans and alkaline phosphatase 
that allow them to be relatively easily isolated and purified. Human pericytes from 
adipose tissue increase the life-span of utrophin and dystrophin double knock-out 
(dko) mice when injected intraperitoneally (Valadares et al., 2014). Pericytes have 
also previously been shown to incorporate into myotubes in mice. These cells may 
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be closely related to the mesoangioblast population due to their same origin in the 
vasculature (Dellavalle et al., 2007). 
 
Mesoangioblasts have been used as a cell therapy method to restore DGC formation 
and localisation to the sarcolemma in the α-sarcoglycanopathy mouse model 
(Sampaolesi et al., 2003). That research group used the same intra-arterial 
administration method to restore dystrophin expression in the golden retriever dog 
model of DMD (GRMD) (Sampaolesi et al., 2006). These in vivo experiments showed 
great potential especially as there were no significant immune reaction noted and the 
phenotype was alleviated in GRDM. However, a clinical trial of HLA-matched donor 
mesoangioblast intra-arterial injection into DMD patient limbs did not stop disease 
progression (Cossu et al., 2015). 
 
Farini et al. (2009) have successfully rescued dystrophin expression in CD133-
positive endothelial circulating progenitor cells with better results than 
haematopoietic-lineage derived stem cells. These cells have also been used in a 
phase I clinical trial, where neovascularisation was observed in DMD patients after 
autologous cells had been corrected and reintroduced. There was a shift in the fibre 
types as well from slow- to fast-twitch fibres (Torrente et al., 2007). However, 
immunological aspects of introducing stem cell therapies in clinic and a lack of 
significant increase in muscle strength in patients caused concern (Lodi et al., 2011). 
Furthermore there could always be immunological consequences to introducing 
dystrophin to the patients’ fibres as was seen in the previously mentioned AAV trial 
(Mendell et al., 2012). 
 
Conditionally immortalised CBA;B10-Tg(H2Kb-tsA58)6Kio/Crl (Immorto) mouse-
derived heterozygous Immorto-mdx mouse cell lines can provide a near infinite 
resource of myoblast cells for in vitro experiments and are applicable for 
transplantation as the immortalising large T antigen from simian vacuolating virus 
(SV40) is thermo-labile and rapidly degrades at 37ºC (Jat et al., 1991) (Morgan et al., 
1994). Whilst these cells are available from the mdx mouse model, they cannot be 
derived from humans and therefore are only useful for proof-of-concept animal 
studies. Nevertheless, these cells bring down the number of animals needed for 
tissue and cell harvesting for conducting experiments and improved models with no 
tumorigenicity upon transplantation are now available (Muses et al., 2011). The T 
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antigen inhibits p53 function, allowing these cells to exit the G1 stage and proliferate. 
It has been suggested that p53 interacts with MyoD to induce muscle CK 
transcription (Tamir & Bengal, 1998) and as such could compromise any results for 
rescue therapies that employ CK release as an outcome measure. However, as 
mentioned above, the T antigen is thermolabile and therefore would not compromise 
p53 function at the conventional 37ºC cell culture temperature.  
 
In conditionally immortalised atrial HL-1 cells the T antigen is expressed under the 
ANP promoter, which makes its expression localised and cardiomyocyte-specific, 
reducing contaminating cells during the cell isolation process (White et al., 2004). 
Whilst these cells are more easily obtained than through conventional cardiac cell 
isolation procedures, they still remain only an animal-model tool for DMD research 
considering ventricles are more severely affected in DMD. A mouse strain has been 
developed that expresses the T antigen under the Nkx2.5 promoter, where it is also 
controlled by a Cre-lox system (Rybkin et al., 2003). Although this provides a more 
suitable model for DMD research as it would be possible to obtain a ventricular cell 
line when crossed with the mdx mouse, it would still only be a resource for animal 
studies and the urgent need for human alternatives remains. 
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1.4.5 Stem Cell Models for DMD Research into Therapies 
Pluripotent stem cells, capable of differentiating into most cell types, are a promising 
resource for testing various rescue therapies as they are essentially a self-
replenishing resource of cells. Until recently stem cell research has been hindered by 
ethical concern. Many scientists initially anticipated blastocyst-derived embryonic 
stem cell (ESC) lines to be an essential resource for conducting in vitro experiments 
(Thomson et al., 1998). After wide press coverage and public opposition further 
development of these resources was restricted by legislation in many countries. The 
destruction of a fertilised egg for research purposes – sacrificing a person in the 
making – was the major ethical counter-argument for using human embryo-derived 
cell lines. Furthermore, a series of publications were retracted when serious 
allegations of fraud and abuse were brought to light in a research group working on 
human oocytes and cloning (Cyranoski, 2009). Fortunately, recent developments in 
the field of stem cell research have led to several alternative methods – with less 
significant ethical concerns – having been established for pluripotent cell line 
creation. 
 
Shinya Yamanaka’s research group has paved the way for deriving pluripotent stem 
cells by transducing fibroblasts with specific transcription factors (in the initial journal 
articles with Oct3/4, Sox2, Klf4 and c-Myc) to reprogram mouse (Takahashi & 
Yamanaka, 2006) and a year later human (Takahashi et al., 2007) cells into induced 
pluripotent stem cells (iPSC), revolutionising stem cell research. There are no ethical 
concerns related to perishing embryos in this process, which meant countries where 
legislation was hampering developments in this field now had a legitimate alternative 
to proceed with their research. However, despite the scientific and legal reasoning for 
allowing iPSC production a survey showed that iPSCs only had a marginally higher 
public approval rate in the US compared to in vitro fertilisation-derived ESCs (Evans 
& Kelley, 2011). 
 
C-Myc’s tumorigenicity was noted at the very start and although other transcription 
factors were used to replace it, there remained no alternative that would have kept 
the success rate as high. Nevertheless, several suggestions for optimising the 
methods and making the process safer have now been published. Glis1 was recently 
reported to be an appropriate substitute for c-Myc (Maekawa et al., 2011). Lithium 
has been shown to increase reprogramming efficiency by also affecting epigenetics 
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(Wang et al., 2011). Integration site specificity has been tackled by using 
transcription activator-like effector nucleases (Hockemeyer et al., 2011). Better 
determination of appropriate markers to select truly reprogrammed cells has 
decreased subjectivity and technical demand (Chan et al., 2009). Biotinylated viral 
capsids (Nesbeth et al., 2006) used with other combinations of transcription factors 
such as Oct4, Sox2, Nanog and Lin28 as well as marker expression selection 
significantly speeds up the process (Dick et al., 2011).  
 
There has been a myriad of publications on reprogramming somatic cells to generate 
cells belonging to different lineages. It has been possible to generate hepatocyte-like 
cells (Sekiya & Suzuki, 2011; Huang et al., 2011), neuronal cells (Pang et al., 2011) 
as well as patient-specific cardiomyocytes (Carvajal-Vergara et al., 2010). DMD 
patient-specific cardiomyocytes have now been generated and used as a model to 
test rescue therapies (Dick et al., 2013). Due to the continual nature of transcription 
factor regulation in myogenesis, it has taken considerably longer to establish a 
replicable protocol for myogenic cell derivation from iPSC, but recently published 
results (Shelton et al., 2015; Chal et al., 2015) have paved the way for DMD iPSC-
derived satellite cell and skeletal muscle derivation, enhancing DMD researchers’ 
toolbox with human models for in vitro trials. 
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1.5 Statement of Aims 
This thesis introduces an in vitro mdx cardiomyocyte hypertrophy model. It is pivotal 
to determine which pathways are involved in this process in order to fully understand 
the mechanisms of cardiac remodelling in dystrophic hearts and to test therapeutic 
targets to ensure the model can be used for in vitro studies. The aims of the three 
results chapters in this thesis were as follows. 
• To establish a model of mdx mouse cardiomyocyte hypertrophy for modelling 
the dystrophic heart in an in vitro setting. 
• To identify signalling pathways and mechanisms of hypertrophy responsible 
for changes in mdx cardiomyocyte size in response to serum starvation. 
• To investigate the efficacy of therapeutic compounds and AAV-mediated µDys 
transduction at reducing serum-induced mdx cardiomyocyte hypertrophy. 
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Chapter 2. Materials and Methods 
 
2.1 Consumables and Equipment 
Item Product Code Supplier 
0.05% Trypsin-EDTA 25300096 Gibco 
0.2ml PCR tube I1402-4308 Starlab 
1.5ml microfuge tube 211-2610 VWR 
1.5ml microfuge tube screw-cap 716261 Greiner 
1000µl pipette filter tips S1122-1830 Starlab 
100mm petri dishes 734-2321 VWR 
10ml serological pipettes 86.1254.001 Sarstedt 
10µl pipette filter tips S1121-3810 Starlab 
13mm⌀ No.1 cover glasses ECN 631-1578 VWR 
15ml centrifuge tubes 430766 Corning 
1kb DNA ladder G571A Promega 
200µl pipette filter tips S1120-8810 Starlab 
20µl pipette filter tips S1120-1810 Starlab 
24-well plates 734-2325 VWR 
25ml serological pipettes 86.1685.001 Sarstedt 
3-8% Tris-Acetate NuPAGE gels EA0378BOX Invitrogen 
384-well PCR plate 785290 Greiner 
4-12% Bis-Tris NuPAGE gels NP0321BOX Invitrogen 
50ml centrifuge tubes 430829 Corning 
50ml serological pipettes 86.1689.001 Sarstedt 
50ml syringes without needles SYR6212 SLS 
5ml serological pipettes 86.1689.001 Sarstedt 
60mm petri dishes 734-2318 VWR 
8-channel spectrophotometer ND-8000 NanoDrop 
96-well PCR plates E1403-5200 Starlab 
ab15277 anti-dystrophin antibody ab15277 Abcam 
Acetic acid A6283-1L Sigma 
Acrodisc 0.2µm sterile filter 514-4126 Pall/VWR 
Agarose NBS-AG500 NBS Biologicals 
Agarose gel electrophoresis tanks 1704405 Bio-Rad 
Agfa X-ray film AGF1824G Vet Direct 
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Alexa Fluor 488 goat anti-mouse IgG A11001 Invitrogen 
Alexa Fluor 488 goat anti-rabbit IgG A11008 Invitrogen 
Alexa Fluor 594 goat anti-mouse IgG A11005 Invitrogen 
Alexa Fluor 594 phalloidin A12381 Invitrogen 
Anti-α-actinin antibody A7811-.2ML Sigma 
Antioxidant solution NP0005 Invitrogen 
Autoclave RS232 Astell 
Autoclave tape 817-0118 VWR 
β1AR (V-19) antibody sc-568 Santa Cruz 
β-mercaptoethanol 31350010 Life Technologies 
Bicinchoninic acid kit BCA1-1KT Sigma 
Bioanalyzer 2100 G2940CA Agilent 
Blue/orange 6x loading dye G190A Promega 
Bovine serum albumin A3294-50G Sigma 
Camera BW AxioCam HRc Zeiss 
Camera RGB DS-Fi2 Nikon 
Captopril C4042-5G Sigma 
cDNA reverse transcription kit 4368814 App’d Biosystems 
Cell scraper 220mm fixed blade CC7600-0220 Starlab 
Chloroform C2432-1L Sigma 
Class 1 airflow cabinet Hera guard Heraeus 
Class 2 airflow cabinet Hera safe Heraeus 
Collagen from calf skin C8919-20ML Sigma 
Collagenase type II 17101-015 Gibco 
cOmplete protease inhibitor tablets 05892791001 Roche 
DEPC-treated water AM9906 Ambion 
Dexamethasone D4902-25MG Sigma 
Digital graphic printer UP-D897 Sony 
Dimethyl sulfoxide (DMSO) D-8779 Sigma 
Dulbecco's modified Eagle medium 41966052 Gibco 
EDTA E5134-500G Sigma 
Encore RNA-Seq Multiplex System 0312-32 NuGen 
Enhanced chemiluminescence kit RPN2232 Amersham 
Ethanol 20821.330 VWR 
Film developer SRX-101A Konica 
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Film developer cassette RPN11643 Amersham 
Fine scales BD BH 110 Denver 
Foetal bovine serum (FBS) EU-000-F SLI 
Freezer -80° U725 NB Scientific 
Fridge/freezer -20° KGV36VW32G Bosch 
GelDoc-It Imaging System GelDoc-It310 UVP 
Glucose G8270-100G Sigma 
Glycine G8898-1KG Sigma 
Goat anti-mouse IgG HRP conjugate G21040 Invitrogen 
Goat anti-rabbit IgG HRP conjugate G21234 Invitrogen 
Haemocytometer 680030 Marienfeld 
Heat sealer 23/2696 Hulme Martin 
Heater magnetic stir block 101N0052 Fisher 
HEPES H3375-100G Sigma 
HiMark Pre-stained protein standards LC5699 Invitrogen 
HiSeq 1500 HiSeq1500 Illumina 
Horse serum (HS) 26050088 Gibco 
HotStarTaq DNA polymerase 203205 Qiagen 
Hsp90ab1 KiCqStart primers M_Hsp90ab1_1 Sigma 
Hybond PVDF membrane RPN303F GE Healthcare 
Hydrochloric acid 84436-1L Sigma 
Incubator Hera cell 240 Heraeus 
Insulin syringe with needle 613-4897 VWR 
Interferon gamma (IFNγ) PMC4031 Invitrogen 
Isopropanol 20842.330 VWR 
KCl potassium chloride P9541-500G Sigma 
Lab Armor beads A1254301 Life Technologies 
LDS sample buffer NP0007 Invitrogen 
Lens tissue 2105-841 Whatman 
MANDRA1 anti-dystrophin antibody ab7164 Abcam 
Medium 199 31150-022 Gibco 
MES SDS protein gel running buffer NP0002 Invitrogen 
Methanol 20846.326 VWR 
Metoprolol tartrate M5391-10G Sigma 
MgSO4  magnesium sulphate 208094-500G-D Sigma 
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Microfuge 5415D Eppendorf 
Microscope confocal A1R Nikon 
Microscope filter DAPI FS02 Zeiss 
Microscope filter GFP FS13 Zeiss 
Microscope filter Rhodamine FS15 Zeiss 
Microscope inverted fluorescence AxioVert200M Zeiss 
Microscope inverted light AE20 Motic 
Microwave oven KOR-8A0R Daewoo 
Milk powder 93327 Marvel 
Mounting medium with DAPI H-1200 Vectorlabs 
NaCl sodium chloride S9888-5KG Sigma 
NaH2PO4   S9638-500G Sigma 
NaOH S5881-500G Sigma 
NCL-DYS1 anti-dystrophin antibody NCL-DYS1-S Novocastra/Leica 
NCL-Hamlet anti-dysferlin antibody Hamlet-CE Novocastra/Leica 
NHE inhibitor KR-33028 KR-33028 Peacock Pharma 
Nitrile gloves 112-2755 VWR 
Novex Mini-gel PAGE tanks 120801-2839 Invitrogen 
Nuclease-free water (NFW) AM9937 Ambion 
Objective CFI Plan Apochromat 20x VC 20x/0.75 Nikon 
Objective CFI Plan Fluor 10x DL-10x F/0.3 Nikon 
Objective Plan Neofluar 10x 10x/0.3 Zeiss 
Objective Plan Neofluar 20x 20x/0.5 Zeiss 
Oregon Green 488 phalloidin O7466 Invitrogen 
p-ERK (E-4) antibody sc-7383 Santa Cruz 
P2RX7 inhibitor A804598 A804598 Tocris 
Parafilm PM-999 Pechiney 
Paraformaldehyde P6148-1KG Sigma 
Pasteur pipettes 230mm 612-1702 VWR 
PBS tablets 18912-014 Gibco 
PCR thermocycler LabCycler Sensoquest 
PCR plate adhesive sealing sheets AB-0558 Thermo 
Penicillin/Streptomycin 15070063 Gibco 
pH meter HI 2210 Hanna 
Phenol:chloroform:isoamyl alcohol 15593031 Ambion 
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Phosphate buffered saline solution 20012068 Gibco 
Plate reader Infinite F200 Tecan 
Plate reader Multiskan 354 Ascent 
Polyethylene glycol (PEG) 400 91893-250ML-F Sigma 
PowerPac HC 1645052 Bio-Rad 
Prednisolone tablets 6565/0914 Sovereign 
Proteinase K 1964372 Roche 
qRT-PCR plate thermocycler QuantStudio7 App’d Biosystems 
Refrigerated centrifuge  5804R Eppendorf 
Refrigerated centrifuge  5810R Eppendorf 
RIPA buffer 10230544 Thermo 
RNAClean XP A63987 Agencourt 
RNase Zap AM9780 Ambion 
RNase-free DNase set 79254 Qiagen 
RNeasy Mini kit 74104 Qiagen 
Rotor A-4-44 Eppendorf 
Rotor F45-30-11 Eppendorf 
Rotor A-4-62 Eppendorf 
SafeView nucleic acid stain NBS-SV1 NBS Biologicals 
Sample reducing agent NP0009 Invitrogen 
Scales HL-200i A&D 
Scalpels no.22 REF0508 Swann-Morton 
SeeBlue Plus2 protein standards LC5925 Invitrogen 
SimplyBlue SafeStain LC6060 Invitrogen 
Sleeve protector 113-0718 VWR 
Sodium dodecyl sulphate (SDS) L3771-500G Sigma 
SYBR Green JumpStart Taq S4438-500RXN Sigma 
T25 flasks 734-2311 VWR 
Tissue homogeniser 9001273 Qiagen 
Tissue ruptor probes 990890 Qiagen 
Tpt1 KiCqStart SYBR Green primers M_Tpt1_1 Sigma 
Tris-Acetate protein gel running buffer LA0041 Invitrogen 
Triton X-100 T8787-50ML Sigma 
Trizma base T1503-1KG Sigma 
TRIzol 15596026 Ambion 
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Trypsin 2.5% 15090-046 Gibco 
Tween 20 P9416-100ML Sigma 
Ultrapure water system D11901 Thermo 
Virkon A01302780 Dupont 
Water bath JB Aqua 18 Plus Grant 
Western blot transfer tanks 1703930 Bio-Rad 
Zymo-Spin columns C1004-50 Zymo Research 
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2.2 Solutions 
 Phosphate buffered saline (PBS)  
· PBS tablets 2 
· dH2O 1000ml 
   
 4% (w/V) paraformaldehyde (PFA) in PBS  
· dH2O 500ml 
· PBS tablets 2 
· NaOH 3 pellets 
· PFA 40g 
· pH adjusted with NaOH 7.4 
· dH2O to 1000ml 
   
 Tris buffered saline (TBS) 10x  
· Trizma base 60.5g 
· NaCl 87.6g 
· pH adjusted with HCl 7.5 
   
 0.5% (V/V) Tween 20 in TBS  
· TBS 10x 100ml 
· dH2O 899.5ml 
· Tween 20 500µl 
   
 4% (w/V) bovine serum albumin (BSA) in TBST  
· BSA 2g 
· TBST to 50ml 
   
 DNA digestion buffer  
· Tris HCl 50mM 
· EDTA 100mM 
· NaCl 100mM 
· Sodium dodecyl sulphate (SDS) 1%(w/V) 
· pH 8 
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 Tris-EDTA (TE) buffer  
· Tris 10mM 
· EDTA 1mM 
· pH 7.4 
   
 Tris acetic acid EDTA (TAE) buffer  
· Tris 400mM 
· EDTA 10mM 
· Acetic acid 11.4% (V/V) 
· pH (with Trizma base and acetic acid) 7.6 
   
 Collagen solution  
· dH2O 179ml 
· Acetic acid 1ml 
· Sterilisation with 0.2µm filtration  
· Collagen from calf skin (see consumables) 20ml 
· stored at 4°C  
   
 Cardiomyocyte buffer solution (CBS)  
· 1M NaCl 116.35ml 
· 1M HEPES 20ml 
· 1M NaH2PO4 1ml 
· 1M KCl 5.366ml 
· 833mM MgSO4 1ml 
· 1M NaOH 8.28ml 
· dH2O 848ml 
· pH 7.4 
   
 Cardiomyocyte enzyme solution (CES)  
· CBS 99ml 
· 1M glucose 540µl 
· Collagenase type II (240U/mg) 33.3mg 
· Sterilisation with 0.2µm filtration  
· 2.5% trypsin added after first isolation step 1% (V/V) 
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 Cardiomyocyte growth medium (CGM)  
· Dulbecco's modified Eagle's medium (DMEM) 340ml 
· Medium 199 85ml 
· Foetal bovine serum (FBS) 25ml 
· Horse serum (HS) 50ml 
· Penicillin/Streptomycin 100x 5ml 
· stored at 4°C  
   
 Immorto-CGM (ICGM)  
· Dulbecco's modified Eagle's medium (DMEM) 340ml 
· Medium 199 85ml 
· FBS 25ml 
· Horse serum (HS) 50ml 
· Penicillin/Streptomycin 100x 5ml 
· Interferon-gamma (IFNγ) 15µg 
· stored at 4°C  
   
 Serum-free CGM (SFCGM)  
· Dulbecco's modified Eagle's medium (DMEM) 34ml 
· Medium 199 8.5ml 
· Penicillin/Streptomycin 100x 430µl 
· stored at 4°C  
   
 Serum starvation CGM (SSCGM)  
· Dulbecco's modified Eagle's medium (DMEM) 34ml 
· Medium 199 8.5ml 
· FBS 430µl 
· Penicillin/Streptomycin 100x 430µl 
   
 Protein lysis buffer (PLB)  
· RIPA buffer 10ml 
· cOmplete ULTRA protease inhibitor tablet 1 
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 Tris-Acetate protein running buffer  
· Tris-Acetate protein running buffer (20x) 35ml 
· dH2O 665ml 
   
 MES SDS protein running buffer  
· MES SDS protein running buffer (20x) 35ml 
· dH2O 665ml 
   
 Western blotting protein transfer buffer (PTB)  
· Trizma base 3.03g 
· Glycine 14.4g 
· dH2O to 800ml 
· Methanol 200ml 
   
 5% milk powder blocking solution  
· Instant dried skimmed milk powder 5g 
· TBST to 100ml 
   
 PVDF membrane protein stripping buffer  
· 50mM β-mercaptoethanol 7.8ml 
· SDS 20g 
· Trizma base 7.57g 
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2.3 Genotyping Mice 
All animal work was conducted following Home Office guidelines under Professor 
Volker Straub’s project licence 60/4137. C57BL/10 (BL/10), C57BL/10ScSn-Dmdmdx 
(mdx) and CBA;B10-Tg(H2Kb-tsA58)6Kio/Crl (Immorto) mouse breeders were set up 
by Elizabeth Greally (laboratory technician) personal licence number 60/10222).  
 
Ear biopsies were taken from progeny of Immorto mice bred with BL/10 or mdx mice 
and collected into 1.5ml microfuge tubes. 500µl of DNA digestion buffer and 12.5µ of 
proteinase K (0.5mg/ml final concentration) were added to the biopsies. These 
samples were incubated at 50°C overnight.  
 
The following day 700µl of phenol/chloroform/isoamyl alcohol was added to each 
sample, the tubes were shaken until white precipitate formed and centrifuged at 
14,000rpm for 5min. The top phase solution from each sample was transferred into 
fresh microfuge tubes and 1ml of ethanol was added. The tubes were inverted and 
incubated at -80°C for 2h. Post-incubation the samples were centrifuged at 4°C, 
14,000rpm for 20min. Supernatants were discarded and pellets resuspended in 1ml 
of 75% ethanol 25% dH2O solution, precooled to -20°C. Tubes were centrifuged at 
4°C, 8,000rpm for 5min, the supernatant discarded and pellets air dried at ambient 
temperature for 30min. Dried pellets were resuspended in 100µl TE buffer and DNA 
quantified with a spectrophotometer and the samples were stored at -20°C. 
 
A mastermix was prepared of polymerase chain reaction (PCR) reagents following 
the manufacturers’ guidelines (Qiagen HotStarTaq DNA polymerase), using the 
following primers (Yang et al., 2000): 
Immorto forward primer: 5’-AGC GCT TGT GTC GCC ATT GTA TTC-3’ 
Immorto reverse primer: 5’-GTC ACA CCA CAG AAG TAA GGT TCC-3’ 
 
The thermocycler was programmed according to the polymerase kit instructions with 
the annealing temperature set to 58°C. A 1% (w/V) agarose solution in TAE buffer 
was prepared and microwaved to solubilise the agarose. The solution was allowed to 
cool, 10µl of SafeView stain was added, the gel poured and allowed to set for 30min. 
2µl of loading dye was added to 10µl of each sample’s PCR product and loaded onto 
the agarose gel along with a 1kbp reference DNA ladder. The DNA samples were 
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separated according to size with a constant voltage electrical current for 30min at 
100V. The gel was imaged under ultraviolet light. Mouse DNA positive for the 
Immorto construct yielded a 1kbp band.  
 
2.4 Collagen-coated Plastics 
Tissue culture vessels used for plating and pre-plating cardiomyocytes were all 
coated with collagen. Collagen solution was added at 100µl/cm2 and incubated at 
ambient temperature overnight. On the following day the collagen solution was 
collected and stored at 4°C along with the remaining stock solution. Coated tissue 
culture vessels were washed with autoclaved distilled water and left to air dry in a 
class 2 tissue culture cabinet. Once dried, the coated vessels were stored in a sterile 
plastic bag at ambient temperature for up to a month. 
 
2.5 Cardiomyocyte Isolation 
The cardiomyocyte isolation protocol was adapted from Sreejit et al. (2008) with help 
and advice from Rita Barresi (lecturer) and Alison Blain (post doctoral associate). 
Female mice from breeding pairs and trios were checked for post-coital vaginal plugs 
daily. Mice were sacrificed using Schedule I procedures, embryos at gestation period 
day 17.5 (E17.5) extracted and stunned by incubating in CBS on a petri dish on ice. 
A mid-abdominal incision was made with dissection scissors and the heart removed 
after bisecting the rib cage along the cranio-caudal axis. All collected hearts from one 
litter were collected into one 15ml centrifugation tube containing 8ml of CBS, pre-
cooled on ice (figure 2.1). 
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Figure 2.1. Pooling transgenic mouse embryo hearts for isolating cardiomyocytes.  
Hearts from male and female E17.5 embryos from dystrophic mdx mouse breeding 
pairs were pooled. When mdx and mdx-Immorto+/- mice were crossed all hearts from 
both male and female E17.5 embryos were still pooled together regardless of their 
genotype. 
 
The hearts were decanted into a 6mm petri dish, gently squeezed with forceps to 
eject any residual coagulated blood, major vessels were removed and remaining 
cardiac tissue cut into ~1mm sized fragments with a scalpel. All fragments were 
subsequently transferred into 5ml CES without trypsin in a 15ml centrifugation tube, 
pre-heated to 37°C. The fragments were incubated at 37°C for 10min in a water bath. 
Tissue fragments were allowed to settle to the bottom of the tube and the 
supernatant was discarded.  
 
8ml of fresh CES with trypsin was added to the heart fragments and the tube 
incubated for 30min at 37°C, tilting the tube ten times every 10min. At the end of the 
incubation the tissue fragments were allowed to settle to the bottom of the tube and 
the supernatant was collected into a 15ml centrifugation tube, which was 
subsequently centrifuged at 1,200g for 5min at 15°C. Fresh CES was added to the 
heart fragments and the tube incubated in the water bath at 37°C. The centrifuged 
supernatant was discarded and the recovered cell pellet resuspended in 1ml of FBS, 
pre-cooled to 4°C. The resuspended cells were stored at 4°C for the duration of the 
subsequent incubation steps.  
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The residual tissue was subjected to another three 30min incubation steps following 
the procedure above, or more in case all the tissue had not dissociated, with 
collecting the cell-rich CES at the end of each step into the tube containing cells in 
FBS. Following the centrifugation at the end of the last incubation step the cell pellet 
was resuspended in 5ml of CGM. The cell suspension was transferred into a 
collagen-coated T25 flask and incubated at 37°C for 2h. The cardiomyocyte-enriched 
supernatant CGM was collected and centrifuged at 1,200g for 5min at 23°C. The 
pelleted cells were counted on a haemocytometer and dispensed onto collagen-
coated tissue culture vessels as required in experiments described below.  
 
Isolated primary cardiomyocytes were dispensed onto 24-well plates. For 
immunocytochemistry the density was ~1.2x105 cells per well. For RNA and protein 
extraction the cell density was ~5x105. Plated cells were cultured at 37°C for 48h 
under 5% CO2, followed by two PBS washes and serum starvation with either 
SFCGM or SSCGM for 24h to 96h at 37°C under 5% CO2. A specific number of wells 
were designated for PFA-fixing, or RNA and protein extraction at each of the five 
serum starvation time-points: 0h, 24h, 48h, 72h and 96h.  
 
2.6 Immunocytochemistry (ICC) 
Following the initial 48h incubation in CGM, all cells were washed twice with PBS for 
5min and the growth medium and wash solution discarded. The wells containing cells 
for 24h, 48h, 72h and 96h of serum starvation were replenished with SFCGM or 
SSCGM and incubated at 37°C. The control 0h cells were PFA-fixed as described 
below. The medium on cells remaining in culture was discarded and replenished 
every 24h with further wells fixed for staining. 
 
Cells were fixed at the appropriate time-point with 4% PFA in PBS over 15min at 
ambient temperature in a fume cupboard, followed by one 5min wash with PBS and a 
second 5min wash with TBS.  The cardiomyocytes were subsequently permeabilised 
with 0.5% Triton X-100 in TBS for 10min, followed by two 5min washes with TBS. 4% 
BSA (w/V) in TBST was used for blocking non-specific protein binding sites, at room 
temperature for 30min. Primary antibodies were dissolved in 4% BSA in TBST and 
staining was performed overnight at 4°C. The cells were washed twice for 5min with 
TBST. The secondary antibody and phalloidin (both prepared in 4% BSA in TBST) 
staining was conducted at room temperature for 1h, protected from light. The 
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cardiomyocytes were washed twice for 5min with TBST and once with dH2O, 
mounted under a coverslip in Vectashield medium containing DAPI and stored at 4°C 
until imaging. Antibody dilutions for ICC were: mouse monoclonal anti-α-actinin 
1/800, mouse monoclonal MANDRA1 anti-dystrophin 1/100, rabbit polyclonal 
ab15277 anti-dystrophin 1/100, Alexa Fluor 488 goat anti-mouse 1/500, Alexa Fluor 
594 goat anti-mouse 1/500, Alexa Fluor 488 goat anti-rabbit 488 1/500. Oregon 
Green conjugated phalloidin and Alexa Fluor 594 conjugated phalloidin were both 
used at a 1/300 dilution. 
 
2.7 Microscopy 
Imaging was conducted on two microscopes. The Zeiss Axiovert 200M inverted 
fluorescence microscope was used with an AxioCam HRc monochrome camera, FS 
02 (DAPI), FS 13 (GFP) and FS15 (Rhodamine) filters, Plan Apocromat 10x/0.45 
Ph1 and LD Achroplan 20x/0.4 Ph2 objectives. The Nikon A1R confocal microscope 
was used with a Galvano scanner, Nikon DS-Fi2 RGB camera, 405nm, 488nm and 
561nm lasers, as well as CFI Plan Fluor DL-10x F/0.3 Ph1 and CFI Plan Apochromat 
VC 20x/0.75 objectives. All exposure times, gain and offset values were maintained 
at constant values within each compared set of experiments. 
Original zvi and nd2 files were retained with the relevant metadata. Prior to image 
analysis, brightness and contrast adjustments were only made on images acquired 
on the Zeiss Axiovert 200M to aid visual detection of α-actinin positive cell 
boundaries. For display purposes look-up table (LUT) adjustments were made on 
images and kept constant in all compared images within a sample set. Scale bars 
were added onto final versions of exported tiff images. All figures with ICC images 
have been compiled using Adobe Photoshop CC and Adobe Illustrator CC, without 
any alterations performed in Adobe software. 
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2.8 Area and Volume Measurements 
All area measurements of images acquired on the Zeiss Axiovert 200M were either 
acquired manually on the AxioVision LE software or automated on the Perkin Elmer 
Volocity software package, using the signal from the α-actinin antibody binding. All 
volume measurements were obtained by three-dimensional construction of Z-stack 
images, acquired on the Nikon A1R confocal microscope and analysed in Volocity in 
the same manner as area measurements. In both cases cells that were 
multinucleated or touching the side of the image were removed from the final 
analysed dataset. Area measurements of images acquired on the Nikon A1R 
confocal microscope were performed using the Nikon Elements 4.0 software area 
recognition function employing the α-actinin channel signal. All area and volume 
measurements were transferred to Microsoft Excel for statistical and further 
analyses. 
 
2.9 RNA Extraction 
BL/10 and mdx adult mouse hearts were surgically removed from mice culled 
following Schedule 1 procedures. The hearts were chopped with a scalpel and tissue 
pieces homogenised with disposable tissue ruptor probes in 1ml Trizol. Cells in the 
tissue homogenate were lysed by aspiration with insulin syringes. A 300µl aliquot of 
each cell lysate in Trizol was transferred into individual screw-cap microfuge tubes 
and used for subsequent RNA extraction steps. The remaining 700µl of each sample 
was stored at -80°C. 
 
300µl aliquots of heart tissue samples in Trizol were centrifuged at 12,000rpm for 
10min at 4°C and the supernatant transferred to a fresh screw-cap 1.5ml microfuge 
tube. 50µl of chloroform was added to each sample and the tubes were vigorously 
shaken for 15s, incubated at ambient temperature for 3min and centrifuged at 
12,000rpm for 15min at 4°C. The resulting transparent top layer was transferred to a 
fresh 1.5ml microfuge tube and RNA was precipitated by mixing with 125µl of 
isopropanol over a 10min incubation at ambient temperature. The samples were 
subsequently centrifuged at 12,000rpm for 10min at 4°C and the supernatant 
discarded. The RNA pellet was washed with 1ml 70% ethanol in DEPC-treated H2O, 
pre-cooled to -20°C. The tubes were centrifuged at 7,500g for 5min at 4°C, the 
supernatant discarded and the pellet air-dried at ambient temperature. The RNA 
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pellets were ultimately dissolved in 25µl of DEPC-treated H2O and quantified using 
the Agilent 2100 Bioanalyzer or the Thermo NanoDrop 8000 following manufacturers’ 
instructions. 
 
For qRT-PCR experiments the Qiagen RNeasy Mini Kit was used to extract RNA 
from cardiomyocytes, following manufacturers’ guidelines. At the relevant collection 
time-point, cardiomyocytes in 24-well plates were washed twice with PBS and 
scraped in 350µl buffer RLT, supplemented with 350µl of 70% ethanol in 30% 
nuclease-free water (NFW) and the 700µl sample solution was transferred to spin 
columns. The columns were centrifuged at 8,000g for 15sec, flow-through discarded, 
350µl of buffer RW1 added to each column, followed by centrifugation at 8,000g for 
15sec. The flow-through was discarded and an on-column 15min DNase I digest 
performed. 350µl of buffer RW1 was added to each column, a centrifugation step at 
8,000g for 15sec performed and the flow-through discarded. 500µl of buffer RPE was 
added and the columns centrifuged at 8,000g for 15sec. Another 500µl RPE was 
added and the columns centrifuged at 8,000g for 2min. The flow-through was 
discarded and columns were dried by centrifugation at maximum speed for 1min. The 
columns were placed into 1.5ml screw-cap microfuge tubes and two elution steps 
with 15µl of NFW and 15sec centrifugation at 8,000g performed. BL/10 and mdx 
heart tissue RNA samples obtained through Trizol extraction were also purified and 
DNase-treated using the RNeasy Mini Kit. All RNA samples were quantified using a 
NanoDrop spectrophotometer and samples were stored at -80°C. 
 
2.10 RNA-Seq 
For whole transcriptome shotgun sequencing (RNA-Seq) experiments, at the relevant 
collection time-point, cardiomyocytes in 24-well plates were washed twice with PBS 
and detached in 300µl of Trizol using a cell-scraper. Detached cells were transferred 
into an individual 1.5ml screw-cap microfuge tubes. Three biological replicates of 
BL/10 and mdx cardiomyocytes at each time-point were shipped to Helmut Blum’s 
research group in Munich for RNA-Seq. 
 
Andrea Klanner (laboratory technician in Helmut Blum’s research group) performed 
all the following steps in this paragraph. RNA was extracted using Zymo-Spin 
columns, quantification and quality control performed using an Agilent Bioanalyzer 
2100. The lowest RNA integrity number (RIN) value accepted for continuing 
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experiments with a given sample was 8. RNA samples were DNase-treated, reverse 
transcriptase first strand and second strand cDNA synthesised. The DNA samples 
were fragmented with sonication, purification performed with RNAClean XP beads, 
adapter sequences ligated with an Encore Complete RNA-Seq Library Multiplexing 
system for multiplexing the samples and strand-specific sequence libraries 
generated. 
 
Stefan Krebs (post doctoral associate in Helmut Blum’s research group) split the 
samples intro two groups, and each group was analysed on a separate Illumina 
HiSeq 1500 lane. Duplicate single-end reads were obtained and used for subsequent 
bioinformatics analyses. 
 
The sequencing results were uploaded onto a Galaxy next-generation sequencing 
analysis web portal (Goecks et al., 2010). Samples were demultiplexed based on 
their reference sequences and fastqsanger files analysed with FastQC for quality 
control (Andrews, 2010) in a Linux server using command-line execution. TopHat2 
(Kim et al., 2013) was used in Galaxy to generate bam files by aligning sequences 
from each sample to the University of California Santa Cruz mm10 reference mouse 
genome, specifying the single-end data type and using gene annotations. The latter 
was required to ensure short intronic inclusions were not causing sequences to be 
dropped. Generated bam files were viewed in the Integrative Genomics Viewer (IGV) 
software (Thorvaldsdóttir et al., 2013) and used with HTSeq (Anders et al., 2015) to 
determine individual counts of gene expression for each sample. The feature type 
parameter in HTSeq analysis was set to “exon”, the attribute used as feature 
identification was set to “gene_id”, the detection mode was set to “intersection-strict” 
and strand specificity was selected. Alex Graf (post doctoral associate in Helmut 
Blum’s research group) wrote an R programming environment (Ihaka & Gentleman, 
1996) script for differential gene expression analysis with DeSeq2 package (Love et 
al., 2014).  
 
Databases of differentially expressed gene comparisons and individual gene fold 
change (FC) values were generated in Microsoft Excel. Gene ontology was 
performed with DAVID (Huang et al., 2009) online software and Genomatix software, 
which uses a PubMed literature mining algorithm for associating genes with each 
other (Frisch et al., 2009). 
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2.11 Quantitative Real-time PCR 
Reverse transcription PCR (RT-PCR) was performed with an Applied Biosystems kit, 
following manufacturers’ guidelines. 10µl of each sample RNA template was added 
to 10µl of the reaction mastermix for reverse transcribing cDNA. The thermocycler 
was programmed as follows: 
Step 1) 10min at 25°C; 
Step 2) 120min at 37°C; 
Step 3) 5min at 85°C; 
Step 4) ∞ at 4°C. 
Samples were diluted with 180µl of NFW, split into 50µl aliquots and stored at -20°C. 
 
Quantitative real-time PCR (qRT-PCR) primers were designed using the National 
Centre for Biotechnology Information (NCBI) gene search tool for each mouse gene 
of interest (GOI), picking the NM number link followed from the mRNA and protein 
section and primers picked based on the following parameters: PCR product size 80-
200bp, minimal primer melting temperature (Tm) 58°C, maximal Tm 62°C, maximal 
ΔTm 2°C and compulsion of exon junction span. Primer pairs were chosen based on 
their GC content (preferably between 50%-60%) and the ΔTm less than 1°C where 
possible. Genes, such as Vegfa had several transcript and primers were designed to 
pick up all of the possible transcripts. Predesigned housekeeping gene (HKG) Tpt1 
and Hsp90ab1 primers were ordered from Sigma-Aldrich. Sequences of these primer 
pairs were not reported here due to proprietary reasons. The following designed 
primer sequences were ordered from Eurofins MWG Biotech:  
Pln forward primer: 5’-TTC CTG CGT AAC AGG TCT CC-3’ 
Pln reverse primer: 5’-TCC ATT ATG CCA GGA AGG CA-3’ 
Ndufa4l2 forward primer: 5’-AAA AGA CAC CCT GGG CTC ATC-3’ 
Ndufa4l2 reverse primer: 5’-GGC AAG TCG CAG CAA GTA GA-3’ 
Fmod forward primer: 5’-AGG GCA ACA GGA TCA ATG AGT T-3’ 
Fmod reverse primer: 5’-GAT CTC GTT CCC ATC CAG GC-3’ 
Nppb forward primer: 5’-TTT GGG CTG TAA CGC ACT GA-3’ 
Nppb reverse primer: 5’-AAG AGA CCC AGG CAG AGT CA-3’ 
Vegfa forward primer: 5’-TGC GGA TCA AAC CTC ACC AA-3’ 
Vegfa reverse primer: 5’-TGT CTT TCT TTG GTC TGC ATT CAC-3’ 
 52 
Primer specificity was tested using end-point PCR (following protocol described in 
section 2.3) for their amplification capacity from DNase-treated RNA samples and 
reverse transcribed cDNA templates. Only those primer pairs were used for qRT-
PCR, which showed a product at the correct anticipated size and only in the cDNA 
amplification reactions. 
 
The SYBR Green JumpStart Taq ReadyMix kit was used for qRT-PCR experiments 
following manufacturers’ instructions. All samples were run in triplicate and with 4 
biological replicates for each mdx and BL/10 cardiomyocyte serum starvation time-
point. BL/10 and mdx heart tissue cDNA samples were also run in triplicate for each 
gene of interest and the HKGs. Each reaction consisted on 5µl of SYBR green mix, 
0.1µl ROX reference dye, 1.9µl of NFW, 0.5µl of the forward primer, 0.5µl of the 
reverse primer and 2µl of cDNA template or NFW for no-template control (NTC) 
reactions. Reactions were prepared in a class 1 laminar flow cabinet and loaded onto 
384-well plates, sealed with an adhesive sheet and centrifuged for 2min at 1,200g. 
The QuantStudio7 thermocycler was set up to quantify primer product amplification 
using the ΔΔCt method, SYBR green chemistry and ROX as the reference dye. The 
following cycling parameters were used: 
Step 1) 2min 50°C for sample warm-up; 
Step 2) 10min 95°C for initial denaturation; 
Step 3) 15sec 95°C for denaturation; 
Step 4) 1min 60°C for annealing, extension and fluorescence reads; 
Step 5) Steps 3 and 4 were repeated for another 39 cycles, followed by: 
Step 6) 15sec 95°C for denaturation 
Step 7) 1min 60°C for annealing and extension 
Step 8) gradual temperature rise at 0.05°C/sec to 95°C for melt curve data. 
 
Results were recorded on the QuantStudio software and exported into Microsoft 
Excel for further analyses. Samples with more than one melt curve peak were 
omitted. Outliers were omitted in sample triplicates where the Ct value range 
exceeded 1 unit. Remaining Ct values were used to calculate the mean value for 
each individual sample and gene combination. ΔCt values for each sample were 
determined by subtracting the HKG Ct value from the GOI Ct value, i.e. ΔCt = 
Ct(GOI) – Ct(HKG). ΔΔCt was determined for each sample comparison within a set 
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of ΔCt expression values for a GOI, i.e. ΔΔCt = ΔCt(sample1) – ΔCt(sample2). These 
values represented the relative expression base 2 logarithm fold change (Log2FC) in 
gene expression. Nominal relative expression FC values were determined by taking 
2 to the power of the negative value of ΔΔCt, i.e. FC = 2-ΔΔCt. 
 
Tpt1 and Hsp90ab1 primer pair efficiency was assessed by creating a scatter plot of 
their qRT-PCR Ct values against the base 10 logarithm (Log10) of the sample RNA 
concentrations reverse transcribed for cDNA template. A line of best fit was drawn in 
Microsoft Excel and the slope of the curve used to calculate efficiency values from 
the following formula: Efficiency=10^(-1/slope). 
 
2.12 Protein Extraction and Western Blotting 
Cardiomyocytes in a 24-well plate well were washed twice with PBS. The cells were 
detached in 100µl of PLB with a cell-scraper and transferred into a 1.5ml screw-cap 
microfuge tube. The well was washed with a further 100µl of PLB and the wash 
solution also transferred to the same microfuge tube. The cells were lysed by 
repeated aspiration with an insulin syringe. Protein content of primary cells was 
quantified using the BCA assay, following manufacturer’s instructions and diluting 
samples as appropriate to obtain absorbance values lying within the range of the 
standard curve. A standard curve was plotted alongside each quantification 
experiment with standards run in triplicate and samples in duplicate. Two absorbance 
values were obtained at both 550nm and 570nm on a Thermo Multiskan Ascent or 
Tecan plate reader. The raw absorbance values were normalised against a baseline 
average from three blank wells (containing PLB) and the measures from both 
wavelengths combined to get an average absorbance value for each standard and 
sample. The standard curve was plotted as a linear line of best fit on a scatter plot of 
average standard measures in Microsoft Excel. The standard curve equation was 
subsequently employed to determine the protein content of each sample by 
incorporating sample average absorbance measures into the equation. Samples 
were stored at -20°C. 
 
Samples were diluted to the lowest concentration in a given set of samples by adding 
the appropriate volume of lysis buffer, LDS and reducing agent. Pre-cast protein gels 
were run at 180V for 1h. Bis-Tris NuPAGE polyacrylamide gels and MES buffer with 
SeeBlue Plus2 standards were used when proteins smaller than 100kDa were 
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detected. Tris-Acetate NuPAGE gels and buffers with HiMark standards were used 
for detecting proteins larger than 100kDa. Protein was transferred from 
polyacrylamide gels onto PVDF membranes at 350mA constant current in a Bio-Rad 
transfer chamber, surrounded by ice, filled with 1l PTB pre-cooled to -10°C. 
SimplyBlue SafeStain was used as a protein loading control. Gels were washed three 
times with dH2O, stained with SimplyBlue SafeStain for 1h and washed twice with 
dH2O, for 1h and overnight at ambient temperature, prior to imaging.  
 
Membranes were washed three times for 10min with TBST, blocked with 5% milk 
powder in TBST for 1h at ambient temperature and probed with primary antibodies 
dissolved in 5% milk powder in TBST overnight at 4°C. The membranes were 
subsequently washed three times with TBST and probed with secondary antibodies 
conjugated with horseradish peroxidase (HRP) dissolved in 5% milk powder in TBST 
for 1h at ambient temperature. Before imaging the membranes were washed three 
times for 10min with TBST. Antibody dilutions for Western blotting were: mouse 
monoclonal NCL-DYS1 anti-dystrophin 1/250, mouse monoclonal anti-phospho-ERK 
1/100, rabbit polyclonal anti-β1AR 1/100, mouse monoclonal Hamlet anti-dysferlin 
1/100, rabbit polyclonal ab15277 anti-dystrophin 1/300, HRP conjugated goat anti-
mouse 1/5,000 and HRP conjugated goat anti-rabbit 1/5,000. 
 
Immunoblotted membranes were then transferred into a darkroom, incubated with 
ECL kit reagents for 5min at ambient temperature and light signal detected in a 
developer cassette using X-ray film. 
 
Protein band intensities were quantified in ImageJ software by drawing identical 
rectangular regions of interest around bands in each lane, then drawing a line under 
the signal peak and using the wand tool to determine the area under the peak curve. 
Microsoft Excel was used to normalise protein expression to skeletal myosin heavy 
chain (MHC) signal on SimplyBlue stained polyacrylamide gel images. The average 
intensity of all MHC bands was determined and expression coefficient values 
determined by dividing individual band intensities to the average value. The 
coefficients were used to multiply protein of interest band intensities to get a 
normalised vale. Contrast and brightness of bands was only adjusted for display 
purposes in Adobe Photoshop CC, but not before image analysis had been 
completed. 
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2.13 Drug Treatment 
Cardiomyocyte drug treatment was started at 24h of serum starvation and the 
therapeutic agent was replenished in SFCGM or SSCGM (specified in each 
individual experiment in results chapters) every 24h until the final time-point at 96h of 
serum starvation. Only 96h serum starvation time-point cells were analysed. The 
drugs trialled for their ability to reduce hypertrophy of embryonic mdx mouse 
cardiomyocytes were prednisolone 10µg/ml – 100pg/ml, dexamethasone 20µg/ml – 
200ng/ml (ethanol was required as the solubilising vehicle at 2% - 0.02% V/V 
corresponding to the drug concentrations), metoprolol 5mg/ml – 5ng/ml, captopril 
100µg/ml – 10ng/ml, A804598 1µM – 10pM (dimethyl sulfoxide was required as the 
solubilising vehicle at either 0.01% - 0.0000001% or 10% - 0.00001% V/V 
corresponding to the drug concentrations and specified in section 5.7) and KR-33028 
100µM – 10nM (polyethylene glycol was required as the solubilising vehicle at 0.85% 
- 0.000085% V/V corresponding to the drug concentrations). 
 
2.14 Viral Transduction 
A set of AAV vectors with naturally occurring serotypes expressing eGFP as a 
marker gene or µDys as a therapeutic gene were kindly provided by Dr. Oliver Müller 
from Heidelberg University. 
 
Cells were transduced at various multiplicity of infection (MOI) values, calculated as 
added viral genomes (vg) divided by the number of cells in culture. The appropriate 
volume of AAV stock solution was added directly to mdx cardiomyocytes in SSCGM 
medium at 24h of serum starvation. Cells were cultured for a further 72h to the final 
96h of serum starvation time-point and then analysed for either size or protein 
expression with assays detailed above or as follows. 
 
AAV construct expression in mdx cardiomyocytes transduced with eGFP was 
determined by imaging live cells in culture on the AxioVert200 every 24h up to 120h 
post-transduction. End-point eGFP expression was analysed in ICC stained cells 
imaged on the Nikon A1R and analysed in Nikon Elements 4.0. AAV construct 
expression in mdx cardiomyocytes transduced with µDys was determined by imaging 
ICC stained cells on the Nikon A1R and analysed in Nikon Elements 4.0, or by 
protein extraction and Western blotting with the ab15277 anti-dystrophin antibody. 
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2.15 Statistical Analyses 
All statistical analyses were performed in Microsoft Excel. Area and volume 
measurement comparisons from samples were analysed with one-tail Student’s t-
test. Skedasticity of data was assessed by Levene’s test, conducted by determining 
the absolute difference from sample average for each data point within the sample, 
followed by a single factor analysis of variance comparison of the absolute difference 
measures of the two samples of interest. The heteroskedasticity cut-off in Levene’s 
test was p-value<0.05. Student’s test significance cut-offs were p-value<0.05 for *, p-
value<0.01 for ** and p-value<0.001 for ***. Standard deviation of the sample was 
used to calculate standard error of the mean values, used for displaying error bars in 
figures.  
 
For cardiomyocyte size correlation testing, BL/10 and mdx cardiomyocyte average 
area measurements were plotted against corresponding volume measurements at 
given time-points of serum starvation. The line of best fit was drawn and the r2 values 
displayed. The Pearson’s product-moment correlation coefficients (r values) from 
BL/10 and mdx datasets were compared against critical r values at three levels of 
significance: 5%, 1% and 0.1%. The null hypothesis for the test stated that there was 
no difference between the samples. Determined r values that were lower than the 
critical r values allowed rejecting the null-hypothesis at the given level of significance 
and therefore concluding that there was significant correlation between the two 
compared parameters. 
 
Pearson’s chi-squared test was used to assess differences in protein expression 
between BL/10 and mdx cardiomyocytes. Normalised BL/10 protein sample band 
intensities were used as the expected values and mdx cardiomyocyte results as the 
observed values. 
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Chapter 3. Modelling Cardiac Hypertrophy with Primary Dystrophic 
Mouse Cardiomyocytes. 
 
3.1 Introduction and Aims 
Many DMD rescue and treatment therapies currently in clinical trials do not target the 
heart as successfully as skeletal muscle. This is due to cardiac tissue being much 
harder to access, and there is also a limited number of in vitro cardiac models for 
testing therapies in early development. For example, phosphodiesterase 5 (PDE5) 
inhibitors (Witting et al., 2014; Leung et al., 2014), peptide-conjugated 
phosporodiamidate morpholino oligonucleotides (PPMO) (Betts et al., 2015) and 
improved viral vectors (Schinkel et al., 2012) could all have been tested with an in 
vitro functional cardiomyocyte-based assay before costly in vivo experiments were 
commenced.  
 
This chapter aims to develop a technology that models the phenotype of the 
dystrophic heart in an in vitro setting. 
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3.2 Overview of the Technique 
In preliminary experiments, cardiomyocytes were isolated from the hearts of mouse 
neonates and embryos using an enzyme digest. Cell yields from embryo-derived 
cardiomyocytes were higher and those cardiomyocytes adhered more readily to 
collagen-coated plastic. Though the heart predominantly consists of contracting 
cardiomyocytes (Maillet et al., 2013), the resulting primary cell population was found 
to be heterogeneous, with fibroblast-like cells being the main other cell type. Pre-
plating on collagen-coated vessels for 2h was identified as the necessary duration to 
enrich the primary cell population for cardiomyocytes prior to plating the cells 
remaining in suspension onto multi-well dishes (collaborative experiment with MRes 
student Tom Slater).  
 
A standardised protocol was designed, where hearts were collected from embryos at 
day 17.5 of gestation (E17.5). This fixed age of mouse embryos was chosen because 
by E15 the murine heart is fully formed (S. M. Evans et al., 2010; Xin et al., 2013) 
and the chosen timing within the gestation time-line was not too close to the female 
birthing. A fixed day was chosen to obtain consistent results, minimising any potential 
effect of remaining developmental changes during rodent gestation. A time-line in 
figure 3.1 depicts the standardised experimental set-up. Cardiomyocytes were 
initially cultured for 48h in high-serum CGM, followed by a change to serum 
starvation CGM and maintained in culture for a further 96h. Cells were fed with fresh 
medium every 24h. 
 
 
Figure 3.1. The time-course of primary cardiomyocyte culture. Cells were cultured in 
serum-rich growth medium for 48h, followed by serum starvation for 96h, feeding with 
fresh medium every 24h. 
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3.3 Establishing a Conditionally Immortalised Primary Cardiomyocyte Cell-line 
The number of cells obtained from each experiment was dependent on the number of 
embryos in the contributing litter. Consequently, experimental design was limited by 
litter size as well as subject to biological variability between litters. This puts 
limitations on the ability to replicate observations due to the large numbers of timed 
matings required to overcome variability. As an alternative to the culture of primary 
cardiomyocytes, attempts were made to isolate an immortalised cardiomyocyte cell 
line culture. Transgenic CBA;B10-Tg(H2Kb-tsA58)6Kio/Crl mice (Immorto mice) on a 
C57BL/10 background (Jat et al., 1991) harbour a construct expressed under the 
mouse major histocompatibility complex class I gene (H2Kb) promoter expressing 
tsA58, a thermolabile mutant region of the simian vacuolating virus 40 (SV40) large 
and small tumour antigens, capable of immortalising cells under permissive 
conditions in vitro. These two permissive conditions were induction of tsA58 construct 
expression by supplementing culture medium with interferon gamma (IFNγ), which 
induces expression from the H2Kb gene promoter, and incubation at 33°C to avoid 
inactivation of the thermolabile tumour antigen products. 
 
A visual summary of mouse breeding procedures to obtain mdx-Immorto mice is 
presented in figure 3.2. Parental transgenic male C57BL/10::H-2Kb-tsA58+/- (BL/10-
Immorto) mice, heterozygous for the Immorto construct, were crossed with 
homozygous C57BL/10ScSn-Dmdmdx (mdx) female mice. Half of the resulting F1 
male progeny in the litters from this crossing were hemizygous for the dystrophin 
mutation and also hemizygous for the conditionally immortalising construct (mdx-::H-
2Kb-tsA58+/-). Presence of the tsA58 construct was confirmed with PCR and agarose 
gel electrophoresis (figure 3.3), where DNA from mice heterozygous for the Immorto-
construct yielded a 1kbp band. The F1 male mdx-Immorto mice were subsequently 
crossed with homozygous mdx female mice. The resulting F2 progeny were all 
homozygous for the mdx mutation and, in proportions predicted by Mendelian 
genetics, half the litters were heterozygous for the presence of tsA58 (figure 3.2). 
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Figure 3.2. Deriving mdx::H-2Kb-tsA58+/- mice. Male heterozygous Immorto-mice on 
the BL/10 background were crossed with mdx female mice. Male F1 progeny 
heterozygous Immorto-mice were crossed again with mdx female mice and F2 
embryos used for cardiomyocyte isolation. 
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Figure 3.3. Genotyping for the Immorto-construct with agarose gel electrophoresis. 
PCR products of gDNA obtained from F1 progeny in lanes 2-11. Samples in lanes 2, 
5, 6, 7 and 8 yielded a 1kbp DNA band, which indicates those pups were 
heterozygous for the immorto construct. Lanes 1 and 14 were loaded with a marker 
containing DNA fragments of known size, lane 12 contains gDNA from a C57BL/10-
Immorto+/- mouse as a positive control for amplification of the 1kbp product and lane 
13 contains TEB as a no-template negative control. 
 
Cardiomyocytes were isolated from the embryos of pregnant mice from the F2 
generation (figure 3.2). 50% of the embryos derived from these crosses were 
predicted to be Immorto positive, conditionally immortalised cardiomyocytes were 
anticipated to outgrow tsA58-negative cells and therefore embryo genotyping was 
unnecessary. These cells were maintained and observed to proliferate when cultured 
under permissive conditions. However, once trypsinised, the cardiomyocytes failed to 
re-adhere to collagen-coated tissue culture vessels. 
 
Furthermore, fibroblasts proliferated much more rapidly and were readherent post-
passaging, overgrowing cardiomyocytes over time. For these reasons clonal 
selection was never performed on mdx-Immorto cardiomyocytes and consequently, 
each subsequent experiment is restricted to cells obtained from the hearts of one 
biological litter with a mixed population of male and female embryonic cells. 
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3.4 Inducing a Hypertrophic Response in Primary Embryonic Cardiomyocytes 
with SFCGM 
 
3.4.1 Area of Primary Cardiomyocytes Cultured in SFCGM 
An endothelin-driven hypertrophic response was initially envisaged as a necessity 
when designing the experimental model (Fujioka et al., 2006). Cardiomyocytes were 
cultured in CGM for 48h, at which point the medium was discarded, cells were rinsed 
with PBS and fresh serum-free CGM (SFCGM) added. Knocking out serum content 
from the medium avoided any undesirable inhibitory effects or interactions stemming 
from factors in sera interacting with endothelin and treatment compounds. Initial 24h 
incubation prior to drug treatment was included in the protocol to allow 
cardiomyocytes to get accustomed to serum starvation. Observations of untreated 
mdx cardiomyocytes revealed that by 96h of serum starvation the cells were 
spontaneously becoming larger and it was therefore hypothesised that serum 
starvation triggered a hypertrophic response in mdx cardiomyocytes even without 
pharmacological induction of hypertrophy, illustrated in figure 3.4. 
 
 63 
Figure 3.4. Primary mdx mouse E17.5-derived cardiomyocytes. Cells at 0h (A), 24h 
(B) and 96h (C) of serum starvation were stained with Alexa Fluor 594 and α-actinin 
in red, as well as Oregon Green-conjugated phalloidin in green and nuclei with DAPI 
in blue. Phalloidin binds to F-actin in the cytoskeleton of all cells, whereas α-actinin 
specifically stains muscle cells, here cardiomyocytes. Panel D depicts cells at 0h 
serum starvation and is a no primary anti-α-actinin antibody control. The scale bar in 
panel A represents 200µm and applies to all four panels. 
 
Primary cardiomyocyte size was quantified by manually measuring the area of cells 
expressing α-actinin, detected by immunocytochemistry (ICC), in AxioVision LE 
software (figure 3.5). These area measurements were subsequently compared to 
BL/10 control mouse cardiomyocyte data, also obtained following the same serum 
starvation and ICC protocol. 
 
 
Figure 3.5. Measuring the area of cardiomyocytes with AxioVision LE software. (A) 
Cardiomyocytes were stained with α-actinin in green; all cells were stained with Alexa 
Fluor 594-conjugated phalloidin in red and nuclei with DAPI in blue. (B) Area 
measurements of cells were obtained by manually drawing boundaries around 
individual cells. 
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The results of this comparison between mdx and BL/10 cardiomyocytes are 
illustrated in figure 3.6. Cardiomyocytes from BL/10 mouse embryos did not show a 
distinguishable response to serum starvation, with the difference in the change in 
average size at 24h and 96h of serum starvation being a slight reduction of 45µm2 
from 1,890µm2 at 24h (n=32) to 1,845µm2 by 96h (n= 24; p=0.426; one-tailed 
Student’s t-test). Cardiomyocytes from mdx embryos increased in size by 1.5-fold 
between 24h and 96h of serum starvation, gaining 835µm2 in area from 1,659µm2 at 
24h (n=20) to 2,494µm2 at the 96h time-point (n=23; p<0.05; one-tailed Student’s t-
test).  
 
Figure 3.6. The average area of cardiomyocytes at 24h and 96h of serum starvation 
with SFCGM. BL/10 cardiomyocytes were unaffected by serum starvation, in contrast 
to mdx cardiomyocytes, which showed a significantly increase in size. Error bars 
represent SEM, NS = Non-significant, * = p-value<0.05, ** = p-value<0.01. 
 
Levene’s test revealed that three of the four possible comparisons between the data 
sets could be considered homoskedastic (with indistinguishable variance; table 3.1) 
while one comparison was heteroskedastic (with higher variance observed in the 
mdx 96h cell areas than mdx 24h). Student’s t-test analyses appropriate to variance 
type revealed that mdx cardiomyocytes serum starved for 96h were significantly 
larger than both, mdx cells serum starved for 24h (p<0.05) and BL/10 cells serum 
starved for 96h (p<0.01). The difference between BL/10 24h and 96h serum starved 
cells, as well as BL/10 24h and mdx 24h serum starved cells did not reach statistical 
significance. These comparisons are summarised in table 3.1. 
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Comparison Levene's Test p-value Variance t-test p-value 
BL/10 24h v BL/10 96h 0.6669 Equal 0.4257 
mdx 24h v mdx 96h 0.0346 Unequal 0.0025 
BL/10 24h v mdx 24h 0.9100 Equal 0.1125 
BL/10 96h v mdx 96h 0.0793 Equal 0.0139 
Table 3.1. Statistical analyses of serum starved cardiomyocyte area measurements. 
A Levene’s test p-value less than 0.05 was necessary to deem variance between two 
sets of data unequal. Skedasticity of data was taken into consideration when 
performing t-tests. 
 
Binning data points into 1,000µm2 data ranges and calculating the percentage of 
cells falling within the boundaries of each bin demonstrated a shift in cell area 
distribution in mdx cardiomyocyte size from 24h to 96h of serum starvation. This 
distribution shift was not replicated in control cells, thus confirming the physiological 
difference in dystrophic cardiomyocytes (figure 3.7). 
 
 
Figure 3.7. Distribution of control and dystrophic cardiomyocyte area. A distribution 
shift from smaller to larger cells across the serum starvation time course was evident 
in mdx E17.5-derived cardiomyocytes, but not in control cells. 
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3.4.2 Volume of Cardiomyocytes Cultured in SFCGM 
BL/10 and mdx cardiomyocyte volume was subsequently quantified by acquiring Z-
stack images on a confocal microscope and semi-automated analysis using Volocity 
software to measure cell volume. A screen-shot of the software masking cells 
positive for α-actinin staining is shown in figure 3.8.  
 
 
Figure 3.8. Using Volocity for semi-automatic quantification of cardiomyocyte volume. 
Cardiomyocytes were automatically detected by the “Find Objects” function, 
detecting cells positive for α-actinin staining, here gated in beige. Objects with 
multiple or no nuclei, detected with DAPI staining in blue, were manually omitted from 
the analysis. 
 
Three litters of BL/10 embryos and six litters of mdx embryos were used to isolate 
primary cardiomyocytes. BSc student Sophie Wright performed the volume 
measurement image analysis for one of the BL/10 and three of the mdx biological 
replicates. MRes student Elizabeth Roberts performed the volume analysis for the 
other two BL/10 and three of the mdx biological replicates. Figure 3.9 depicts the 
mean value of average volume measurements from biological replicates at each 
time-point. BL/10 cardiomyocytes were on average 5,000µm3 smaller by 96h serum 
starvation (49,000µm3; n=1,174), in comparison to the 24h time-point (54,000µm3; 
n=1,223), but this reduction was non-significant. Cardiomyocytes from mdx embryos, 
 67 
on the other hand, became significantly larger, by 1.5-fold from an average of 
66,000µm3 at 24h of serum starvation (n=1,197) to 99,000µm3 by 96h of serum 
starvation (n=826). All of the compared datasets showed equal variance when 
compared with Levene’s test set to p<0.05 stringency for detecting 
heteroskedasticity. The statistical data from volume measurements are summarised 
in table 3.2 and the results complemented the hypertrophic trends displayed in area 
measurements. 
 
 
Figure 3.9. The average volume of cardiomyocytes at 24h and 96h of serum 
starvation with SFCGM. BL/10 cardiomyocyte volume remained similar throughout 
the course of serum starvation, contrary to mdx cardiomyocytes, which significantly 
gained in size. Error bars represent SEM, NS = Non-significant, * = p-value<0.05, ** 
= p-value<0.01. 
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Comparison 
Levene's Test 
p-value Variance 
t-test p-
value 
BL/10 24h v BL/10 96h 0.9591 Equal 0.4116 
mdx 24h v mdx 96h 0.2832 Equal 0.0270 
BL/10 24h v mdx 24h 0.7029 Equal 0.2955 
BL/10 96h v mdx 96h 0.4472 Equal 0.0051 
Table 3.2. Statistical analyses of serum starved cardiomyocyte volume measurement 
comparisons. A Levene’s test p-value of less than 0.05 was necessary to deem 
variance between two sets of data unequal. Skedasticity of data was taken into 
consideration when performing t-tests. 
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3.5 Dystrophin Expression in E17.5-derived Cardiomyocytes 
It was subsequently determined whether dystrophin was expressed in E17.5-derived 
BL/10 cardiomyocytes. ICC was used to detect dystrophin protein expression with 
MANDRA1 and ab15277 primary antibodies. MANDRA1 detection gave inconsistent 
results with very faint halos of positive signal surrounding some cells, shown with an 
arrow in panel A of figure 3.10. This signal was obtained only at maximum laser 
power and 130V gain and most of the cardiomyocytes showed punctate cytosolic 
signal, which was also faintly visible as a background hue in the no-primary-antibody 
control image, taken with the same acquisition parameters (panel B in figure 3.10). 
Contrastingly, the ab15277 antibody only detected nuclear signal for dystrophin, both 
in cardiomyocytes (also positive for α-actinin signal), shown with arrowheads in panel 
C of figure 3.10, and other cells (negative for α-actinin signal) in the same culture 
sample. The nuclear signal, however, was not present in the control sample (panel D, 
figure 3.10). 
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Figure 3.10. Dystrophin signal in ICC images of BL/10 E17.5 cardiomyocytes. Panel 
A shows dystrophin expression in BL/10 cardiomyocytes with MANDRA1 signal in 
green, indicated by an arrow, and panel B is the corresponding control image where 
no primary antibody was used. Panel C depicts cardiomyocytes stained with α-
actinin, in green, and ab15277 signal for dystrophin in red. The arrowheads indicate 
cardiomyocytes showing nuclear dystrophin staining, not present in the 
corresponding no primary antibody control image in panel D. Nuclei were detected in 
all images with DAPI, in blue. In panels A and B scale bars represent 50µm, in 
panels C and D 200µm. 
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Protein lysates from mdx and BL/10 cardiomyocytes at each 24h time-point of serum 
starvation were prepared. A total of five samples (0h, 24h, 48h, 72h and 96h 
following serum starvation) for BL/10 and mdx were used for a Western blot, probed 
with NCL-Dys1 primary antibody against dystrophin. The results are shown in figure 
3.11 and confirm that BL/10 E17.5-derived cardiomyocytes express dystrophin 
throughout the serum starvation time-course, whilst mdx cardiomyocyte lysates do 
not show detectable dystrophin protein. 
 
 
Figure 3.11. Detecting dystrophin expression by Western blotting with NCL-Dys1 
antibody. The expected band for dystrophin (in the range of 427kDa) is visible in 
BL/10 cardiomyocyte samples in lanes 2-6 and remains constant throughout the 
serum starvation time-course, whilst mdx E17.5-derived cardiomyocytes (lanes 7-11) 
do not express dystrophin.  
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3.6 Optimising Image Analysis and Serum Starvation 
 
3.6.1 Semi-automation of Area Measurements Using Nikon Elements Software 
The analysis process of cardiomyocyte ICC images was semi-automated with NIS-
Elements software. A signal threshold-based algorithm automatically drew 
boundaries around events targeted by a mouse cursor click. The area from within 
each boundary was identified and added to a list of measured data reads in the 
software, illustrated in figure 3.12.  
 
 
Figure 3.12. Semi-automation of cardiomyocyte area measurements with NIS-
Elements. Cardiomyocytes were identified by α-actinin signal, here in red. The area 
of each cell was automatically detected in response to a mouse cursor click that 
triggered a boundary to be drawn around the cell, based on a signal threshold 
algorithm. For illustrative purposes three information boxes have been included in 
this figure, showing individual area reads for the adjacent cardiomyocytes. 
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3.6.2 Effect of 1% FBS in Serum Starvation Medium 
It was observed that a large number of cells were not surviving the complete 
omission of serum from CGM. The medium was therefore supplemented with 1% 
FBS (SSCGM) in order to improve cell survival. Comparative BL/10 and mdx 
cardiomyocyte culture experiments were performed to assess the effect of complete 
serum omission (SFCGM), low serum presence (SSCGM) and full serum (CGM) on 
cell size, summarised in figure 3.13 and the corresponding statistics shown in table 
3.3. The BL/10 cell isolation yielded enough cardiomyocytes to investigate 
intermediate time-points for all three culture media (0h n=1,231; SFCGM 24h n=353, 
48h n=98, 72h n=62, 96h n=76; SSCGM 24h n=531, 48h n=321, 72h n=806, 96h 
n=523; CGM 24h n=775, 48h n=305, 72h n=550, 96h n=418), whilst there were only 
enough mdx cardiomyocytes for 0h, 24h and 96h samples (0h n=226; SFCGM 24h 
n=154, 96h n=85; SSCGM 24h n=159, 96h n=78; CGM 24h n=175, 96h n=94).  
 
Both control and dystrophic cardiomyocytes showed improved survival and became 
larger when cultured in NCGM, accompanied by an increased fibroblast expansion 
rate and presence in the culture. This outcome was anticipated, due to increased 
availability of nutrients. However, for the purpose of therapeutic treatment of the 
hypertrophic response seen in mdx cardiomyocytes, serum presence was 
undesirable and culture in the full serum content CGM was not further explored. 96h 
culture in SSCGM caused BL/10 cardiomyocytes to become significantly larger than 
equivalent cells cultured in SFCGM. In contrast, mdx cardiomyocyte survival was 
improved, but the average area was not significantly affected by changing SFCGM to 
SSCGM. However, the BL/10 cardiomyocytes cultured in this experiment also 
showed a significant increase in area when serum starved both with SFCGM and 
SSCGM, a finding that contradicted with previous results. 
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Figure 3.13. The effect of CGM serum content on cardiomyocyte area. BL/10 and 
mdx cardiomyocytes were cultured in SFCGM (SF), SSCGM (SS) and CGM (N) and 
the average area value determined. Error bars represent SEM, NS = Non-significant, 
* = p-value<0.05, ** = p-value<0.01, *** = p-value<0.001. 
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Comparison 
Levene's Test 
p-value Variance t-test p-value 
BL/10 24h SF v BL/10 96h SF 0.000465839 Unequal 5.96575E-06 
BL/10 24h SS v BL/10 96h SS 2.03152E-16 Unequal 9.16971E-43 
mdx 24h SF v mdx 96h SF 9.15309E-09 Unequal 2.28576E-11 
mdx 24h SS v mdx 96h SS 8.65022E-05 Unequal 0.023747657 
BL/10 96h SF v BL/10 96h SS 0.051731444 Equal 0.007666469 
mdx 96h SF v mdx 96h SS 0.084729137 Equal 0.104364852 
Table 3.3. Statistical analyses of cultured cardiomyocyte area measurements. A 
Levene’s test p-value less than 0.05 was necessary to deem variance between two 
sets of data unequal. Skedasticity of data was taken into consideration when 
performing t-tests. 
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3.6.3 Correlation between Cardiomyocyte Area and Volume Data 
A study was conducted to verify the correlation between volume and area 
measurements in C57BL/10 and mdx cardiomyocytes. Six biological replicates of 
BL/10 cardiomyocytes at each of the five time-points – 0h (nArea=3,513; nVol=2,071), 
24h (nArea=2,594; nVol=1,467), 48h (nArea=2,263; nVol=1,252), 72h (nArea=1,788; 
nVol=1,111) and 96h (nArea=1,704; nVol=1,034) of serum starvation – were used to 
acquire area and volume measurements. Three biological replicates of mdx 
cardiomyocyte populations at each of three time-points – 0h (nArea=1,698; 
nVol=1,593), 24h (nArea=1,946; nVol=1,224) and 96h (nArea=2,249; nVol=1,028) of serum 
starvation – and two replicates at each of 48h (nArea=541; nVol=344) and 72h 
(nArea=493; nVol=288) of serum starvation time-points were used for acquiring volume 
and area measurements. Comparative analysis of Pearson product-moment 
correlation coefficients from SSCGM-treated control and dystrophic cells 
demonstrated a significant correlation between area and volume measurements in 
dystrophic, but not control cardiomyocytes (figure 3.14 and table 3.4). 
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Figure 3.14. Correlation plots of BL/10 and mdx cardiomyocyte area against volume. 
Each data point represents the area and volume measurements from the same 
sample at a specific time-point of serum starvation. 
 
Sample r Value n 
Deg. of 
F 
Critical 
Value 
p=0.05 
Critical 
Value 
p=0.01 
Critical 
Value 
p=0.001 Reject H0 
mdx 0.94262 13 11 0.553 0.684 0.801 Yes 
BL/10 0.24869 30 28 0.361 0.463 0.57 No 
Table 3.4. Correlation analysis of BL/10 and mdx cardiomyocyte area and volume 
measurements. Dystrophic mdx cardiomyocytes showed a significant positive 
correlation between increasing area and volume measurements (p<0.001=***). 
Control BL/10 cardiomyocytes showed a statistically non-significant positive 
correlation between size increases in area and volume measurements. 
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3.7 Large-Scale Serum Starvation Study 
In order to ensure the model was robust, thirteen biological replicates of BL/10 and 
ten of mdx cardiomyocytes were used for area measurements. Out of the thirteen 
BL/10 replicates three had enough data for 0h, 24h and 96h time-points, ten had 
measurements at all five serum starvation time-points – 0h, 24h, 48h, 72h and 96h. 
Out of the ten mdx replicates five had data for the same three time-points and the 
other five for all time-points. 
 
Volume measurements were also obtained from six of the BL/10 biological replicates, 
at all five time-points of serum starvation. One of the mdx replicates was used to 
obtain 0h, 24h and 96h serum starvation volume measurements, whilst another two 
were used for acquiring data from all five serum starvation time-points. These 
samples were also used for the correlation study in figure 3.14. 
 
3.7.1 Comparison of Combined Area and Volume Data 
The mean values of averaged cardiomyocyte size at each time-point of serum 
starvation were obtained to avoid biological replicates with larger population sizes 
having a disproportionate weight on overall results. Both area and volume 
measurements are compared and summarised in figure 3.15. On average mdx 
cardiomyocytes increased in area from 2,870µm2 at 24h of serum starvation to 
4,070µm2 at 96h, which equates to a nominal change of 1,200µm2 and a 1.4-fold 
increase in size (BL/10 0h n=8,216; BL/10 24h n=6,284; BL/10 48h n=3,331; BL/10 
72h n=3,378; BL/10 96h n=4063; mdx 0h n=7,726; mdx 24h n=5,624; mdx 48h 
n=2,858; mdx 72h n=1,847; mdx 96h n=5,112). The equivalent volume data showed 
a nominal increase of 65,000µm3 and a 1.5-fold increase of mdx cardiomyocyte size 
from 119,000µm3 at 24h to 184,000µm3 at 96h of serum starvation (n numbers 
equivalent to those stated in sub-section 3.6.3). 
 
In area measurements mdx cardiomyocytes were only significantly larger than BL/10 
cardiomyocytes at 72h (p<0.05) of serum starvation. The average volume of mdx 
cardiomyocytes was significantly greater at 72h (p<0.001) and 96h (p<0.01), but non-
significantly larger at 0h, 24h and 48h of serum starvation. The statistical analyses of 
these datasets are summarised in table 3.5. 
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Figure 3.15. Average area and volume of BL/10 and mdx cardiomyocytes across the 
serum starvation time-scale. One-tail Student’s t-tests were performed, taking sample 
variance into consideration. Error bars represent SEM, NS = Non-significant, * = p-
value<0.05, ** = p-value<0.01, *** = p-value<0.001. 
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Measurement Comparison 
Levene's Test  
p-value Variance 
t-test  
p-value 
Area BL/10 0h v mdx 0h 0.17586204 Equal 0.0748 
Area BL/10 24h v mdx 24h 0.220130292 Equal 0.4069 
Area BL/10 48h v mdx 48h 0.914752501 Equal 0.3724 
Area BL/10 72h v mdx 72h 0.006473062 Unequal 0.0101 
Area BL/10 96h v mdx 96h 0.258105054 Equal 0.2984 
Volume BL/10 0h v mdx 0h 0.003326526 Unequal 0.1374 
Volume BL/10 24h v mdx 24h 0.218634779 Equal 0.0676 
Volume BL/10 48h v mdx 48h 0.125922308 Equal 0.0676 
Volume BL/10 72h v mdx 72h 0.314641411 Equal 0.0001 
Volume BL/10 96h v mdx 96h 0.152576297 Equal 0.0010 
Table 3.5. Statistical analyses of serum starved cardiomyocyte area and volume 
measurement comparisons. A Levene’s test p-value less than 0.05 was necessary to 
deem variance between two sets of data unequal. Skedasticity of data was taken into 
consideration when performing t-tests. 
 
3.7.2 Combined Area Data Distribution 
Cardiomyocyte area measurements were binned into 48 size range bins, increasing 
at 250µm2 per bin from 0<250µm2 as the lowest bin range to events above 
12,000µm2 as the highest bin. Biological replicate data at each time-point were 
individually binned and the relative frequency of events falling into bins independently 
determined. The mean of biological replicate frequency values in bins were 
calculated and plotted as line graphs for time-points of serum starvation (figure 3.16). 
The distribution of BL/10 and mdx cardiomyocyte area measurements was fairly 
similar. Longer serum starvation caused the distribution to spread out, the frequency 
peak to shrink and shift towards higher value range bins in both BL/10 and mdx 
cardiomyocyte samples.  
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Figure 3.16. BL/10 and mdx cardiomyocyte area measurement data distribution. Area 
measurements of BL/10 and mdx serum starved cardiomyocytes were binned into 
size ranges and the relative frequencies determined for each biological replicate. 
Mean frequencies were calculated and plotted for each serum starvation time-point 
for both BL/10 (A) and mdx (B) samples. With increasing serum starvation time the 
distribution peaks spread across the size range bins and shifted towards higher 
ranges. 
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3.7.3 Combined Volume Data Distribution 
Cardiomyocyte volume measurements were also binned into 48 size range bins, 
increasing in 10,000µm3 increments per bin from 0<10,000µm3 as the lowest bin 
range and above 480,000µm3 as the highest bin. The relative frequencies were 
calculated in the same way as for area measurements and the mean values for each 
time-point plotted for both BL/10 and mdx cardiomyocytes. The distribution of BL/10 
and mdx volume data differed drastically. While both showed spreading out of the 
data and lowering peak frequency values with increasing serum starvation time, the 
differences in mdx samples were much greater (figure 3.17). There was a clear shift 
in volume distribution from 0h to 24h of serum starvation in both, BL/10 and mdx, 
cardiomyocyte populations, but whilst the mdx distribution plots continued to shift 
towards larger bin ranges with increasing serum starvation duration, BL/10 samples 
contrasted by remaining more or less constant in the same place as the 24h plot. 
These data supplement the significant increase in mdx cardiomyocyte average 
volume as opposed to BL/10 data and further illustrate the differences between 
control and dystrophic cardiomyocytes. 
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Figure 3.17. BL/10 and mdx cardiomyocyte volume measurement data distribution. 
Volume measurements of BL/10 and mdx serum starved cardiomyocytes were 
binned into size ranges and the relative frequencies determined for each biological 
replicate. Mean frequencies were subsequently calculated and plotted for each 
serum starvation time-point for both BL/10 (A) and mdx (B) samples. An increase in 
serum starvation time caused both BL/10 and mdx cardiomyocytes to become larger 
and thus spread the mean frequency plots out, reducing the nominal peak frequency 
value and shifting it towards larger bin ranges. This trend was augmented throughout 
the serum starvation time-course in mdx cardiomyocyte volume data, but not in 
BL/10 samples, where an initial shift within the first 24h of serum starvation did not 
continue to magnify. 
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3.8 Discussion 
The primary mouse E17.5-derived cardiomyocyte serum starvation protocol was 
developed to provide an outcome measure for testing novel therapies aimed at 
rescuing the cardiac phenotype of DMD. The technique was optimised in several 
ways to reduce variables and increase consistency in the model, allowing it to be 
used to assess differences between control BL/10 and dystrophic mdx 
cardiomyocytes. It was concluded that, in response to serum starvation, mdx 
cardiomyocytes became significantly larger than BL/10 cardiomyocytes. 
 
3.8.1 Establishing Conditionally Immortalised Cardiomyocyte Cell Lines 
Previous attempts to use SV40-based conditional immortalisation to develop 
cardiomyocyte cell lines have only yielded one widely published cell line that can be 
passaged in vitro and recovered after freezing (White et al., 2004). The HL-1 cells 
have been derived from AT-1 cells, where the SV40 tumour antigen is expressed 
under the ANP promoter. AT-1 cells are atrial cardiomyocytes, derived from atrial 
tumours, and early attempts to produce such cardiac-specific transgenic models 
were met with disappointing results, such as tumorigenesis and arrhythmias due to 
the tumour antigen expression (Field, 1988). In the context of DMD it is pivotal to use 
ventricular or both ventricular and atrial cardiomyocytes for testing therapeutics. This 
is due to the DMD phenotype being more severe in ventricular muscle. Hence, it was 
not considered an optimal choice to develop conditionally immortalised 
cardiomyocyte cell lines from crossing mdx mice with the mice which AT-1 cells 
originated from. Rybkin et al. (2003) developed an Nkx2.5 promoter-driven large T 
antigen ventricular tumour-derived cell line. Despite these cells displaying voltage-
dependent contractile potential, they did not fully differentiate and did not consistently 
maintain contractile properties when electrically stimulated. 
 
Consequently, the Immorto-mouse described in this chapter – with an H2Kb 
promoter-driven tsA58 construct – was chosen to generate a model by crossing with 
mdx mice. The primary cells isolated from embryo hearts were universally 
conditionally immortalised and thus also allowed both ventricular and atrial 
cardiomyocytes to be extracted and cultured. However, much like previous attempts 
to establish cardiac immortalised cell lines, it was cell adhesion post-trypsinising and 
freezing that remained an issue for passaging these cardiomyocytes. Various 
freezing media and a multi-step detachment protocol (Maltsev et al., 1994) were 
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tested to solve these issues, but with little success. Therefore, establishing a 
conditionally immortalised mdx cardiomyocyte cell line from mdx-Immorto mouse 
embryo hearts was not pursued any further. 
 
3.8.2 Differences in BL/10 and mdx Mouse Cardiomyocyte Response to Serum 
Starvation 
Preliminary data from cardiomyocytes serum starved with SFCGM implied that mdx 
cardiomyocytes became larger in area when compared to control cardiomyocytes. It 
was subsequently confirmed that the cells were not becoming flatter in culture and 
gained in size when volume measurements from Z-stack images were acquired and 
compared between dystrophic and control cells. However, when serum starved with 
SSCGM, subsequent comparison of the two types of cardiomyocytes revealed that 
BL/10 cardiomyocytes were gaining size in area measurements, whilst the volume of 
these cells did not catch up in the same way. 
 
These opposing results in two types of measurements indicated that the control 
cardiomyocytes were becoming flatter in adherent culture, whilst mdx 
cardiomyocytes were increasing in size in three dimensions. The correlation (figure 
3.14 and table 3.4) as well as size distribution studies (figures 3.16 and 3.17) 
supported this conclusion. BL/10 cardiomyocyte area and volume measurements did 
not show a significant positive correlation and therefore cells that were becoming 
larger in area were not necessarily increasing in volume, whilst mdx cardiomyocyte 
area and volume measurements displayed a strongly significant positive correlation. 
There was also a clear difference in the distribution of area and volume 
measurements when BL/10 and mdx cardiomyocyte data were compared. The 
changes in cardiomyocyte size distribution were similar in area measurements, whilst 
mdx cardiomyocytes presented a clear shift towards higher size, observed in both the 
bin with highest counts and general spread of data across a wider range of larger 
size bins. 
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3.8.3 Further Optimisation, Functional Studies and Translating the Technique 
to Human Cardiomyocytes 
Despite the limitations of experimental design due to small cell numbers per 
biological replicate, it would be interesting to see if atrial or ventricular cells were 
more likely to become hypertrophic and whether removing either from the cultured 
population affected the remaining cells’ response to serum starvation. Atrial 
cardiomyocytes have a strong contribution to ANP-led hypertrophic signalling (Zois et 
al., 2014) and therefore specifically enriching the population for cells of ventricular 
origin may have significant effects on the hypertrophic response. A better idea of 
whether specifically ANP-signalling was going to be an important factor in the 
hypertrophic response was established when analysing data from gene expression 
studies, discussed in more detail in chapter 4. 
 
Fluorescence-activated cell sorting (FACS) may have helped to purify the 
cardiomyocyte population even further in comparison to pre-plating. However, 
removing myofibroblasts altogether from the heterogeneous population of primary 
cells may have had effects on the hypertrophic response of the cardiomyocytes 
(Kamo et al., 2015). It can also be argued that a low presence of contaminating cell 
types in cardiomyocyte culture may be beneficial for cell survival and pivotal for 
maintaining contractile interactions (Parodi & Kuhn, 2014). 
 
Several research groups have derived DMD patient iPSC lines. Some of these have 
also been differentiated into cardiomyocytes and used for testing various rescue 
therapies (Dick et al., 2013; Lin et al., 2015). Taking into consideration the recorded 
effects of choosing the tissue of origin for cells to be reprogrammed into iPSCs, the 
epigenetic memory of fibroblasts (the most prevalently reprogrammed cell type) may 
not allow for as close of a comparison in cardiomyocyte hypertrophy between iPSC-
derived and primary cardiomyocytes (Lee et al., 2014) (Dixit & Katare, 2015). 
Accordingly, data on DMD patient iPSC-derived cardiomyocyte hypertrophic 
response to serum starvation will be much anticipated in order to establish any 
differences from mouse E17.5-derived cardiomyocytes. Should human 
cardiomyocytes show a similar response to serum starvation then the model could be 
improved by not only allowing therapeutic testing in human cells, but also by 
introducing a limitless supply of biological replicate cardiomyocytes. 
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Considering this platform was developed as an outcome measure for therapies it was 
concluded that mdx cardiomyocyte area measurements were subsequently to be 
used for rescue therapy studies. The reasons for this were that although the relative 
size increase from 24h to 96h of serum starvation dropped from 1.5-fold in SFCGM-
induced hypertrophy to 1.4-fold in SSCGM-induced hypertrophy, the nominal 
difference increased from 850µm2 to 1,200µm2, respectively.  
 
It was encouraging to witness a wider nominal area change margin emerge between 
the 24h and 96h serum starvation time-points, because these were deemed the start 
and end-point for assessing efficacy of therapeutics. A wider margin in nominal 
values therefore improved the sensitivity of this model, improving interpretation of 
subtler changes in cardiomyocyte size in response to therapies, witnessed in some of 
the therapeutic compound trials in chapter 5. 
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3.8.4 Potential for an mdx Cardiomyocyte-based Model in Research 
As briefly mentioned in the introduction section of this chapter, several potential 
therapeutic avenues for DMD treatment could be tested using this model. There is an 
increasing range of PPMO compounds constantly being developed and tested for 
their efficacy (Betts et al., 2012; Betts et al., 2015). A screen using this hypertrophy 
model to test delivery to cardiac cells in vitro may improve the work-flow of testing 
therapeutic potential of the new chemical variations. 
 
When discussing the much-anticipated, but discouraging results from the sildenafil 
clinical trials it was noted that tadalafil may exhibit higher specificity towards PDE5 
inhibition (Leung et al., 2014). In fact, it has been reported that tadalafil improves Z-
disc organisation in dystrophic hearts (De Arcangelis et al., 2015) in a similar way 
reported in sildenafil treatment of hypertensive dogs (Bishu et al., 2011). These 
results could be replicated in the mdx cardiomyocyte model and would also elucidate 
the compounds’ functional effect on hypertrophy. Testing both tadalafil as well as 
sildenafil using the mdx cardiomyocyte model may give an answer not only to any 
differences in compound efficacy, but also to any differences between therapeutic 
assessment in an early symptomatic environment as opposed to adult individuals. 
The two sildenafil clinical trials (Leung et al., 2014; Witting et al., 2014) showed no 
significant effect on the cardiac phenotype, but only recruited adult patients with 
progressed heart disease or BMD patients who have a milder and slowly progressing 
phenotype. Hypertrophy studies in mdx cardiomyocytes utilising this model may 
therefore provide results for assessment of therapeutic potential in an earlier 
pathological setting. 
 
Many viral vectors are being optimised for delivery of gene therapy to DMD patients 
and some have reached clinical trial phase. Improved skeletal muscle in vitro testing 
techniques have been published (Jørgensen et al., 2009), but an in vitro model for 
fast screening in a cardiac setting is also required. The potential of this mdx 
cardiomyocyte hypertrophy model as a method for viral vector delivery is assessed 
and discussed in chapter 5 of this thesis. 
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Chapter 4. RNA-Seq Analysis of Cardiomyocytes 
 
4.1 Introduction and Aims 
Current developments in understanding the DMD cardiac pathology are limited due 
to lack of tissue availability and appropriate models. The plummeting cost of 
sequencing over the past decade has made whole transcriptome studies in rare 
diseases more attainable and cost-effective, helping to identify disease causing 
genes and phenotype progression mechanisms (Wang et al., 2013; Jia et al., 2013; 
Lin et al., 2015). 
 
This chapter aims to identify signalling pathways and mechanisms of hypertrophy 
responsible for changes in the size of mdx cardiomyocytes in response to serum 
starvation. 
 
4.2 Overview of the Experimental Setup 
BL/10 and mdx cardiomyocytes were isolated from E17.5 hearts and cells were 
collected for RNA extraction at five time-points following serum starvation: 0h, 24h, 
48h, 72h and 96h. The time-line of the experimental design for RNA collection is 
summarised in figure 4.1. 
 
 
Figure 4.1. Experimental time-course of primary cardiomyocyte RNA sample 
collection. Cells were cultured in serum-rich growth medium for 48h, followed by 
serum starvation for 96h, feeding with fresh medium every 24h. Cells were harvested 
for RNA extraction at the start of and at each of the subsequent 24h time-point of 
serum starvation. 
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Three biological replicates of BL/10 and mdx samples were collected in Trizol at each 
time-point and shipped to Helmut Blum’s research group for RNA-Seq analysis. 
Andrea Klanner (laboratory technician in Helmut Blum’s research group) extracted 
RNA and performed quality control analysis on the samples using an Agilent 2100 
Bioanalyser, data from which is summarised in table 4.1 and figure 4.2. The RNA 
integrity number (RIN) value cut-off for including samples in further analyses was 8. 
Three of the thirty analysed samples showed RNA degradation and RIN values 
below 8. All three belonged to the same BL/10 biological replicate (named B56) and 
were the 48h, 72h and 96h time-point of the same biological replicate. All five time-
point samples of the B56 biological replicate were excluded from subsequent 
experimental procedures. After cDNA synthesis and fragmentation, unique barcodes 
were added to each set of fragmented DNA samples. Samples were combined and 
Stefan Krebs (post doctoral associate in Helmut Blum’s research group) performed 
the sequencing on an Illumina HiSeq 1500. 
 
 
Figure 4.2. RNA quality control on Agilent 2100 Bioanalyzer. The y-axis on the 
graphs represents fluorescence units and the x-axis shows elution time in seconds. 
RIN stands for RNA integrity number and rRNA is ribosomal RNA. Samples 
indicating RNA degradation were omitted from subsequent experiments. 
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Sample 
Mouse 
strain 
Time-
point 
Illumina Barcode 
Sequence 
[RNA] 
ng/µl RIN QC % Mapped 
B53 0h BL/10 0h AAGGGA 98 9.5 Pass 46.7 
B53 24h BL/10 24h GGATGT 82 10 Pass 66.9 
B53 48h BL/10 48h AAGGGA 52 9.6 Pass 56.0 
B53 72h BL/10 72h GGATGT 65 9.8 Pass 58.1 
B53 96h BL/10 96h CCTTCA 57 9.7 Pass 56.1 
B56 0h BL/10 0h N/A 143 9 Pass N/A 
B56 24h BL/10 24h N/A 94 9.4 Pass N/A 
B56 48h BL/10 48h N/A 48 6.4 Fail N/A 
B56 72h BL/10 72h N/A 32 2.8 Fail N/A 
B56 96h BL/10 96h N/A 32 2.9 Fail N/A 
B57 0h BL/10 0h CCTTCA 122 9.6 Pass 61.0 
B57 24h BL/10 24h TTCGCT 131 9.9 Pass 59.5 
B57 48h BL/10 48h GGACCC 109 8.9 Pass 61.1 
B57 72h BL/10 72h TTCGCT 95 8.8 Pass 42.0 
B57 96h BL/10 96h ACACGA 74 8.2 Pass 44.0 
m68 0h mdx 0h GGACCC 129 9.1 Pass 44.7 
m68 24h mdx 24h TTCAGC 102 9.8 Pass 54.7 
m68 48h mdx 48h ACACGA 119 9.5 Pass 47.1 
m68 72h mdx 72h CACACA 100 9.7 Pass 59.7 
m68 96h mdx 96h CACACA 105 9.6 Pass 62.5 
m70 0h mdx 0h GTGTTA 157 9.7 Pass 40.0 
m70 24h mdx 24h GTGTTA 144 10 Pass 58.8 
m70 48h mdx 48h TTCAGC 140 9.6 Pass 54.5 
m70 72h mdx 72h AAGACG 165 9.9 Pass 43.4 
m70 96h mdx 96h TGTGAA 141 9.8 Pass 58.2 
m71 0h mdx 0h AAGACG 151 9.4 Pass 47.6 
m71 24h mdx 24h CCTCGG 167 9.6 Pass 61.8 
m71 48h mdx 48h CCTCGG 125 9 Pass 56.3 
m71 72h mdx 72h TGTGAA 102 8.2 Pass 59.2 
m71 96h mdx 96h ACAAAC 98 8.2 Pass 49.8 
Table 4.1. Quality control and DNA barcode adaptors for RNA-Seq samples. BL/10 
and mdx cardiomyocyte RNA was quantified and analysed on the Agilent 2100 
Bioanalyser. Each sample’s cDNA fragments were tagged with six nucleotide 
reference sequence adaptors for multiplexed runs on Illumina HiSeq 1500.  
 
 92 
4.3 RNA-Seq Data Analysis 
Sequencing data from Illumina HiSeq 1500 was uploaded to Galaxy next-generation 
sequencing analysis web portal (Goecks et al., 2010) and demultiplexed based on 
reference sequences detailed in table 4.1. The resulting fastqsanger files were 
analysed with the FastQC quality control package (Andrews, 2010). Results were 
visualised in html format summary files. All samples gave high quality sequences 
(above 28) per base sequence analysis with none of the sequences flagged as poor 
quality (figure 4.3). Sequence trimming was therefore unnecessary (Kroll et al., 
2014). 
 
 
Figure 4.3 FastQC base quality analysis of B53 0h sample sequences. This graph 
showed a typical pattern for sequences from RNA-Seq runs with the first six bases 
having a lower median quality value (red line in the yellow boxes), representing the 
six base adapter sequences. The declining quality further along the sequence is 
typical for Illumina sequencing platform results. The whiskers in these (representing 
90% of the data) plots were also showing very high quality in most reads.  
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All fastqsanger files were individually aligned to the mm10 reference mouse genome 
with TopHat2 (Kim et al., 2013) in Galaxy. Resulting bam files were visualised in 
Integrative Genomics Viewer (IGV) software (Thorvaldsdóttir et al., 2013) and the 
single nucleotide C->T mutation in exon 23 of the Dmd gene in mdx mouse samples 
confirmed (figure 4.4) (Sicinski et al., 1989). Alignment summary files from TopHat2 
runs gave information about the proportion of sequences mapped from each sample, 
the lowest value was 40% and highest 66.9% (table 4.1). 
 
 
Figure 4.4 Visualising aligned sequencing data in IGV. The m68 72h sample .bam file 
was viewed in IGV software to visualise the mdx mouse point mutation in the Dmd 
gene. 
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Individual counts of gene expression were determined from TopHat2 accepted hits 
files for each sample. This was again performed in Galaxy, using the HTSeq package 
(Anders et al., 2015). The read count files were used to draw data saturation plots for 
each sample (figure 4.5) in order to assess completeness of data. All of the samples 
were considered to have yielded high quality data based on the overall number of 
mapped reads and the level of transcripts above the set 10x coverage. Most sample 
plots reached a plateau stage where additional reads had a reduced impact on 
improving coverage. Therefore, all samples were included in differential gene 
expression analyses. 
 
Figure 4.5. BL/10 and mdx cardiomyocyte RNA-Seq sample gene count saturation 
plots. This graph illustrates how each subsequent bin of 1 million sequence reads on 
the x-axis cumulatively increased the number of genes covered above a set 
threshold of transcripts (here minimum of 10) on the y-axis. All sample plots were 
expected to plateau beyond a certain number of reads. A failed sample would not 
have shown an exponential increase at the start, reached a comparable level of 
coverage along the y-axis (sequences not mapped or poor quality), or would have 
shown a short curve along the x-axis (not enough reads sequenced). Samples from 
these sequencing replicates all showed similar saturation curves and were therefore 
included in differential gene expression analyses.  
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4.4 Differential Gene Expression 
An R programming environment (Ihaka & Gentleman, 1996) script to analyse 
differential gene expression with DeSeq2 package (Love et al., 2014) was written by 
Alex Graf (post doctoral associate in Helmut Blum’s research group). Read count 
tab-delimited files from HTSeq were used as input data and the script was 
customised to allow selection of input samples to identify differentially expressed 
genes from a range of comparisons (summarised in table 4.2) in regularised 
logarithmic (rLog) transformation expression data, at a false discovery rate (FDR) of 
0.05, based on Benjamini-Hochberg correction adjusted p-values (Benjamini & 
Hochberg, 1995). The output format for quantifying gene expression changes was in 
base 2 logarithm fold change (Log2FC) format. In addition to comparisons based on 
contrasting one factor at a time, a multi-factor analysis was performed with DeSeq2 
to identify genes that were differentially expressed when accounting for both sample 
type (BL/10 to mdx) and the effect of serum starvation (0h to 24h, to 48h, to 72h, to 
96h). This multi-factor method therefore provided a two-dimensional analysis, which 
gave a list of genes with altered expression patterns in dystrophic cardiomyocytes 
across the serum starvation time-course. 
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4.4.1 Quality Control of Differential Gene Expression Data 
Scripts invoked DeSeq2 to perform sample quality control in each of the 
comparisons. Principal component analysis (PCA) was conducted on sample sets in 
each comparison. These plots, some of which are shown in figure 4.6, revealed that 
it was not possible to separate genotype clusters when all BL/10 and mdx samples 
were analysed together on a two variance scale (figure 4.6 A). However, when 
samples from each time-point were compared then BL/10 and mdx samples formed 
distinct groups with no overlap between each other, indicating that genotype samples 
clustered together based on their gene expression variance measures. 
 
Figure 4.6. Principal component analyses of BL/10 and mdx cardiomyocyte samples. 
Axes of the graphs show the two strongest dimensions of variance, and where each 
plotted sample lies on those scales. Samples with closer clustering showed greater 
similarity than those more distant from each other. (A) The comparison of all BL/10 
and mdx samples did not allow separation of sample populations from each other 
based on genotype. However, comparison of biological replicates from the strains at 
individual time-points (B-F) allowed distinct separation of samples based on their 
genotype, highlighted by shapes drawn around BL/10 samples in blue and mdx 
samples in red. Samples from mdx cardiomyocytes clustered closely at the 0h time-
point, but showed increased variability from each other further along the serum 
starvation time-course. BL/10 cardiomyocyte samples showed close clustering after 
the initial 24h response to serum starvation and later showed similarities on the first 
principal component, but a greater distance along the second principal component. 
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A heatmap was drawn to compare and contrast gene expression between samples. 
The heatmap in figure 4.7 features all the samples and their distances between one 
another based on gene expression patterns. This form of data representation helped 
to understand why BL/10 and mdx samples did not cluster together in the PCA plot in 
panel A of figure 4.6. All the BL/10 and mdx samples at the start of serum starvation 
(0h) clustered together, implying that they showed a greater overall similarity in gene 
expression to one another rather than the samples at different time-points of serum 
starvation drawn from the same genotype. This trend of sample clustering remained 
the same at the 24h and 48h time-points of serum starvation; there was greater 
similarity between the samples at the same time-points across genotypes than 
across time points of the same genotype. All samples at these two time-points 
clustered together to form one branch, with the exception of one BL/10 48h sample. 
In contrast, a clear divide between BL/10 and mdx samples emerged by the 72h and 
96h serum starvation time-points, where sample gene expression diverged from the 
earlier pattern to form branches based on the genotype of sample origin. BL/10 72h 
and 96h samples formed one group, whilst mdx 72h and 96h samples were part of a 
separate branch. As a clear outlier, the BL/10 48h sample that did not cluster with the 
other 24h and 48h samples clustered with the same group as 72h and 96h mdx 
samples.  
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Figure 4.7. BL/10 and mdx cardiomyocyte gene expression sample-to-sample 
distances. Samples that were not serum starved formed cluster A. Samples in the 
first half of the serum starvation time-course (24h and 48h) also grouped together 
into cluster C, with the exception of one BL/10 48h sample, which fell into cluster D. 
Samples in the second half of the serum starvation time-course grouped together 
based on their genotype: BL/10 72h and 96h samples formed cluster B, mdx 72h and 
96h samples formed cluster D.   
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MA-plots to visualise the spread of Log2FC reads of all individual genes in a 
comparison were drawn using DeSeq2. These plots are based on the Bland-Altman 
plot and the name – MA-plot – is derived from the way it originally represented 
microarray (MA) data in the form of log ratios (M, here Log2FC) against the mean of 
normalised counts (A). The plot allows visual representation of the fold changes for 
all genes as well as distinguishing the differentially expressed genes that were 
significant based on meeting the set FDR adjusted p-value cut-off (figure 4.8). 
 
 
Figure 4.8. Gene expression MA-plot of BL/10 against mdx sample comparison. 
Each point on the graph is a gene, either up- or downregulated on a Log2FC scale. 
The x-axis represents the mean count of a given gene, normalised to values across 
all the samples in the comparison. Significant differentially expressed genes are 
shown in red (adjusted p-value<0.1).  
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4.4.2 Clustering Genes Based on Trends in Expression Data 
A second heatmap was drawn from each pair of samples, where rLog transformation 
data was used to contrast expression levels of genes that were differentially 
expressed in a given comparison. As an example, depicted in figure 4.9, when 
comparing all BL/10 samples against mdx samples the differentially expressed genes 
formed four visually distinct clusters. The first cluster had one gene, Erdr1, which 
showed a much higher expression level in BL/10 cardiomyocytes in comparison to 
mdx samples. The second cluster of ten genes included those, which showed a 
similar pattern of higher expression in BL/10 samples. The Dmd gene was one of 
these ten genes. The third cluster again only had one gene, 3110056K07Rik, which 
was expressed at a higher level in mdx samples. The fourth cluster was comprised of 
those genes which did not show a distinct pattern of expression differences between 
samples, although most appeared to have higher expression in mdx samples in 
comparison to BL/10 cardiomyocytes. 
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Figure 4.9 Heatmap of differentially expressed genes between BL/10 and mdx 
cardiomyocytes. All BL/10 cardiomyocyte samples were compared with all mdx 
samples. DeSeq2 identified genes that were differentially expressed and plotted their 
relative expression data into the heatmap. Gene-to-gene distance analysis revealed 
four clusters with distinct expression patterns (A-D). 
  
 103 
In order to improve the understanding of gene expression patterns between samples, 
a self-organising tree algorithm (SOTA) analysis (Herrero et al., 2001) was performed 
to statistically cluster together genes with similar expression patterns. Figure 4.10 
represents the four clusters of gene expression patterns that emerged when 
performing SOTA analysis on the 340 genes with a significantly altered expression 
pattern in the two-dimensional differential expression analysis between BL/10 and 
mdx cardiomyocytes across the duration of serum starvation.  
 
The first cluster consisted of a group of 137 genes which showed an average higher 
expression in BL/10 samples in comparison to mdx samples. The second cluster had 
123 genes and showed a reduction in gene expression levels along the time-course 
of serum starvation in BL/10 cardiomyocytes, whilst two of the three mdx biological 
replicates showed more or less stable expression levels for these genes as opposed 
to one replicate where a reduction of average expression levels was seen by the 72h 
and 96h time-points. The third cluster consisted of 25 genes with an increasing 
expression pattern across the serum starvation time-course in both BL/10 and mdx 
samples and a stronger upregulation in one mdx sample in comparison to BL/10 and 
the other two mdx samples. The fourth cluster comprised of 55 genes with a lower 
relative expression level in BL/10 samples in comparison to mdx samples serum 
starved for 24h or longer.  
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Figure 4.10. SOTA analysis gene clusters. Each cluster contained a set of significant 
differentially expressed genes which displayed similar expression patterns, where 
significant indicates that a Benjamini-Hochberg corrected p-value<0.05 was recorded 
for each of the clustered genes. Cluster 1 showed a higher average expression level 
in BL/10 cardiomyocytes compared to mdx samples. Cluster 2 showed a diminishing 
level of expression along the serum starvation time-course in both BL/10 and one of 
the mdx samples, as opposed to a stably higher expression level in the other two 
mdx samples. Cluster 3 showed escalating gene expression levels for both BL/10 
and mdx samples, with one mdx sample showing a higher increase in expression 
levels across the serum starvation time-course than other samples. Genes in cluster 
4 showed a lower average expression level in all BL/10 and mdx 0h samples, with 
higher expression levels in serum starved mdx samples (24h-96h). Samples were 
arranged along the x-axis of the graphs, with ascending serum starvation time from 
0h to 96h, first in BL/10 samples, followed by mdx samples. Each grey line 
represents the expression pattern for one gene. The black line links the relative mean 
rLog gene expression values of all the genes in each sample, compared to the 
average of all samples and genes in the cluster. The red area represents +/- 1 
standard deviation (SD) from the mean and the yellow area combined with the red 
area represents +/- 2 SDs from the mean. 
 
4.4.3 Filtering Differentially Expressed Gene Lists and Building Expression 
Databases 
All lists of genes were filtered based on their false discovery rate (FDR), in order to 
improve data quality and confidence for further analyses. The FDR cut-off was 
originally set to adjusted p-value<0.05. It was now lowered to 1% (Benjamini-
Hochberg corrected p-value <0.01) to further correct for multiple testing. A differential 
expression fold change cut-off was subsequently introduced to eliminate any 
statistically significant differentially expressed genes that had a small change in 
expression level. The Log2FC cut-off was set to +/-0.6, which equals to a nominal +/-
1.5-fold change (FC). Table 4.2 summarises the changes in the numbers of 
differentially expressed genes after introducing each of the cut-offs for DeSeq2 
results. 
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Log2FC cut-off None None +/-0.6 
adjusted p-value 0.05 0.01 0.01 
Condition 1 Condition 2 Differentially Expressed Genes 
All BL/10 All mdx 28 8 5 
Type Time 340 109 12 
BL/10 0h mdx 0h 10 7 7 
BL/10 24h mdx 24h 166 85 62 
BL/10 48h mdx 48h 1 1 1 
BL/10 72h mdx 72h 19 12 12 
BL/10 96h mdx 96h 365 217 217 
BL/10 0h BL/10 24h 190 89 89 
BL/10 0h BL/10 48h 509 222 222 
BL/10 0h BL/10 72h 1263 749 749 
BL/10 0h BL/10 96h 1580 1041 1041 
BL/10 24h BL/10 48h 100 48 47 
BL/10 24h BL/10 72h 813 547 533 
BL/10 24h BL/10 96h 1120 760 750 
BL/10 48h BL/10 72h 261 129 129 
BL/10 48h BL/10 96h 525 355 355 
BL/10 72h BL/10 96h 45 22 22 
mdx 0h mdx 24h 1094 605 327 
mdx 0h mdx 48h 1065 986 842 
mdx 0h mdx 72h 1255 714 704 
mdx 0h mdx 96h 2495 1690 1413 
mdx 24h mdx 48h 253 117 99 
mdx 24h mdx 72h 470 264 260 
mdx 24h mdx 96h 1065 640 502 
mdx 48h mdx 72h 2 1 1 
mdx 48h mdx 96h 112 44 42 
mdx 72h mdx 96h 0 0 0 
Total unique 4209 2807 2507 
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Table 4.2. Filtering lists of significant differentially expressed genes. Here significant 
indicates a Benjamini-Hochberg adjusted p-value<0.05 or <0.01 recorded for each 
gene, depending on the level indicated in the second row of the table. Differential 
gene expression comparisons were performed in DeSeq2. A multi-factor analysis, 
taking the time-course into consideration, was performed between BL/10 and mdx 
samples was performed in addition to conducting an overall comparison of averaged 
BL/10 gene expression against mdx samples. Lists of genes were filtered further to 
include only those with adjusted p-values below 0.01 and subsequently also filtered 
for a fold change cut-off at Log2FC +/-0.6, which equates to nominal FC +/-1.5.  
 
Altering the FDR reduced the number of significant genes in all but two of the sample 
comparisons: BL/10 48h v mdx 48h comparison only identified one gene with a low 
adjusted p-value, the mdx 72h v mdx 96h comparison did not return differentially 
expressed genes even at the <0.05 p-adjusted level. Introducing the +/-0.6 Log2FC 
cut-off eliminated almost 90% of the remaining genes in the multi-factor (type versus 
time) comparison and whilst there were many significant genes with low expression 
differentials in the intra-mdx time-point comparisons, the numbers of genes in intra-
BL/10 time-point sample comparisons remained unchanged. This was probably down 
to the fact that each time-point only had two samples and therefore the FC levels 
needed to be higher to meet the stringent FDR criterion. 
 
These 27 modified lists of differentially expressed genes were combined into two 
databases in Microsoft Excel to improve ease of access to the relevant data. These 
databases combined the FC information as well as flagging which comparisons 
included the specific gene’s expression change as significant (figure 4.11). These 
databases complemented each other and were used simultaneously when 
investigating the expression patterns of genes on an individual basis. Data from the 
database with FC information was also subsequently used to derive gene ontology 
diagrams. Appendix 1 includes differential expression data for all the genes 
discussed in this thesis, but not the complete databases. 
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Figure 4.11. Snapshots of gene expression databases. Database A gave information 
about which comparisons flagged a gene as significant (adjusted p-value<0.01) and 
Log2FC above or below +/-0.6. Each column represented a comparison and each 
row represented a gene. When a gene was differentially expressed according to the 
stated criteria in each comparison then its name was present in the relevant column. 
When the expression levels were not significantly altered in a given comparison then 
the cell was left blank. Database B combined all FC data for each gene in each of the 
DeSeq2 comparisons, flagged in any of the comparisons as having a significantly 
altered expression pattern. These databases were used in tandem when 
investigating gene expression patterns. 
 
4.4.4 Secondary Analysis of Gene Expression Data 
Further lists of genes were derived from the 27 comparisons shown in table 4.2. 
Venn diagrams in figure 4.12 show the rationale in creating these additional lists of 
genes with the example of showing relationships between significantly regulated 
genes from intra-BL/10 inter-time, intra-mdx inter-time and inter-type (BL/10 against 
mdx) comparisons. Furthermore, diagram B in figure 4.12 illustrates the categorising 
of genes from the mdx 0h against mdx 96h and BL/10 0h against BL/10 96h 
comparisons. New lists of genes were created based on these comparisons 
containing groups of genes unique to control cardiomyocytes, dystrophic phenotype 
or both. Such comparisons improved the workflow for showing distinct enrichment 
terms and pathways only involved in dystrophic pathology.  
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Figure 4.12. Venn diagrams of differentially expressed genes. Diagram A gives an 
outline of the genes from all comparisons of BL/10 serum starvation time-points 
relative to each other (in blue), all mdx serum starvation time-point comparisons (in 
red) and those comparisons between BL/10 and mdx samples at specific time-points, 
including the overarching comparison of all BL/10 samples against mdx samples in 
both the type-only and two-dimensional basis (in green). Diagram B illustrates how 
the two comparisons of the 0h time-point against the 96h time-point of serum 
starvation in BL/10 (in blue) and mdx samples (in red) give further information when 
genes are sub-categorised to those unique to either the BL/10 or mdx comparisons 
or overlapping in both comparisons. 
  
 111 
4.5 Gene Ontology Analysis with DAVID 
Gene ontology (GO) is routinely used for identifying gene enrichment for terms, 
processes or pathways. Lists of differentially expressed genes derived from the 
analyses above were used for GO analyses. A term enrichment analysis was 
conducted with the complete list of differentially expressed genes from all 
comparisons using the Database for Annotation, Visualization and Integrated 
Discovery (DAVID) (Huang et al., 2009), an online-access free software package. 
Annotation clusters with the highest enrichment scores (ES) were related to 
translation, sarcomere structure, mitochondria, extracellular matrix and the 
cytoskeleton. With an ES score of 8.19 hypertrophic cardiomyopathy and dilated 
cardiomyopathy cluster together, with Benjamini-Hochberg corrected p-values of 
7.1x10-10 and 3.5x10-9, respectively. Hypertrophic cardiomyopathy disease process 
schematics were drawn in DAVID, based on Kyoto Encyclopedia of Genes and 
Genomes (KEGG) (Ogata et al., 1999) pathway information, to visualise the involved 
genes and processes in cardiac myocytes (figure 4.13). 
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Figure 4.13. Gene ontology analysis with DAVID. This schematic shows hypertrophic 
cardiomyopathy pathways and processes in cardiomyocytes. Genes and groups of 
genes are highlighted in boxes, with those differentially expressed in the analyses 
above on a red background. The diagram illustrates how aberrant Ca2+ handling and 
sarcomeric abnormalities lead to a hypertrophic response in the heart. Adapted from 
the Kanehisa Laboratories’ KEGG image (05410 5/29/12) returned as part of DAVID 
GO analysis results. 
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4.6 Gene Ontology Analysis with Genomatix 
Genomatix software was used to create an in-depth understanding of gene 
interactions and associations. The software package allowed investigating individual 
gene lists as well as combined lists and drawing interaction maps based on genes 
identified in literature searches (Frisch et al., 2009). 
 
4.6.1 Tissue, Disease, Biological Processes and Molecular Function Analyses 
Ontology level confirmation of anticipated characteristics of the dataset was 
performed when investigating enrichment of significantly altered genes, summarised 
in table 4.3. Genomatix gave two types of enrichment lists for tissues, based on 
Genomatix literature mining algorithms and those of the UniGene transcriptome 
database. The former resulted in skeletal muscle, heart and myocardium coming out 
as top three enriched tissue types, whilst the latter gave the cardiovascular system, 
heart and lung in descending order of significance as the top three tissues. The heart 
showed the highest nominal number of genes and the myocardium the highest 
proportional representation from Genomatix literature mining. UniGene enrichment 
resulted in lung tissue showing the highest nominal number of associated genes 
whilst heart tissue had the highest proportional representation. 
 
Enrichment for diseases based on Medical Subject Headings (MeSH) and Genomatix 
literature mining returned heart disease, cardiomegaly (twice), cardiovascular 
disease and animal diseases as the top five disease groups for the former and 
hypoxia, cardiomegaly, adverse event associated with the vascular system, 
cardiomyopathies and hypertrophy for the latter. Cardiomegaly and cardiomyopathies 
were represented by the highest proportion of potential genes in the MeSH and the 
Genomatix libraries, respectively. 
 
Ontology analysis for biological processes identified translational termination, 
translational elongation, single-organism metabolic process, cellular component 
organisation or biogenesis and extracellular matrix organisation as the top five terms. 
Protein binding, structural constituent of ribosome, structural molecule activity, 
binding and cytoskeletal protein binding were the five highest enriched GO terms for 
molecular functions. 
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Tissues (Genomatix Lit. Mining) p-value Genes Represented 
Muscle, skeletal 7.35E-40 255 of 988 25.81% 
Heart 8.46E-37 281 of 1170 24.02% 
Myocardium 8.78E-37 164 of 520 31.54% 
Tissues (UniGene) p-value Genes Represented 
Cardiovascular system 3.49E-144 1569 of 9886 15.87% 
Heart 3.13E-137 1502 of 9319 16.12% 
Lung 1.14E-132 1732 of 11956 14.48% 
Diseases (Genomatix Lit. Mining) p-value Genes Represented 
Hypoxia 4.78E-30 213 of 848 25.12% 
Cardiomegaly 2.17E-23 116 of 386 30.05% 
Adverse event associated with the 
vascular system 6.38E-21 154 of 625 24.64% 
Cardiomyopathies 1.54E-18 89 of 293 30.38% 
Hypertrophy 1.31E-16 124 of 509 24.36% 
Diseases (MeSH) p-value Genes Represented 
Heart Disease 1.34E-64 943 of 5693 16.56% 
Cardiomegaly 4.13E-64 483 of 2170 22.26% 
Cardiomegaly 6.24E-64 424 of 1784 23.77% 
Cardiovascular Disease 3.68E-63 1217 of 8196 14.85% 
Animal Diseases 1.11E-62 1210 of 8142 14.86% 
Biological Processes (GO) p-value Genes Represented 
Translational termination 8.19E-30 57 of 91 62.64% 
Translational elongation 2.92E-28 61 of 108 56.48% 
Single-organism metabolic process 1.50E-27 572 of 3160 18.10% 
Cellular Component Organization or 
Biogenesis 4.31E-27 756 of 4518 16.73% 
Extracellular Matrix Organization 4.77E-26 110 of 315 34.92% 
Molecular Functions (GO) p-value Genes Represented 
Protein Binding 3.11E-28 1109 of 7521 14.75% 
Structural Constituent of Ribosome 4.99E-27 72 of 155 46.45% 
Structural Molecule Activity 1.24E-22 161 of 627 25.68% 
Binding 2.17E-15 1541 of 11958 12.89% 
Cytoskeletal Protein Binding 1.01E-14 150 of 681 22.03% 
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Table 4.3. GO analysis of tissues, diseases, biological processes and molecular 
functions. Genomatix software was used to analyse the complete list of differentially 
expressed genes. The resulting top three tissues based on literature mining and the 
top five diseases, biological processes and molecular functions are summarised 
above based on their p-values and gene representation. 
 
4.6.2 Cell Signalling and Interaction Pathways 
Results from signalling pathway analysis corresponded to the gene association 
analyses on tissue types, diseases and biological processes. Several pathways 
associated with the vascular system were identified when analysing the complete list 
of genes, for example angiogenesis and hypoxia-related pathways were highly 
represented. Pathways conventionally regarded to be involved in hypertrophy and 
dystrophic cardiomyopathy, such as matrix metalloproteinase (MMP) and 
transforming growth factor beta (TGFβ) signalling (Nadarajah et al., 2011), were also 
represented in the list of most significantly represented pathways, summarised in 
table 4.4. The three pathways with the highest significance values in the combined 
gene list were angiogenesis, vascular endothelial growth factor and hypoxia-inducible 
factor 1 alpha (HIF-1α) signalling. 
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Pathway p-value Genes Representation 
Angiogenesis 4.91E-16 84 of 251 33.47% 
Vascular Endothelial Growth Factor 8.99E-12 66 of 207 31.88% 
Hypoxia Inducible Factor 1, Alpha 5.00E-09 53 of 173 30.64% 
Integrin Linked Kinase 7.02E-08 32 of 88 36.36% 
Thrombospondin 1 1.25E-07 24 of 57 42.11% 
Rho Ras Homolog 2.87E-07 67 of 266 25.19% 
Focal Adhesion Kinase 4.48E-07 56 of 121 46.28% 
Matrix Metalloproteinase 1.21E-06 62 of 249 24.90% 
TGF Beta 2.10E-06 126 of 623 20.22% 
Mothers Against DPP Homolog 6.12E-05 77 of 367 20.98% 
Endothelin 1.01E-04 28 of 99 28.28% 
Protein Kinase 1.01E-04 30 of 109 27.52% 
Platelet Derived Growth Factor 1.18E-04 36 of 141 25.53% 
Nitric Oxide 1.37E-04 39 of 158 24.68% 
Cellular Growth 1.44E-04 67 of 317 21.14% 
Redox 2.29E-04 50 of 223 22.42% 
Peroxisome Proliferative Activated 
Receptor Alpha 2.33E-04 31 of 119 26.05% 
Low Density Lipoprotein Receptor 
Related Protein 2.75E-04 39 of 163 23.93% 
Caveolin 3.47E-04 29 of 111 26.13% 
Tek Tyrosine Kinase 4.43E-04 13 of 35 37.14% 
Nitric Oxide Synthase 5.34E-04 35 of 146 23.97% 
Lipid 6.22E-04 89 of 468 19.02% 
Rho Associated, Coiled Coil 
Containing Protein Kinase 6.43E-04 32 of 131 24.43% 
Natriuretic Peptide Receptor A 
Guanylate Cyclase 7.07E-04 10 of 24 41.67% 
Table 4.4. GO pathway analysis of the combined differentially expressed genes list. 
Most significantly represented pathways based on gene enrichment from the 
combined list of genes. 
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In order to identify pathways specific for dystrophic cells the lists of genes derived on 
the basis represented in diagram A of figure 4.12 were used and analysed in 
Genomatix. The top three signal transduction pathways based on significance values 
for each list of genes were compiled into table 4.5. Angiogenesis and hypoxia-related 
pathways were at the top of both the resulting analyses from the BL/10 and mdx 
complete gene lists as well as the overlapping genes (intersection) of the two groups. 
However, when only genes specific for BL/10 or mdx comparisons within the same 
genotype samples were investigated, only vascular endothelial growth factor (VEGF) 
remained significant in the group of genes differentially expressed only in mdx 
sample comparisons. 
 
Signal Transduction Pathways p-value Genes Represented 
All BL/10 v BL/10 Comparisons       
Vascular Endothelial Growth Factor 2.22E-11 59 of 218 27.06% 
Hypoxia Inducible Factor 1, Alpha Subunit 2.08E-07 42 of 168 25.00% 
Thrombospondin 1 9.42E-07 20 of 56 35.71% 
All mdx v mdx Comparisons       
Vascular Endothelial Growth Factor 8.86E-13 67 of 218 30.73% 
Hypoxia Inducible Factor 1, Alpha Subunit 7.72E-09 49 of 168 29.17% 
Thrombospondin 1 1.94E-06 21 of 56 37.50% 
Only BL/10 v BL/10 Comparisons       
Actin Related Protein 2 1.77E-05 7 of 22 31.82% 
Integrin Linked Kinase 4.60E-05 13 of 87 14.94% 
E2F Transcription Factor 1 4.11E-04 12 of 94 12.77% 
Only mdx v mdx Comparisons       
Cyclin G2 5.61E-03 5 of 21 23.81% 
Vascular Endothelial Growth Factor 6.41E-03 22 of 218 10.09% 
Potassium Voltage Gated Channel 6.93E-03 5 of 22 22.73% 
Intersect BL/10vBL/10 and mdx v mdx       
Vascular Endothelial Growth Factor 1.92E-11 45 of 218 20.64% 
Hypoxia Inducible Factor 1, Alpha Subunit 1.02E-08 34 of 168 20.24% 
Thrombospondin 1 7.37E-07 16 of 56 28.57% 
Table 4.5. Comparative GO pathway analysis of BL/10 and mdx lists of differentially 
expressed genes. 
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Pathway interaction maps were drawn in Genomatix using gene expression data 
derived from DeSeq2. The FC values for each comparison were uploaded to the 
system and colour-coded based on expression levels. Figures 4.14 and 4.15 show 
differentially expressed genes involved in the angiogenesis and VEGF signalling 
pathways, respectively, and colour-coded with FC data from the BL/10 96h against 
mdx 96h comparison. Figures 4.16 and 4.17 show differentially expressed genes 
involved in the HIF-1α pathway with only the 26 significant genes in the BL/10 96h 
against mdx 96h comparison shown in the former and the whole pathway in the 
latter. 
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Figure 4.14. Angiogenesis signalling pathway in cardiomyocyte hypertrophy. The 
diagram shows interactions between the 84 differentially expressed genes from the 
combined gene list. Expression levels are shown for the BL/10 96h against mdx 96h 
comparison, represented in red where upregulated and blue where downregulated in 
mdx samples. 
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Figure 4.15. VEGF signalling pathway in cardiomyocyte hypertrophy. The diagram 
shows interactions between the 66 differentially expressed genes from the combined 
gene list. Expression levels are shown for the BL/10 96h against mdx 96h 
comparison, represented in red where upregulated and blue where downregulated in 
mdx samples. 
 
 
 
Figure 4.16. HIF-1α signalling pathway in cardiomyocyte hypertrophy. The diagram 
shows interactions between the 26 differentially expressed genes from the BL/10 96h 
against mdx 96h comparison gene list. All gene expression levels from this group 
were upregulated in mdx samples relative to BL/10. 
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Figure 4.17. Canonical HIF-1α signalling pathway. The diagram shows interactions 
within the whole pathway. 26 differentially expressed genes from the BL/10 96h 
against mdx 96h comparison gene list. All gene expression levels from this group 
were upregulated in mdx samples relative to BL/10. 
 
4.7 qRT-PCR Validation of Genes Differentially Expressed in RNA-Seq Data 
A group of five genes was used for validating RNA-Seq data with quantitative real-
time PCR (qRT-PCR). These genes were chosen based on their expression patterns 
and expected moderate to high expression levels in the target tissue. The single 
criterion that had to be met by all five was that they were identified in at least one of 
the DeSeq2 comparisons as a differentially expressed gene.  
 
The selection of genes for validation was based on several factors. Differentially 
expressed gene Log2FC values from both the BL/10 0h against BL/10 96h and mdx 
0h against 96h comparisons were plotted against each other (figure 4.18). Sod3 and 
Fmod were strongly upregulated in both BL/10 and mdx comparisons, while Acta1 
and Angptl4 were strongly downregulated. Nppb was downregulated in both 
comparisons, but to a lesser extent in mdx serum starvation. Fibromodulin (Fmod) 
and brain natriuretic peptide (BNP, Nppb) were chosen as candidates for validation 
based on their large shift in expression across the serum starvation time-course. 
Phospholamban (PLN, Pln gene) was chosen based on previous literature showing 
its role in the dystrophic phenotype (Barry et al., 2008). Pln was also highlighted in 
the graph in figure 4.18 to compare its differential expression to other tested genes. 
Vascular endothelial growth factor A (VEGFA, Vegfa) was chosen based on GO 
results, where this gene played a central role in several signalling pathways (figures 
4.14-16). Ubiquinone 1 alpha subcomplex 4-like 2 (NDUFA4L2, Ndufa4l2) was 
chosen due to its upregulation in mdx serum starvation (mdx 0h v mdx 96h) and 
downregulation in BL/10 serum starvation (BL/10 0h v BL/10 96h), thus giving a high 
overall upregulation in mdx samples when BL/10 96h and mdx 96h samples were 
compared against each other. In addition to four biological replicates of BL/10 and 
mdx samples across the serum starvation time-course (0h to 96h), expression levels 
of these genes in mdx and BL/10 heart tissue were also assessed. Vegfa was only 
significantly regulated in the BL/10 0h v 96h comparison and Ndufa4l2 was 
significantly upregulated in the BL/10 96h v mdx 96h comparison, but not in either of 
the comparisons used to create figure 4.18. 
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Figure 4.18. Differential Expression Patterns. The Log2FC expression values of 
genes that were differentially expressed in both of the following two comparisons 
were plotted against each other: the BL/10 0h against 96h and mdx 0h against 96h 
comparisons. Fmod, Nppb and Pln were chosen for RNA-Seq validation with qRT-
PCR and are highlighted in the diagram. Other potential candidates for further 
studies were also identified: Acta1, Angptl4, Sod3 and Clic5. 
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4.7.1 Assessing Housekeeping Genes 
Choosing housekeeping genes for qRT-PCR validation of RNA-Seq data was made 
challenging by most orthodox mouse housekeeping genes, such as Gapdh 
(glyceraldehyde 3-phosphate dehydrogenase) and Actb (beta-actin), having come up 
in differential expression comparisons as genes with significantly altered expression 
patterns. Two housekeeping genes – Tpt1 and Hsp90ab1 – were trialled. Hsp90ab1 
was used as one of twelve genes in a mouse housekeeping gene array product 
supplied by Qiagen (PAMM-000Z). Tpt1 has previously been published as a relevant 
housekeeping gene in gene expression studies conducted on murine cardiac tissue 
(Pilbrow et al., 2008). Neither was included in any of the pre-filtered gene lists 
including all events at FDR below 0.05. Hsp90ab1 expresses heat shock protein 90-
beta and Tpt1 encodes a translationally-controlled tumour protein. 
 
Results in expression patterns from one qRT-PCR experiment for Tpt1 with 30 
cardiomyocyte samples were compared against two experiments for Hsp90ab1 with 
ten samples in each run. One clear outlier with an RNA concentration of 0.29 ng/µl 
was removed from the Tpt1 dataset. Tpt1 showed much more reliable primer 
efficiency (figure 4.19) than Hsp90ab1 (figure 4.20) when the Ct values of each 
sample were plotted against their base ten logarithm (Log10) of RNA concentration. 
Tpt1 samples gave a linear line of best fit slope value of -3.3235, which equals to 
99.93% primer amplification efficiency. Hsp90ab1 primer amplification efficiencies 
were 81.79% and 34.96%, determined from the slope values of -3.8524 and -7.6799 
in runs A and B, respectively. There was no background amplification in the no 
template control samples using either of the trialled housekeeping gene primer sets. 
However, Tpt1 nominal Ct values were considerably and consistently lower than 
Hsp90ab1 Ct values. Therefore, based on higher amplification efficiency and lower 
Ct values Tpt1 was chosen as the housekeeping gene for all qRT-PCR differential 
expression analyses with the ΔΔCt method.  
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Figure 4.19. Assessing Tpt1 as a housekeeping gene for qRT-PCR. Sample Ct 
values were plotted against the Log10 of RNA concentration and the linear line of best 
fit was drawn to calculate primer amplification efficiency. 
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Figure 4.20. Assessing Hsp90ab1 as a housekeeping gene for qRT-PCR. Sample Ct 
values were plotted against the Log10 of RNA concentration and the linear line of best 
fit was drawn for both run A and run B to calculate primer amplification efficiency. 
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4.7.2 Validating Expression Patterns of Differentially Expressed Genes. 
BNP is upregulated in response to cardiac pathology (Zois et al., 2014). The Nppb 
mouse gene was markedly upregulated in mdx adult mouse heart tissue, compared 
to BL/ 10 control tissue, by 6.9-fold in nominal FC and a factor of 2.8 in Log2FC 
(figure 4.21). A similar 8-fold upregulation was seen in the BL/10 96h against mdx 
96h time-point comparison in RNA-Seq data. However, the opposite trend was 
revealed when different biological replicates were compared by qRT-PCR, where a -
2.25-fold downregulation was seen. This was due to a diminished downregulatory 
effect in BL/10 cardiomyocytes in response to serum starvation in qRT-PCR results 
in contrast to RNA-Seq data. However, the same downregulation effect was seen in 
all but the BL/10 24h v BL/10 96h comparison, where the downregulation fold change 
did not cross the -0.6 Log2FC cut-off set for RNA-Seq results (-3.66 Log2FC seen by 
RNA-Seq and -0.18 by qRT-PCR analysis). RNA-Seq identified downregulation of 
Nppb in response to serum starvation. This was validated with qRT-PCR, where 
comparable regulation levels were seen. 
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Figure 4.21. Nppb gene expression analyses with qRT-PCR and RNA-Seq. The 
Log2FC +/-0.6 cut-off points are highlighted with blue lines across the graph. Where 
Nppb was a significant differentially expressed gene the comparison has been 
underlined. 
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PLN inhibits Ca2+ reuptake into the sarcoplasmic reticulum (SR) by inhibiting the 
cardiac SR luminal Ca2+-ATPase (SERCA) and consequently exacerbating Ca2+-
controlled pathways of cardiac pathology (Barry et al., 2008). Figure 4.22 
summarises the Pln expression pattern. It was upregulated in RNA-Seq expression 
analyses, but downregulated in qRT-PCR data in both BL/10 and mdx 
cardiomyocytes in response to serum starvation. When Pln expression was 
compared between BL/10 and mdx cardiomyocytes it was downregulated in mdx 
cardiomyocytes in RNA-Seq data, but upregulated in qRT-PCR quantification. It was 
also upregulated in adult mdx heart tissue in comparison to BL/10 hearts. 
 
 
Figure 4.22. Pln gene expression analyses with qRT-PCR and RNA-Seq. The 
Log2FC +/-0.6 cut-off points are highlighted with blue lines across the graph. Where 
Pln was a significant differentially expressed gene the comparison has been 
underlined. 
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Fibromodulin (encoded by the Fmod gene) is a protein that is involved in ECM 
assembly and composition (Kalamajski & Oldberg, 2010), the TGFβ signalling 
pathway and angiogenesis (Hildebrand et al., 1994; Adini et al., 2014). Fmod 
expression was significantly upregulated in BL/10 and mdx cardiomyocytes by serum 
starvation in both RNA-Seq and qRT-PCR results (figure 4.23). Interestingly, qRT-
PCR results indicated that Fmod was even more strongly upregulated by serum 
starvation than expected from RNA-Seq analysis. However, whilst the RNA-Seq data 
showed a slight, but non-significant upregulation of Fmod in mdx samples when 
BL/10 samples were compared against mdx samples at individual time-points of 
serum starvation, the opposite effect was identified in qRT-PCR results. In four 
comparisons (BL/10 0h v mdx 0h, BL/10 24h v mdx 24h, BL/10 48h v mdx 48h and 
BL/10 96h v mdx 96h) the average Log2FC even exceeded the -0.6 cut-off used to 
filter RNA-Seq gene lists. Fmod was also 1.8-fold downregulated in mdx adult heart 
in comparison to BL/10 adult heart tissue. 
 
Figure 4.23. Fmod gene expression analyses with qRT-PCR and RNA-Seq. The 
Log2FC +/-0.6 cut-off points are highlighted with blue lines across the graph. Where 
Fmod was a significant differentially expressed gene the comparison has been 
underlined. 
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VEGFA signalling is involved in several cellular responses, such as vasodilation, 
angiogenesis, cell survival and recruitment of vascular progenitor cells (Taimeh et al., 
2013). Gene expression of Vegfa in mice was significantly upregulated in mdx 
cardiomyocytes in comparison to BL/10 cardiomyocytes at the 24h and 96h serum 
starvation time-points (figure 4.24), by 1.8 and 2.6 nominal FC, respectively. 
However, these trends were not confirmed by qRT-PCR. Instead, at the 96h time-
point a 2.1-fold downregulation was observed. A similar contradictory data point was 
the BL/10 0h against BL/10 96h comparison, where an opposite to expected gene 
expression profile was also observed. None of the other significant differential 
expression comparisons showed anomalous results by qRT-PCR. The mdx 48h v 
mdx 72h and mdx 48h v mdx 96h comparisons also crossed the differential 
expression cut-off whilst the corresponding RNA-Seq data points did not. There was 
only a slight reduction in Vegfa expression in mdx adult heart tissue in comparison to 
BL/10 heart tissue. 
 
Figure 4.24. Vegfa gene expression analyses with qRT-PCR and RNA-Seq. The 
Log2FC +/-0.6 cut-off points are highlighted with blue lines across the graph. Where 
Vegfa was a significant differentially expressed gene the comparison has been 
underlined. 
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Ndufa4l2 encodes a mitochondrial protein involved in hypoxia, regulated by HIF-1α 
(Tello et al., 2011). This gene was significantly upregulated by serum starvation in 
mdx cardiomyocytes, whilst being downregulated by serum starvation in BL/10 
samples. As a result, RNA-Seq data showed a significant increase in Ndufa4l2 
expression in mdx cardiomyocytes at the 96h serum starvation time-point in contrast 
to BL/10 96h samples. These results, however, did not entirely replicate in qRT-PCR 
validation. Based on qRT-PCR results Ndufa4l2 was upregulated by serum starvation 
in both BL/10 and mdx samples, therefore diminishing the differential expression 
between the two seen in RNA-Seq results. However, comparisons of mdx 0h 
samples against subsequent serum starvation time-points closely replicated RNA-
Seq results, as seen in figure 4.25. Ndufa4l2 expression was near equal in adult mdx 
and BL/10 heart tissue. 
 
Figure 4.25. Ndufa4l2 gene expression analyses with qRT-PCR and RNA-Seq. The 
Log2FC +/-0.6 cut-off points are highlighted with blue lines across the graph. Where 
Ndufa4l2 was a significant differentially expressed gene the comparison has been 
underlined. 
 134 
Gene expression values in Log2FC from RNA-Seq and corresponding qRT-PCR 
validation datasets were summarised and are shown in table 4.6. Significant results 
from RNA-Seq analysis were highlighted for direct comparison in qRT-PCR results. 
 
Log2FC Fmod Ndufa4l2 Nppb Pln Vegfa   
Comparison R-S qP R-S qP R-S qP R-S qP R-S qP 
B0 v m0 0.18 -1.77 0.01 0.72 -0.15 -0.35 -0.14 0.58 0.12 0.27 
B24 v m24 0.19 -1.40 0.46 0.56 0.38 -0.53 -0.59 1.05 0.87 0.04 
B48 v m48 0.44 -1.58 0.00 0.01 0.03 -0.57 0.16 -0.06 -0.08 -0.06 
B72 v m72 0.13 -0.43 0.73 -0.02 0.61 -0.16 -0.54 1.18 0.65 -0.43 
B96 v m96 0.15 -0.77 2.28 -0.37 3.00 -1.17 -1.01 1.77 1.36 -1.07 
B0 v B24 0.29 1.83 0.32 1.03 -0.46 -0.44 0.47 -1.40 -0.34 0.25 
B0 v B48 1.56 3.01 0.95 1.69 -0.49 -1.06 0.23 -0.66 0.12 0.48 
B0 v B72 3.61 4.12 0.23 1.62 -5.07 -1.39 1.26 -1.03 -1.46 0.23 
B0 v B96 4.34 5.83 -1.59 2.06 -4.18 -0.62 1.58 -2.10 -2.03 0.80 
B24 v B48 0.81 1.18 0.50 0.66 -0.14 -0.61 -0.22 0.74 0.21 0.23 
B24 v B72 2.95 2.30 -0.12 0.58 -4.51 -0.95 0.60 -0.37 -1.11 -0.02 
B24 v B96 2.60 4.00 -1.88 1.03 -3.66 -0.18 1.04 -0.70 -1.69 0.55 
B48 v B72 1.56 1.12 -0.63 -0.08 -0.71 -0.34 0.94 -0.37 -0.80 -0.25 
B48 v B96 2.26 2.82 -2.34 0.37 -0.81 0.44 1.27 -1.44 -1.43 0.32 
B72 v B96 0.21 1.71 -0.93 0.44 0.77 0.77 0.23 -1.07 -0.44 0.57 
m0 v m24 0.24 2.20 0.77 0.87 0.11 -0.63 -0.25 -0.92 0.40 0.02 
m0 v m48 1.15 3.19 0.99 0.98 -0.88 -1.29 0.65 -1.29 -0.20 0.14 
m0 v m72 3.09 5.46 1.12 0.88 -0.79 -1.21 0.80 -0.42 -0.73 -0.48 
m0 v m96 2.88 6.83 0.94 0.96 -0.87 -1.44 0.72 -0.91 0.05 -0.54 
m24 v m48 0.66 1.00 0.13 0.11 -1.03 -0.65 0.81 -0.37 -0.53 0.13 
m24 v m72 2.54 3.26 0.27 0.01 -0.62 -0.58 0.97 0.50 -1.02 -0.49 
m24 v m96 2.34 4.63 0.05 0.09 -0.99 -0.81 0.92 0.01 -0.24 -0.56 
m48 v m72 0.29 2.26 0.11 -0.11 -0.09 0.08 0.13 0.87 -0.35 -0.62 
m48 v m96 0.56 3.63 -0.07 -0.02 0.16 -0.16 0.05 0.38 0.11 -0.68 
m72 v m96 0.55 1.37 -0.17 0.09 0.16 -0.24 -0.09 -0.48 0.31 -0.06 
BH v mH   -0.88   -0.04   2.79   1.83   -0.12 
Table 4.6. Summary of RNA-Seq validation data from qRT-PCR. All data points that 
were significant and above or below the +/-0.6 Log2FC cut-off are highlighted in red. 
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4.8 Discussion 
Triplicates of BL/10 and mdx samples at each time-point of serum starvation were 
obtained, but only duplicates of BL/10 samples sequenced due low RNA quality in 
some samples of one biological replicate. Sample quality control was also performed 
at the sequence level with FastQC and ensuring the Dmd gene mutation was present 
in mdx samples. 
 
Gene expression heatmaps showing expression pattern distances in figure 4.9 
featured the Dmd gene as one of the differentially expressed genes when comparing 
BL/10 cardiomyocytes against mdx cardiomyocytes at all time-points. Dmd clustered 
with other genes showing higher expression in BL/10 than mdx samples, which 
follows previously published data on the lower expression level of the gene in the 
mdx mouse (Chamberlain et al., 1991).  
 
Gene lists were filtered by increasing the confidence interval to 99% (adjusted p-
value<0.01) and introducing a fold-change cut-off at +/-0.6 Log2FC. The results 
showed a noteworthy tendency in the number of genes differentially expressed in 
comparisons between serum starvation time-points within each genotype. BL/10 
cardiomyocyte time-point comparisons showed a lower number of genes than mdx 
cardiomyocytes in the earlier time-point comparisons: BL/10 0h v 24h resulted in 89 
genes, whereas mdx 0h v 24h resulted in 327 statistically significant differentially 
expressed genes. The opposite was witnessed later in the time-course. For instance, 
in the BL/10 48h v 96h comparison 355 genes were differentially expressed, while 
only 42 were identified from the mdx 48h v 96h comparison. The fact that the mdx 
72h v 96h comparison did not return any statistically significant differentially 
expressed genes crossing the Log2FC cut-off suggests that the process of 
hypertrophy as modelled here is complete on the gene expression level by the 72h 
time-point, whereas the adaptation continues in BL/10 cardiomyocytes. This could be 
interpreted as the process being faster in the mdx model, compared to BL/10 
cardiomyocytes. However, it may also be that BL/10 cardiomyocytes adapt better to 
serum starvation, in a less rushed way and without the need to regulate as many 
genes initially to counteract the environmental cues in a hypertrophic fashion. It may 
only be in the later comparisons where BL/10 cardiomyocytes need to regulate more 
genes to avoid becoming hypertrophic. 
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4.8.1 Genes with the Highest Expression Response to Serum Starvation 
Expression patterns of genes identified in both BL/10 and mdx 0h against 96h serum 
starvation comparisons revealed a set of genes that had distinct regulation patterns 
(figure 4.18). Clic5 was one of the highlighted genes in the differential expression 
comparison graph. It was the only gene that was significantly upregulated in the mdx 
comparison (mdx 0h v mdx 96h by 1.6-fold) and downregulated in the BL/10 
comparison (BL/10 0h v BL/10 96h by -2.2-fold). The opposing directions of 
regulation in the mouse models resulted in a 3.3-fold upregulation in the BL/10 96h v 
mdx 96h comparison. Clic5 was originally omitted from the qRT-PCR validation panel 
of genes due to its lower nominal change within BL/10 and mdx comparisons, but 
based on validation results it would have been useful to see whether the differential 
expression between mdx and BL/10 samples would have replicated. The overall 
trend of expression based on RNA-Seq results showed initial upregulation as a result 
of serum starvation in both BL/10 and mdx samples within the 24-48h, followed by a 
sharp downregulation in BL/10 as opposed to comparatively stable expression levels 
in mdx throughout the remaining time-course. This expression pattern indicates that 
mdx cardiomyocytes keep the signalling pathways and transcription factors required 
for Clic5 expression activated, while BL/10 cardiomyocytes must have inhibited the 
upstream signals driving the gene’s expression. Clic5 encodes for the chloride 
intracellular protein 5, which phosphorylates ezrin, in turn responsible for actin 
polymerisation in kidney tissue podocytes, colocalising with conjugated phalloidin in 
ICC fluorescence imaging (Al-Momany et al., 2014). Its role in cardiac muscle has 
not been characterised, but it has been reported to increase C2C12 cell myogenesis 
when overexpressed, hindering cell proliferation and accelerating differentiation (Li et 
al., 2010). 
 
Serum starvation of BL/10 and mdx cardiomyocytes substantially downregulated 
Angptl4 expression in cells from both mouse strains. Angiopoietin-like 4 (ANGPTL4) 
has protective properties against myocardial infarct size and ischaemic stroke 
damage by inhibiting Src-mediated VEGF signal transduction (Galaup et al., 2012) 
(Bouleti et al., 2013). ANGPTL4 expression is activated by peroxisome proliferator-
activated receptor delta (PPARδ) and a PPARδ agonist has been shown to alleviate 
heart hypertrophy through Angptl4 expression-mediated mechanisms (Kojonazarov 
et al., 2013). The PPARδ gene Ppard was not differentially expressed in the RNA-
Seq dataset. ANGPTL4 enhances wound healing by increasing inducible nitric oxide 
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synthase (iNOS) expression via the Integrin/JAK/STAT3 pathway (Chong et al., 
2014). It has been postulated that iNOS overexpression and the concomitant 
increase in nitric oxide (NO) exacerbates dystrophic cardiomyopathy by activating 
ryanodine receptors (RyR) and consequently releasing SR-stored Ca2+ to the 
intracellular space (Finsterer & Cripe, 2014). However, the iNOS gene Nos2 was not 
differentially expressed in the RNA-Seq dataset. These results show that although 
Angptl4 is a candidate for further studies into hypertrophy in dystrophic 
cardiomyocytes, its function needs to be assessed by identifying protein activation 
levels in the relevant pathways rather than on gene expression alone, before it could 
be hypothesised to be a target for therapeutic testing. 
 
Superoxide dismutase 3 (SOD3) is an extracellular SOD, expressed by the Sod3 
gene, which was substantially upregulated in response to serum starvation in both 
BL/10 and mdx cardiomyocytes: in BL/10 0h v 96h by 14.7-fold and in mdx 0h v mdx 
96h by 12-fold. SOD3 knockout mice develop cardiac hypertrophy and fibrosis in 
response to transverse aortic constriction, with a significant increase in MMP2 and 
MMP9 levels (Lu et al., 2008). While Mmp9 levels were not significantly affected in 
the RNA-Seq dataset, Mmp2 levels were elevated close to 3-fold by 96h of 
cardiomyocyte serum starvation in both BL/10 and mdx samples. SOD3 is located in 
the extracellular matrix (ECM), where it clears superoxides by converting them into 
hydrogen peroxide (Gongora & Harrison, 2008). Elevated levels of Sod3 expression 
may be indicative of increased superoxide presence in the culture model, but can 
also be indicative of effective management of stretch-induced reactive oxygen 
species (ROS) levels, including superoxides. In this model SOD3 may compensate 
for mislocalised nNOS function tackling ROS. 
 
Skeletal α-actin (Acta1 gene, also highlighted in figure 4.18) expression in embryonic 
hearts is gradually replaced by cardiac α-actin (Actc1 gene) expression during 
development and the latter structural protein is predominant in adult hearts (Cox & 
Marsh, 2014). A return to Acta1 expression in adult cardiomyocytes is a hallmark of 
foetal gene program (FGP) activation. The emergence of FGP markers in adult 
cardiac tissue is indicative of heart dysfunction (Taegtmeyer et al., 2010). In this 
model of cardiomyocyte hypertrophy both Acta1 and Actc1 were downregulated by -
1.8-fold in the mdx 0h v 96h comparison, and in the BL/10 0h v 96h cardiomyocyte 
comparison by -3.3-fold and -4.4-fold, respectively. 
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4.8.2 The Foetal Gene Program 
In addition to the shift from Actc1 to Acta1, there are other indicators of FGP onset. 
Regulation and effect of natriuretic peptide expression is discussed in sub-section 
4.8.3. Another transcriptional shift in cardiac hypertrophy is the reduction in myosin 
heavy chain alpha (MHCα, Myh6 gene) and increase in myosin heavy chain beta 
(MHCβ, Myh7 gene) (Rajabi et al., 2007). This trend was confirmed by RNA-Seq in 
serum starved BL/10 and mdx cardiomyocytes, where Myh6 was significantly 
downregulated in both cell types. Although Myh7 was significantly upregulated in the 
BL/10 0h v BL/10 48h and BL/10 0h v BL/10 72h comparisons by 2.5-fold and 2-fold, 
respectively, there was a clear reversal of the trend and non-significant 
downregulation in the final 48h of serum starvation. This was not the case in mdx 
cardiomyocytes where a 2-fold upregulation between the 0h and 96h serum starved 
samples ended up being non-significant and the general trend was gradual 
upregulation during the time-course. Consequently, the BL/10 96h v mdx 96h 
comparison also resulted in a significant 1.8-fold upregulation of Myh7 in mdx 
cardiomyocytes. 
 
Other FGP factors that follow similar downregulation patterns in both BL/10 and mdx 
cardiomyocytes in the RNA-Seq dataset include carnitine palmitoyltransferase I 
(Cpt1b), pyruvate dehydrogenase kinase isoform 4 (Pdk4), muscle creatine kinase 
(Ckm) and muscle glycogen synthase (Gys1) (Rajabi et al., 2007). 
 
Cytoplasmic nuclear factor of activated T-cells 4 (NFATc4, previously named NFAT3) 
has been shown to induce cardiac hypertrophy when phosphorylated by calcineurin 
(Molkentin et al., 1998). The Nfatc4 gene was upregulated in both BL/10 and mdx 
cardiomyocytes, but only significantly in mdx 0h v mdx 48h and mdx 0h v mdx 96h 
comparisons, by 2-fold and 2.3-fold, respectively. Calcineurin was not differentially 
expressed in the RNA-Seq dataset. However, in order to confirm NFATc4 
involvement in the hypertrophic onset in mdx cardiomyocytes, studies would be 
required to look into its activation levels and compared between both BL/10 and mdx 
cardiomyocytes, particularly as NFATc4 might not be as powerful at driving a 
calcineurin-activated hypertrophic response in comparison to NFATc1, NFATc2 and 
NFATc3 (Wilkins et al., 2002; Enwere et al., 2014). None of the other NFAT genes 
were differentially expressed in this model of mdx cardiomyocyte hypertrophy. 
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It has been shown that inhibition of nuclear factor kappa B (NFκB), also a FGP 
marker (Oka et al., 2007), has cardioprotective effects on the dystrophin and utrophin 
double knockout (dko) mouse model (Delfín et al., 2012). Although the NFκB genes 
Nfkb1 and Nfkb2 were not differentially expressed in the cardiomyocyte 
transcriptome, the inhibitor of kappa B alpha (IκBα) gene Nfkbia was downregulated 
around 2-fold in both BL/10 and mdx cardiomyocytes in response to serum 
starvation. This could mean that NFκB is more likely to be constitutively active due to 
reduced IκBα levels (Haskill et al., 1991) and could lead to higher activation of gene 
expression for mediators of hypertrophy. 
 
Cardiac-specific upregulation of serum response factor (SRF) results in 
cardiomyopathy (Zhang et al., 2001). Srf is another developmental gene, which is 
included on the FGP transcription factor panel (Oka et al., 2007). However, in the 
cardiomyocyte serum starvation model the Srf gene was downregulated in both 
BL/10 and mdx cardiomyocytes. It is important to also mention that in addition to the 
discussed FGP transcription factors, some others were not differentially expressed in 
the RNA-Seq results, such as Gata4, the homeobox protein Nkx-2.5 gene Nkx2-5 
and the four myocyte enhancer factor-2 (MEF2) genes (Mef2a, Mef2b, Mef2c and 
Mef2d) (Oka et al., 2007).  
 
The fact that many FGP transcription factor markers were unaltered in the 
cardiomyocytes indicates that the FGP initiation seen in the model primarily affects 
the structural proteins (actins, MHCs). It may also suggest that transcription factor 
modulation is not required for the type of hypertrophy seen in mdx cardiomyocytes. 
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4.8.3 The Effect of Natriuretic Peptides 
Atrial natriuretic peptide (ANP) and BNP, also known as B-type natriuretic peptide 
and ventricular natriuretic peptide, are secreted in the myocardium in response to 
stress signals and they also form part of the FGP response mechanism to cardiac 
pathology (Taegtmeyer et al., 2010). The C-type natriuretic peptide was not 
expressed in embryonic cardiomyocytes. 
 
Expression of the ANP gene, Nppa, was significantly elevated in mdx 
cardiomyocytes in response to serum starvation: in mdx 0h v mdx 48h by 2-fold, in 
mdx 0h v mdx 72h by 1.7-fold and in mdx 0h v mdx 96h by 1.8-fold. Expression of 
the BNP gene, Nppb, was significantly downregulated in both BL/10 and mdx 
cardiomyocytes in response to serum starvation: BL/10 0h v BL/10 96h by 18-fold 
and mdx 0h v mdx 96h by 1.8-fold. This resulted in a strong 8-fold upregulation in the 
BL/10 96h v mdx 96h comparison of Nppb expression. Conversely, Nppb levels in 
qRT-PCR validation experiments between BL/10 and mdx serum starved 
cardiomyocytes (figure 4.21) did not replicate the upregulation trend seen in RNA-
Seq data. A 2.3-fold reduction in mdx 96h serum starved samples was seen in 
comparison to BL/10 96h samples. However, all other statistically significant 
reductions in intra-BL/10 and intra-mdx samples were replicated based on the -0.6 
Log2FC cut-off, apart from the BL/10 24h v BL/10 96h comparison, where a near 13-
fold reduction seen in RNA-Seq data was not replicated by a 1.1-fold downregulation.  
 
Both ANP and BNP mediate their effect via natriuretic peptide receptors (NPR), 
mostly through NPRA, but also at a lower affinity via NPRB and NPRC (Zois et al., 
2014). The NPRA gene Npr1 was not differentially expressed in any of the RNA-Seq 
comparisons, while the NPRB gene Npr2 was significantly elevated in mdx samples 
in response to serum starvation, by 2.2-fold in the mdx 0h v mdx 96h comparison. 
The NPRC gene Npr3 was significantly upregulated by 2-fold in BL/10 
cardiomyocytes between the 24h and 48h time-points of serum starvation. It was 
subsequently downregulated by -2.1-fold between 48h and 72h, and by -2.7-fold 
between 48h and 96h. Npr3 was not differentially expressed along the serum 
starvation time-course in mdx cardiomyocytes, but it was upregulated by 1.8-fold in 
the BL/10 against mdx comparison at the 24h serum starvation time-point. These 
differences make NPRC a candidate target for further investigations in the mdx 
cardiomyocyte hypertrophic response.  
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It became evident from raw HTSeq transcript number counts that the Npr1 gene was 
not expressed in BL/10 or mdx embryonic cardiomyocytes. NPRA and NPRB are 
both linked to guanylyl cyclases (GC) that produce cyclic guanosine monophosphate 
(cGMP), which in turn activates the cGMP-activated protein kinase G (PKG) and 
consequently has an effect on Ca2+ transporters and inhibits PLN (Zois et al., 2014). 
NPRC has multiple functions. It was initially thought to only have a clearance function 
by internalising secreted natriuretic peptides and directing them for intracellular 
storage and degradation (Koller & Goeddel, 1992), but was then linked to adenylyl 
cyclase (AC) inhibition in vascular smooth muscle, where it also activated 
phospholipase C (PLC) and inositol triphosphate (IP3) signalling, leading to increased 
intracellular Ca2+ concentration ([Ca2+]i) via IP3 receptor (IP3R) activation and 
consequent SR-stored Ca2+ release (Mouawad et al., 2004). All three IP3R genes – 
Itpr1, Itpr2 and Itpr3 – were expressed in both BL/10 and mdx cardiomyocytes, but 
no differential expression was observed. PLC can activate canonical transient 
receptor potential (TRPC) channels (Rowell et al., 2010), shown to be involved in 
mdx skeletal muscle pathology (Vandebrouck et al., 2002). While TRPC-knockout 
mice developed muscular dystrophy, their hearts were unaffected (Millay et al., 
2009). Out of all the seven TRPC genes only Trpc6 was expressed and Trpc4 at very 
low levels. Neither was differentially expressed. TRPCs may therefore not be 
involved in the hypertrophic response seen in embryo-derived mdx cardiomyocytes. 
The combination of higher levels of BNP and NPRC could, however, lead to Ca2+-
augmented pathology in mdx cardiomyocytes via IP3 activation. 
 
Furthermore, based on RNA-Seq data, expression of the ANP and BNP convertase 
furin (Ichiki et al., 2013) was significantly downregulated in BL/10 cardiomyocytes, 
particularly in the BL/10 24h v BL/10 96h comparison where its transcript levels are 
reduced by 2.8-fold. In comparison, Furin remains relatively stably expressed 
throughout serum starvation in mdx samples. Corin is another natriuretic peptide 
convertase (Yan et al., 2000) with the same function as furin, but Corin was not 
differentially expressed and was present at much lower levels than Furin in both 
BL/10 and mdx cardiomyocytes. It has previously been shown that in a dog model of 
heart failure corin expression is downregulated and furin levels are elevated (Ichiki et 
al., 2013). Although not upregulated in the RNA-Seq dataset, the differential trend in 
 142 
regulation between mdx and BL/10 cardiomyocytes could mean that natriuretic 
peptide effects are elevated in mdx cardiomyocytes. 
 
Results from Nppb differential gene expression validation with qRT-PCR illustrated 
how different techniques replicated datasets to a limited degree, particularly in terms 
of the two axes of comparison – mouse line and serum starvation. Here the data 
suggested that although overall trends in Nppb reduction were valid in both BL/10 
and mdx samples across serum starvation, the opposite effect was seen when the 
mouse models were compared against each other. Based on the protein modification 
requirements for both ANP and BNP and the reduction in furin expression in BL/10 
samples, it would be pivotal to quantify natriuretic peptides on the protein level with 
Western blotting. Both peptides also have a short half-life (Mezo et al., 2012; 
Semenov et al., 2011). Although transcripts are upregulated the translated proteins 
may not reach a functional form before being degraded. The mechanisms of 
natriuretic peptide involvement in mdx cardiomyocyte pathology are summarised in 
figure 4.26. The higher level of Nppa and Npr2 in mdx cardiomyocytes in response to 
serum starvation, as well as elevated Nppb and Npr3 in comparison to BL/10 
cardiomyocytes taken together suggests that natriuretic peptides play an active role 
in mdx cardiomyocyte hypertrophy in this model. 
 
 
Figure 4.26. Natriuretic peptides in serum starved cardiomyocytes. Atrial natriuretic 
peptide (ANP) and brain natriuretic peptide (BNP) are cleaved into their active forms 
by furin. These active peptides interact with the two natriuretic peptide receptors A 
and B (NPRA, NPRB). NPRB is a guanylyl cyclase (GC) coupled receptor and has a 
cardioprotective effect by reducing the intracellular calcium ion concentration 
([Ca2+]i). On the contrary, NPRC increases [Ca2+]i via inositol triphosphate (IP3) 
activation and can thus cause cardiac hypertrophy. 
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4.8.4 Phospholamban and Calcium Ion-handling 
There are several regulators of Ca2+-handling in cardiac myocytes, summarised in 
figure 4.27. In general, high [Ca2+]i can lead to hypertrophy and apoptosis of 
cardiomyocytes through calmodulin and calcineurin activation (Frey et al., 2004; 
Barry et al., 2008). In the previous sub-section it was already discussed that TRPCs 
are probably not involved in the mdx cardiomyocyte hypertrophic response. Another 
group of TRP channels is the vanilloid transient receptor potential (TRPV) channels, 
of which TRPV1 causes muscle hypertrophy through nNOS activation (Ito et al., 
2013), but the only TRPV gene that was expressed in cardiomyocytes was Trpv2 and 
there were no significant changes in its expression levels. The importance of nNOS 
relocalisation to the SR has been recently reported by many research groups 
investigating engineered dystrophin constructs for gene therapy (Lai et al., 2013). It is 
significant to note that the dystrophin-associated nNOS gene Nos1 was not 
expressed in BL/10 or mdx cardiomyocyte samples. This means the cardiomyocyte 
model cannot be used to test recruitment of nNOS as part of the DGC to the 
sarcolemma of mdx cardiomyocytes. 
 
In addition to NPRs, NO also activates PKG (Zois et al., 2014), which affects three 
Ca2+ channels. PKG inhibits L-type calcium channels (CaV1, also known as 
dihydropyridine receptors), which transport extracellular Ca2+ into cardiomyocytes 
(Sodi et al., 2008). The two CaV1s expressed in BL/10 and mdx cardiomyocytes were 
CaV1.2 (Cacna1c) and CaV1.3 (Cacna1d). Cacna1c was not differentially expressed, 
but Cacna1d was significantly upregulated in BL/10 from 0h to 96h serum starvation 
by 6.3-fold. The second PKG effect is inhibition of the sodium-hydrogen exchanger 
(NHE) (Pérez et al., 2007), which consequently allows the sodium-calcium exchanger 
(NCX) to lower [Ca2+]i (Bkaily et al., 2015). The NCX gene Slc8a1 was 
downregulated in both BL/10 and mdx cardiomyocytes: -2.1-fold in BL/10 0h v BL/10 
72h, -2.2-fold in BL/10 0h v BL/10 96h, -1.7-fold in mdx 0h v mdx 72h. The NHE gene 
Slc9a1 was not differentially expressed in the cardiomyocyte gene expression 
analyses. The third function of PKG is deactivation of PLN by phosphorylating it and 
allowing SERCA to reduce [Ca2+]i by transporting Ca2+ into the SR (Zois et al., 2014). 
 
The SERCA gene Atp2a2 was significantly downregulated in BL/10 cardiomyocytes 
in response to serum starvation within the first 48h: BL/10 0h v BL/10 24h by -1.7-fold 
and BL/10 0h v BL/10 48h by -1.8-fold. This trend was subsequently reversed and 
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the gene was significantly upregulated: by 1.7-fold in both BL/10 24h v BL/10 96h 
and BL/10 48h v BL/10 96h. However, in mdx cardiomyocytes Atp2a2 remained 
downregulated: by -1.5-fold in the first 24h of serum starvation and by -1.7 in the mdx 
0h v mdx 72h comparison. The SR has a much higher Ca2+ concentration than the 
sarcoplasm so to aid SERCA’s function calpastatin (Cast), calsequestrin (Casq1 and 
Casq2) and sarcalumenin (Srl) help sequester Ca2+ ions in the SR (Mosqueira et al., 
2013). While Cast was not differentially expressed in response to serum starvation, 
both Casq1 and Srl were downregulated: in BL/10 0h v BL/10 96h by -3.8 and -3.2-
fold, in mdx 0h v mdx 96h by -2.4 and -2.1-fold, respectively. Reduced Ca2+ 
sequestration may make SERCA less efficient at reducing [Ca2+]i, but it was 
unexpected that calsequestrin and sarcalumenin were downregulated by a stronger 
factor in BL/10 cardiomyocytes. 
 
PLN is also phosphorylated by protein kinase A (PKA), downstream of beta-
adrenergic receptor (βAR) activation (MacLennan & Kranias, 2003; Haghighi et al., 
2014). Pln was chosen as one of the genes used for RNA-Seq data validation. 
Unexpectedly, all of the comparisons were Pln was significantly downregulated 
based on RNA-Seq data showed upregulation in qRT-PCR data and, vice versa, 
where Pln was upregulated in RNA-Seq data, it was downregulated in qRT-PCR 
analysis (figure 4.22). 
 
RyRs release SR-stored Ca2+ and can be activated by higher [Ca2+]i as well as NO 
(discussed in sub-section 4.8.2) and RyR2 is upregulated in adult mdx hearts 
(Williams & Allen, 2007). There are three RyRs, encoded by the Ryr1, Ryr2 and Ryr3 
genes. Ryr1 was not expressed in BL/10 or mdx cardiomyocytes and the cardiac 
receptor gene Ryr2 was predominant, but not differentially expressed. Ryr3 is the 
brain RyR gene and the least studied, but both RyR2 and RyR3 are more easily 
activated by [Ca2+]i (Lanner et al., 2010). Ryr3 expression was downregulated in two 
of the mdx cardiomyocyte comparisons: by -2-fold in both mdx 24h v mdx 48h and 
mdx 24h v mdx 72h. 
 
Store-operated calcium entry (SOCE) is mediated by the SR-bound stromal 
interaction molecule (STIM) responding to lowered SR Ca2+ levels by coupling with 
the sarcolemma-bound calcium release-activated calcium channel (ORAI) protein 
causing it to form a pore for Ca2+ influx from the extracellular space (Collins et al., 
 145 
2013). SOCE is enhanced in mdx skeletal muscle (Onopiuk et al., 2015), but its role 
in mdx cardiac tissue has not been assessed. The STIM and ORAI genes – Stim1, 
Stim2, Orai1 and Orai2 – were all expressed in both BL/10 and mdx cardiomyocytes, 
but there were no significant differences between any of the comparison groups. 
 
In addition to NCX, plasma membrane Ca2+-transporting ATPases (PMCA) are the 
second major group of sarcolemmal channels lowering [Ca2+]i by pumping Ca2+ into 
the extracellular space against a high concentration gradient with ATP-supplied 
energy (MacLennan & Kranias, 2003). There are four PMCE genes: Atp2b1, Atp2b2, 
Atp2b3 and Atp2b4. Out of these Atp2b1 was the highest expressed, Atp2b2 and 
Atp2b3 were not expressed at all and only Atp2b4 was differentially expressed, in the 
mdx 0h v mdx 24h comparison it was upregulated by 1.6-fold. A partner of STIM1 
(POST) protein has been identified (Krapivinsky et al., 2011) as an inhibitor of PMCA 
in mdx skeletal muscle (Cully et al., 2012), but the POST gene Slc35g1 was not 
differentially expressed in the RNA-Seq dataset. 
 
Many Ca2+ channel genes remain unregulated or follow a similar trend of gene 
expression changes in both BL/10 and mdx serum starved cardiomyocytes. 
However, an initial downregulation of the SERCA gene Atp2a2 in BL/10 
cardiomyocytes was followed by a significant upregulation in these cells. On the 
contrary, in mdx cardiomyocytes Atp2a2 was downregulated initially in the same way, 
but not subsequently upregulated. The failure of mdx cardiomyocytes to counteract 
an initial downregulation of SERCA may affect their ability to handle elevated [Ca2+]i 
and therefore lead to onset of the hypertrophic effect. 
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Figure 4.27 Phospholamban and calcium-handling in cardiomyocytes. Nitric oxide 
(NO) and natriuretic peptide receptor B (NPRB) lead to protein kinase G (PKG) 
activation. PKG inhibits the Na+/H+ exchanger (NHE) reducing intracellular Na+ and 
therefore improving the Na+/Ca2+ exchanger’s (NCX) function to eject Ca2+ from the 
sarcoplasm to the extracellular space. PKG also inhibits L-type Ca2+ channels 
(CaV1), which bring in Ca2+ from the extracellular space. Phospholamban (PLN) is 
inhibited by phosphorylation by PKG and protein kinase A (PKA), which is activated 
by beta-adrenergic receptor (βAR) stimulation. In its phosphorylated state PLN is 
detached from the sarcoplasmic reticulum luminal Ca2+-ATPase (SERCA), allowing 
the latter to store intracellular Ca2+ in the sarcoplasmic reticulum (SR). Calpastatin, 
calsequestrin and sarcalumenin sequester SR-stored Ca2+, improving SERCA’s 
function of pumping Ca2+ into the SR against a concentration gradient. Natriuretic 
peptide receptor C (NPRC) triggers IP3 release and the SR-located IP3 receptor 
(IP3R) activation, resulting in Ca2+ release from the SR to the sarcoplasm. IP3R-
mediated reduction of SR Ca2+ activates the SR-bound stromal interaction molecule 
(STIM), which then opens the Ca2+ release-activated Ca2+ channel (ORAI), causing a 
Ca2+ influx to the sarcoplasm. RyR are another type of SR-stored Ca2+ release 
channel, therefore also stimulating STIM1. Plasma membrane Ca2+-transporting 
ATPases (PMCA) reduce [Ca2+]i by using energy from ATP to pump Ca2+ into the 
extracellular space. 
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4.8.5 SLRPs and MMPs in mdx Cardiomyocytes 
Fibromodulin is a class II small leucine-rich proteoglycan (SLRP), which aids 
collagen fibril arrangement in the ECM and has been shown to be upregulated in 
fibrosis (Kalamajski & Oldberg, 2010). The protein is encoded by the Fmod gene, 
which showed one of the strongest differential upregulation values across the serum 
starvation time-course in both BL/10 and mdx cardiomyocytes in RNA-Seq results. 
These data were replicated with qRT-PCR. Fmod expression has been shown to be 
upregulated by TGFβ2 (Westergren-Thorsson et al., 1993). The TGFβ2 gene Tgfb2 
was significantly down-regulated in BL/10 cardiomyocytes in many of the time-point 
comparisons along the serum starvation time-course in RNA-Seq data. In contrast, it 
was not significantly dysregulated in mdx cardiomyocytes following serum starvation. 
Tgfb2 was 1.7-fold upregulated in mdx cardiomyocytes in the BL/10 96h v mdx 96h 
comparison. This could also be the reason why upregulation of Fmod was more 
pronounced across the serum starvation time-course in both qRT-PCR data, but 
does not explain why the opposite (greater upregulation in BL/10 by serum 
starvation) was seen in RNA-Seq data (figure 4.23). Fmod expression comparison 
between BL/10 and mdx adult heart tissue followed the downregulation trend in qRT-
PCR results from BL/10 v mdx comparisons.  
 
Fibromodulin sequesters TGFβ1 in the ECM and consequently reduces its 
bioavailability (Hildebrand et al., 1994). Macrophages express MMP8, which is a 
collagenase and also cleaves fibromodulin, modulating its ability to sequester TGFβ1 
in the ECM and consequently increasing TGFβ1 bioavailability (Wen et al., 2015). 
However, MMP8 also cleaves full-length decorin into an active shorter form of the 
protein that then actively reduces TGFβ1 bioavailability in breast cancer (Soria-Valles 
et al., 2014). Mmp8 levels were significantly reduced in three RNA-Seq data 
comparisons: -3.4-fold in BL/10 24h v BL/10 96h, -3.7-fold in mdx 0h v mdx 96h and -
2.1-fold in mdx 24h v mdx 96h. Further investigations are required to identify which of 
these two proposed MMP8-altered TGFβ1 signalling patterns is more prevalent in 
cardiomyocytes. However, the downregulation of Mmp8 could be a cofactor in 
increased tissue fibrosis in response to hypertrophic remodelling of the heart due to 
its function as a collagenase. 
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MMP9 (a gelatinase) has been reported as a biomarker gradually elevated in DMD 
disease progression (Nadarajah et al., 2011). It can directly lead to increased TGFβ1 
levels in mdx mouse skeletal muscle and knocking down MMP9 helps the dystrophic 
phenotype seen in muscle tissue (Li et al., 2009), but there are no data on its effect in 
the dystrophic heart. MMP9 has also been reported to have an analogous 
fibromodulin cleaving function as MMP8, although MMP13 is most efficient at 
cleaving fibromodulin (Heathfield et al., 2004). Neither Mmp9 nor Mmp13 was 
differentially expressed in the RNA-Seq dataset. Lumican, which is also a SLRP like 
fibromodulin, has been shown to reduce MMP9 levels in endothelial cells (Brézillon et 
al., 2013). Interestingly, lumican was also recently identified as a serum biomarker 
significantly reduced in mdx mice when compared to BL/10 control mice (Hathout et 
al., 2014). Furthermore, lumican knockout mice have been shown to develop cardiac 
hypertrophy (Dupuis et al., 2015). Cardiomyocyte RNA-Seq analysis revealed that 
the lumican gene (Lum) was in fact upregulated in both BL/10 and mdx 
cardiomyocytes across the serum starvation time-course and not differentially 
expressed when BL/10 and mdx samples were compared against each other. 
 
Fibromodulin, decorin and biglycan have all been shown to bind TGFβ isoforms 
(Hildebrand et al., 1994). Decorin (expressed by the Dcn gene) has already been 
shown to be involved in muscle hypertrophy (Kanzleiter et al., 2014) and was also 
significantly upregulated in mdx, but not BL/10 cardiomyocytes in an immediate 
response to serum starvation within the first 24-48h: 1.6-fold in mdx 0h v mdx 24h, 
2.5-fold in mdx 0h v mdx 48h, 2.3-fold in mdx 0h v mdx 72h and 2.6-fold in mdx 0h v 
mdx 96h. 
  
Biglycan (expressed by the Bgn gene) binds to α-dystroglycan and has been shown 
to be upregulated in mdx skeletal muscle (Bowe et al., 2000). In cardiomyocyte RNA-
Seq data Bgn was upregulated by serum starvation in both BL/10 and mdx 
cardiomyocytes and not differentially expressed when BL/10 and mdx 
cardiomyocytes were compared against each other. The reason for contradicting 
results may be down to differences between skeletal and cardiac muscle, or simply 
due to the fact that Bowe et al. only noted biglycan reduction in 
immunohistochemistry images and did not show protein level quantification with 
Western blots. The antibody signal pattern in their published images showed a shift 
from an exclusively sarcolemmal signal in control wild type muscle to both 
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sarcolemmal and punctate sarcoplasmic signal in mdx muscle fibres. These results 
may have been a consequence of the mislocalisation of DGC complex members, 
including α-dystroglycan, in mdx muscle and biglycan binding to the cytosol-retained 
dystroglycan protein. 
 
Tissue inhibitors of metallopreoteinases (TIMP) have been shown to be reduced in 
mdx mouse pathology (Delfín et al., 2012). TIMP2 knockout mouse hearts become 
hypertrophic and TIMP3 knockout mice exhibit increased tissue fibrosis in the heart 
(Fan et al., 2014). Timp2 and Timp3 were both upregulated in BL/10 and mdx 
cardiomyocytes in response to serum starvation, possibly indicating their role in 
counteracting the trends in their environment, but there was no differential expression 
of either gene between the BL/10 and mdx samples. Considering the complications 
with developing pharmacological intervention on the MMP level, it may be beneficial 
to also evaluate TIMP regulation in dystrophic pathology (Delfín et al., 2012; Spinale 
& Villarreal, 2014). 
 
Fibromodulin-associated pathways discussed in this sub-section have been 
summarised in figure 4.28. It will be essential to investigate the interaction of 
fibromodulin and other SLRPs with TGFβ1 and tissue fibrosis in the cardiac setting 
before drawing conclusions on the role SLRPs play in the hypertrophic response in 
mdx cardiomyocytes. If these are validated it would indicate that treatment with MMP 
inhibitors would be a potential therapeutic option in DMD cardiac disease. 
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Figure 4.28. SLRPs and mdx cardiomyocyte hypertrophy. Small leucine-rich 
proteoglycans (SLRP) fibromodulin and decorin inhibit transforming growth factor 
beta (TGFβ) mediated hypertrophy. Fibromodulin and lumican hinder tissue fibrosis 
by facilitating extracellular matrix (ECM) assembly. Matrix metalloproteinases (MMP) 
modulate SLRPs and negatively affect ECM assembly. All three SLRPs, in red, were 
upregulated in mdx cardiomyocytes undergoing a serum starvation-induced 
hypertrophic response. 
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4.8.6 Angiogenesis and VEGF Signalling 
The Genomatix GO pathway analysis results for angiogenesis (figure 4.14) and 
VEGF (figure 4.15) pathways resulted in overlapping central genes with several 
similar interactions. The key genes from both pathways were Vegfa, Kdr, Hgf, Nos3 
and Mmp2. It is important to consider the heterogeneous origin of cells in the 
cardiomyocyte hypertrophy model and that many angiogenesis pathway regulators 
may be affected in the cardiomyocytes themselves, but a feedback loop via any 
endothelial or myofibroblast cells cannot be ruled out in this discussion. 
 
Vegfa expressing the VEGFA protein, which has been shown to be important in 
angiogenesis in dystrophic hearts (Shimizu-Motohashi & Asakura, 2014). Vegfa 
delivery with recombinant adeno-associated viruses (AAV) reduces skeletal muscle 
pathology in mdx mice through improved angiogenesis (Messina et al., 2007). Vegfa 
expression was downregulated in both BL/10 and mdx cardiomyocytes, near equally 
at the only time-point comparison that was significant in both BL/10 and mdx serum 
starved cardiomyocytes: BL/10 24h v BL/10 72h by -2.1-fold and mdx 24h v mdx 72h 
by -2-fold. Consistent with previously published data, suggesting a delayed and 
fluctuating VEGFA expression pattern in hypoxia-conditioned mdx cardiomyocytes as 
opposed to control cardiomyocytes and mdx endothelial cells (Nowak et al., 2011), 
gene expression was significantly higher in mdx cardiomyocytes at the 24h and 96h 
serum starvation time-points: BL/10 24h v mdx 24h by 1.8-fold and BL/10 96h v mdx 
96h by 2.6-fold. These RNA-Seq expression data were not replicated in qRT-PCR 
analysis experiments, where the average trend of Vegfa expression was also 
fluctuating in BL/10 cardiomyocyte samples but in the upregulation direction. It is 
therefore complicated to draw conclusions from the transcriptional regulation data.  
 
VEGFA exerts its function by activating VEGF receptor 2 (VEGFR2, also known as 
Flk-1 and encoded by the Kdr gene) (Ennen et al., 2013). It also binds at a higher 
affinity to VEGFR1 (also known as Flt1 and expressed by the Flt1 gene), which has a 
soluble isoform, acting as a decoy receptor and inhibiting the VEGFA response by 
sequestering it (Taimeh et al., 2013). However, expression of the Kdr gene was 
significantly downregulated in both mdx and BL/10 cardiomyocytes in response to 
serum starvation: BL/10 0h v BL/10 96h by -7.4-fold and mdx 0h v mdx 96h by -9.4-
fold. The Flt1 gene was not differentially expressed.  
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VEGFR2 activates the phosphatidylinositide 3-kinase (PI3K) and protein kinase B 
(Akt) signalling pathway is also able to trigger the PI3K/Akt/mTOR (mammalian target 
of rapamycin) pathway (Kim et al., 2013). Both of these pathways induce 
angiogenesis in endothelial cells, but mTOR has been shown to promote hypertrophy 
in a range of tissues, including the heart (Neishabouri et al., 2015). A recent 
publication showed that downregulation of the Pik3ip1 gene, which expresses an 
inhibitor of the PI3K/Akt/mTOR pathway, induced cardiac hypertrophy (Song et al., 
2015). Pik3ip1 was upregulated by 10.8-fold in the BL/10 0h v BL/10 96h comparison 
and only 4.4-fold in the mdx 0h v mdx 96h comparison in RNA-Seq data. This 
reduced effect seen in mdx cardiomyocytes could potentially be one of the reasons 
for the increased hypertrophic response. Pik3ip1 and its protein product should 
therefore be further investigated as a potential target for inhibiting dystrophic 
hypertrophy. 
 
The hepatocyte growth factor (HGF) gene Hgf was significantly upregulated only in 
the mdx 0h v mdx 96h comparison, by 2.5-fold. It was also upregulated in BL/10 
cardiomyocytes but this increase in gene expression did not reach statistical 
significance. However, the HGF receptor gene Met was significantly downregulated 
in response to serum starvation, by -1.7-fold in the mdx 0h v mdx 96h comparison. 
The roles of HGF and its receptor in the heart are still in the process of being 
established. Constitutive activation of the receptor has been shown to cause 
hypertrophy in cardiomyocytes (Leo et al., 2011). Downregulation of Met could 
therefore be a protective mechanism that mdx cardiomyocytes undergo in response 
to other signals or even a negative feedback loop in response to the upregulation of 
Hgf. 
 
Nos3 expresses endothelial nitric oxide synthase (eNOS), which was the only 
abundantly and differentially expressed NOS in BL/10 and mdx cardiomyocytes. The 
gene was downregulated by -6.4-fold in the BL/10 0h v BL/10 96h comparison and -
2.6-fold in the mdx 0h v mdx 96h comparison, although, the difference between 
expression in BL/10 and mdx cardiomyocytes at the 96h time-point was non-
significant. VEGFA can initiate vasorelaxation by activating NO production by eNOS 
via the PI3K/Akt pathway (Taimeh et al., 2013). It was mentioned in sub-section 4.8.4 
that the nNOS gene Nos1 was not expressed in BL/10 or mdx cardiomyocytes. The 
combined effect of nNOS absence and Kdr downregulation-caused blunting of 
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VEGFA signalling resulting in reduced activation of eNOS on a non-vascularised cell 
culture system, such as the cardiomyocyte serum starvation model, remains to be 
elucidated. Perhaps upregulation of Angptl4 (discussed in sub-section 4.8.1) may 
counteract the severe NO-deficiency in the cardiomyocyte model by increasing 
iNOS-produced NO, but considering the low expression level of Nos2 it may not 
suffice for a cardioprotective effect. There is mounting evidence that cGMP-specific 
phosphodiesterase type 5 (PDE5) inhibitors can attenuate dystrophin deficiency-
related skeletal and cardiac muscle pathology (Khairallah et al., 2008; Kobayashi et 
al., 2008; Martin et al., 2012; Nelson et al., 2014). Considering the aberrant NO 
production identified in these results, and despite sildenafil (a PDE5 inhibitor) not 
having shown desirable effects in a recently aborted clinical trial (Leung et al., 2014), 
it will be useful to identify whether other PDE5 inhibitors are capable of reducing mdx 
cardiomyocyte hypertrophy in this model. Furthermore, the Pde5a gene was 
upregulated in both BL/10 and mdx cardiomyocytes in response to serum starvation, 
but only significantly in the mdx 0h v mdx 96h comparison, by 1.9-fold. This suggests 
that PDE5 may play a role in mdx cardiomyocyte hypertrophy and gives further 
confirmation of the model’s potential for testing inhibitors of the protein. 
 
VEGFA can induce Mmp2 expression via VEGFR2 (Wagner et al., 2003). The nearly 
equally 3-fold elevated expression pattern of Mmp2 in both BL/10 and mdx 
cardiomyocytes in response to serum starvation was discussed in sub-section 4.8.1. 
MMP2 is also capable of increasing TGFβ bioavailability via cleaving fibromodulin, 
but the counteractive function of decorin (also upregulated) may balance this effect 
(discussed in sub-section 4.8.5) (Wen et al., 2015). 
 
It is possible that VEGFA triggers a hypertrophic response in serum starved 
cardiomyocytes through angiogenesis-related signalling. It must also be considered 
whether these candidate pathways, responsible for differences between BL/10 and 
mdx cardiomyocytes, act in an autocrine fashion (expressed and affecting the same 
cell) or in concert with other cells in culture. Based on observations reported in this 
sub-section PI3K and mTOR pathway activation and PDE5 inhibitors will be the 
primary targets for further investigations.  
 
 154 
4.8.7 Hypoxia Signalling Pathways 
The HIF-1α hypoxia signalling pathway was identified in GO analysis of BL/10 and 
mdx cardiomyocyte RNA-Seq data (shown in figures 4.16 and 4.17). HIF-1α is the 
oxygen-regulated subunit of the HIF-1 heterodimer, formed with HIF-1β, which is 
constitutively expressed (Wang et al., 1995). HIF-1 induces gene expression by 
binding to hypoxia response elements of genes, regulating over a thousand genes in 
humans (Semenza, 2014). The Hif1a gene, which expresses the HIF-1α subunit in 
mice, was significantly upregulated in BL/10 cardiomyocytes in response to serum 
starvation, by 2.3-fold in the BL/10 0h v BL/10 96h comparison, 2.4-fold in BL/10 24h 
v BL/10 96h and 2.1-fold in BL/10 48h v BL/10 96h. It was also significantly 
upregulated in the mdx 24h v mdx 96h comparison, by 1.8-fold. 
 
In the Genomatix GO analysis pathway maps in figures 4.16 and 4.17 all of the 
differentially expressed HIF-1α related genes were red and therefore upregulated in 
the BL/10 96h v mdx 96h serum starvation time-point comparison. This was striking 
considering the slightly lower upregulation of HIF-1α in mdx cardiomyocytes and a 
non-significant -1.4-fold downregulation in the BL/10 and mdx cardiomyocyte 
comparison at 96h of serum starvation. Furthermore, investigating expression 
patterns of HIF-1 target genes Bhlhe40, Eno1, Hk1 and Hk2 revealed a trend where 
most genes were down-regulated in BL/10 cardiomyocytes compared to mdx cells.  
 
It was recently discovered that hypoxic cardiomyocytes are capable of going through 
cell cycling and thus contribute towards regeneration in adult mouse hearts (Kimura 
et al., 2015). The publication listed several cell cycle genes that were upregulated in 
hypoxic cardiomyocytes, out of which none were differentially expressed in the RNA-
Seq dataset, apart from Ccnb1, which was conversely downregulated in both BL/10 
and mdx cardiomyocytes in response to serum starvation. Furthermore, prolyl 
hydroxylase 3 (Egln3 gene), which inhibits HIF-1α (Henze et al., 2014), was  
drastically downregulated in the BL/10 0h v BL/10 96h comparison, by almost 10-
fold, whilst in mdx cardiomyocytes its expression remained stable. This should be 
indicative of stronger negative regulation of HIF-1 functionality in mdx 
cardiomyocytes and makes it even more striking that many HIF-1 target genes are 
downregulated to a greater extent in BL/10 cardiomyocytes. It may be that whilst on 
the transcriptome level there is not as great an increase in Hif1a expression, 
increased [Ca2+]i is improving Hif1a translation and despite lower mRNA there is 
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more HIF-1α protein expressed and therefore the balance of HIF-1 effect is shifted 
towards upregulation in mdx cardiomyocytes as compared to BL/10 cells (Hui et al., 
2006). 
 
HIF-1 regulates many mitochondrial genes in response to hypoxic conditions (Hwang 
et al., 2015). It positively regulates Bnip3, encoding Bcl-2/adenovirus E1B 19kDa-
interacting protein 3, which activates apoptosis and mitochondrial autophagy while 
impairing mitochondrial respiration (Rikka et al., 2011). The Bnip3 gene was 
markedly downregulated in BL/10 cardiomyocytes in response to serum starvation 
(BL/10 0h v BL/10 96h by -4.7-fold), but not differentially expressed in mdx 
cardiomyocytes. This could mean that BL/10 cardiomyocytes adapt to survive in the 
serum starvation condition, whereas mdx cardiomyocytes are less able to inhibit 
apoptotic signals. 
 
The mitochondrial HIF-1 target gene Ndufa4l2 expresses a protein shown to inhibit 
complex I activity and consequently reduce ROS in hypoxic conditions (Tello et al., 
2011). The gene was also upregulated in skeletal muscle of mdx mice treaded with 
tadalafil, a PDE5 inhibitor (De Arcangelis et al., 2015). Ndufa4l2 was initially 
upregulated by 48h of serum starvation and subsequently downregulated by 96h in 
BL/10 cardiomyocytes (but only significantly in the 24h v 96h and 48h v 96h 
comparisons), as opposed to being significantly upregulated in the first 24h, followed 
by stable expression in mdx cardiomyocytes, resulting in significant upregulation in 
the 0h v 24h, 0h v 48h, 0h v 72h comparisons (figure 4.25). The mdx cardiomyocyte 
expression pattern was very closely replicated with qRT-PCR experiments, which did 
not show the same expression patterns seen in BL/10 cardiomyocytes analysed with 
RNA-Seq. Consequently, the significant upregulation of Ndufa4l2 witnessed in the 
BL/10 96h v mdx 96h comparison was diminished to a slight downregulation, which 
did not cross the FC cut-off limit in qRT-PCR data. Although the differences in BL/10 
cardiomyocyte Ndufa4l2 expression were unexpected, the close replication of mdx 
cardiomyocyte gene expression response to serum starvation was a positive result 
and it would be interesting to see whether PDE5 inhibitor treatment in this mdx model 
of hypertrophy would also upregulate Ndufa4l2 expression in cardiomyocytes. 
 
Results on hypoxia signalling indicate that mdx cardiomyocytes exhibit higher HIF-1 
function and a consequent deficiency in the coping-mechanism to tackle the effect of 
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serum starvation in comparison to BL/10 cells, based on stronger downregulation of 
HIF-1 target genes, the HIF-1 inhibitor Egln3 and apoptosis-inducing Bnip3 in BL/10 
cardiomyocytes. Upregulation of Ndufa4l2 by higher HIF-1 activity in mdx 
cardiomyocytes may also suggest an alternative mechanism for tackling oxidative 
stress and reduce ROS in tandem with upregulated SOD3 (sub-section 4.8.1) to 
compensate for compromised NOS activity (sub-section 4.8.6). 
 
4.8.8 Summary 
In addition to the many pathways and genes already discussed, there were many 
differentially expressed genes that there is little known about. For example, Erdr1 
was significantly downregulated in BL/10 cardiomyocytes in response to serum 
starvation, but not expressed at all in mdx cells. The gene expresses an erythroid 
differentiation regulator, which is upregulated in adult mdx mouse heart tissue 
compared to BL/6 hearts (Spurney et al., 2008) and induces apoptosis in 
keratinocytes (Kim et al., 2011), which makes it an interesting target for further 
investigations.  
 
Near negligible expression of Erdr1 in mdx cardiomyocytes and a relatively low level 
of nominal transcript level in BL/10 cardiomyocytes, based on HT-Seq data, were 
reasons for omitting the gene from qPCR validation. In fact, out of all the genes in 
figure 4.9, only Erdr1, Dmd, Cxcl12, Gm20939 and 3110056K07Rik remained as 
significant differentially expressed genes once the adjusted p-value cut-off was 
lowered to 0.01 and a fold change cut-off introduced at Log2FC=+/-0.6. Out of these 
Gm20939 is a predicted gene only identified in mouse genome and the function of 
the Riken gene has not been determined yet. The disease-causing Dmd gene was 
omitted from qPCR validation because it was not seen as valuable for confirming 
potential members of pathways affecting the hypertrophic response. Cxcl12 had the 
highest fold change in the BL/10 96h v mdx 96h comparison, where it was only 
upregulated 2-fold and therefore genes with higher maximum fold changes identified 
from other comparisons were chosen. Furthermore, Clic5 was identified as the only 
gene significantly regulated in opposite directions when comparing control cell serum 
starvation to dystrophic cardiomyocyte hypertrophic response: downregulated in 
BL/10 0h v 96h by -2.2-fold and upregulated in mdx 0h v 96h by 1.6-fold (figure 4.18 
and appendix 1). Whilst it was not one of the highest regulated genes in the BL/10 
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96h v mdx 96h comparison it remains one of the strongest candidates for further 
RNA-Seq data validation with qPCR. 
 
In a similar way to Erdr1, there is a lot of cross-talk between the various signalling 
pathways already discussed in this chapter. For instance, mTOR can also be 
activated by Ca2+-mediated signals and therefore it may be high [Ca2+]i rather than 
VEGFA driving the mTOR hypertrophic pathway (Zhang et al., 2012).  
 
A significant limitation to the Illumina HiSeq platform for RNA-Seq studies is the lack 
of micro-RNA (miRNA) expression data due to the sequencing technique the 
machine employs. Several roles of miRNAs in DMD pathology (Jeanson-Leh et al., 
2014) and cardiovascular diseases (Pan et al., 2010) have emerged, but their roles in 
mdx cardiomyocyte serum starvation-induced hypertrophy could not be assessed. 
Many FGP markers had the same trends in both BL/10 and mdx cardiomyocytes in 
response to serum starvation. This is indicative of a hypertrophic response emerging 
in both mouse models. However, BL/10 cardiomyocytes seem to adapt better to 
serum starvation and arrest their size increase. Markers of cardiac hypertrophy, both 
confirmed and novel, that were differentially expressed in the RNA-Seq dataset need 
validation on protein level to confirm functional compromise in mdx cardiomyocytes. 
The blunted levels of differential expression seen when qRT-PCR data were 
compared to RNA-Seq data Nppb expression validation and the augmented effect 
witnessed in Fmod validation, coupled with irregular discrepancies in confirming low 
level regulation trends in Vegfa and Pln showed that low levels of differential 
expression were challenging to validate with qRT-PCR, despite very close replication 
of mdx cardiomyocyte Ndufa4l2 expression seen in both RNA-Seq and qRT-PCR 
analyses.  
 
These differences between the two techniques may have been caused by the 
omission of one set of BL/10 biological replicate samples from sequencing. Whilst the 
RNA-Seq method has more methodological steps open to variability factors in 
comparison to performing gene-by-gene analyses with qRT-PCR, DeSeq2 
normalises gene expression to the geometric mean of counts across the samples for 
every given gene separately and then divides the nominal count by the geometric 
mean (Love et al., 2014). This eliminates potential sample-to-sample composition 
variability, dependence on primer efficiency and normalisation to house-keeping 
 158 
genes, providing more reliable differential expression data. Having a third biological 
replicate of BL/10 cardiomyocytes for RNA-Seq analysis could have improved the 
power of this study, but in this case it was also important to investigate two factors: 
the differences between BL/10 and mdx cardiomyocytes, as well as the effect serum 
starvation had on the cells. Whilst there were less differentially expressed genes 
identified from genotype comparisons at certain time-points, data obtained from 
serum starvation time-point comparisons also gave information about genotype 
differences, independent of direct comparisons between BL/10 and mdx 
cardiomyocyte samples. Considering the number of comparisons performed with 
each dataset, the number of quality control steps and increasing cut-offs on both the 
FDR and FC level, the filtered results provided a powerful tool for investigating genes 
and pathways involved in mdx cardiomyocyte hypertrophy. 
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Chapter 5. Influencing the mdx Cardiomyocyte Hypertrophic 
Response with DMD Therapies 
 
5.1 Introduction and Aims 
Several therapies for Duchenne muscular dystrophy (DMD) have now reached 
clinical trial stage. Ataluren, a small molecule drug designed to promote stop codon 
read-through, has recently been conditionally approved for use as a prescription 
medicine for patient with nonsense mutation DMD (Haas et al., 2015). This drug, 
however, only provides hope for a fraction of the DMD patient cohort with nonsense 
mutations, whereas the majority of patients have large deletions (Bladen et al., 
2015). Several adeno-associated virus (AAV) vector therapies for either restoring the 
reading frame or reintroducing dystrophin gene expression are also moving closer to 
approval (Okada & Takeda, 2013). The European Medicine Agency’s approval of an 
AAV drug designed for lipoprotein lipase replacement (Ylä-Herttuala, 2012) also 
paved the way for AAV therapies in DMD. Until there is a universal cure available it is 
pivotal to provide the best patient care possible to manage DMD disease 
progression. A range of pharmacological compounds are currently prescribed to 
dystrophinopathy patients to manage their skeletal muscle and cardiac symptoms. 
These include corticosteroids, angiotensin converting enzyme (ACE) inhibitors and 
beta-adrenergic receptor (βAR) blockers (Bushby et al., 2010a).  
 
This chapter aims to test a range of pharmacological compounds already prescribed 
to DMD patients for managing the progression of their disease, as well as novel 
treatment compounds and rescue therapies, to assess their ability to reduce mdx 
cardiomyocyte hypertrophy as a model for how these compounds affect, or could 
influence, the progression of cardiac symptoms in DMD. 
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5.2 Overview of the Experimental Setup 
Cardiomyocytes were isolated from BL/10 and mdx E17.5 mouse hearts and cultured 
for 48h (figure 5.1). Treatment with therapeutic compounds or viral transductions 
were performed at the 24h time-point. At the subsequent 48h and 72h serum 
starvation time-points cells were fed with fresh medium and treatment compounds 
were replenished in samples undergoing therapeutic testing. Samples at specific 
time-points of serum starvation were fixed for ICC or collected for protein extraction. 
 
 
Figure 5.1. Experimental time-course of primary cardiomyocyte treatment. Cells were 
cultured in cardiomyocyte growth medium for 48h, followed by serum starvation for 
96h, feeding with fresh medium every 24h. Viral transductions were performed at the 
24h serum starvation time-point. Samples used for trialling therapeutic compounds 
were drug treated at the 24h serum starvation time-point and fresh compounds were 
added every subsequent 24h. 
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5.3 Corticosteroid Treatment 
Prescribing corticosteroids to DMD patients is now included in care guides for 
disease management (Kinnett et al., 2015). Prednisolone is a corticosteroid that 
delays loss of ambulation in DMD patients (Takeuchi et al., 2013). Dexamethasone 
and prednisolone were tested for their efficacy at reducing mdx cardiomyocyte 
hypertrophy. Cardiomyocytes were serum starved for 96h with serum-free 
cardiomyocyte growth medium (SFCGM) or serum starvation cardiomyocyte medium 
(SSCGM), supplemented with 1% foetal bovine serum (FBS). Corticosteroid 
treatment was commenced at 24h serum starvation time-point.  
 
5.3.1 Prednisolone Treatment 
Prednisolone was most effective at inhibiting mdx cardiomyocyte hypertrophy when 
used at 100ng/ml (average area 2631µm2). However, the observed 13% reduction in 
area, in comparison to untreated 96h serum starved cells (average area 3026µm2), 
was not significant when compared using a one-tailed Student’s t-test at equal 
variance based on Levene’s test (figure 5.2). Cells were serum starved with SFCGM. 
ICC and image analysis were performed by MRes student Elizabeth Roberts. 
Skedasticity and t-test results from data comparisons are shown in table 5.1. 
 
Comparison Levene's Test p-value Variance t-test p-value 
96h v 24h 1.51319E-05 Unequal 2.3479E-18 
96h v 10µg/ml 0.78086589 Equal 0.2261 
96h v 1µg/ml 0.481370467 Equal 0.3518 
96h v 100ng/ml 0.559064721 Equal 0.0709 
96h v 10ng/ml 0.034323749 Unequal 0.1864 
96h v 1ng/ml 0.691998928 Equal 0.3742 
96h v 100pg/ml 0.234368987 Equal 0.2803 
Table 5.1. Prednisolone treatment statistical analyses results. The first column 
represents Levene’s test and Student’s t-test comparisons. 24h and 96h represent 
the time of non-treated control serum starvation duration. Concentrations represent 
prednisolone-treated 96h serum starved samples. Significant t-test p-value<0.05 is 
underlined. 
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Figure 5.2. The effect of prednisolone on mdx cardiomyocyte hypertrophy. Serum 
starved cardiomyocytes were treated with a range of prednisolone concentrations 
from the 24h serum starvation time-point (red columns). Non-treated control 
cardiomyocytes (blue columns) serum starved for 96h were significantly larger than 
cells serum starved for 24h (*** corresponds to p-value<0.001). The average area 
measurements of cardiomyocytes treated with 1µg/ml, 100ng/ml and 10ng/ml 
prednisolone in SFCGM were smaller than the non-treated sample, but none of these 
reductions in area were statistically significant (NS stands for non-significant), based 
on one-tailed Student’s t-test analysis. Error bars represent standard error of the 
mean. 
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5.3.2 Dexamethasone Treatment 
Dexamethasone is a more potent agonist of glucocorticoid receptors (GCR) and has 
a longer half-life than prednisolone (Longui, 2007). It has also been shown that 
dexamethasone has a beneficial effect on maintaining beating functions in embryoid 
bodies (Dehghani et al., 2013). Serum starvation cardiomyocyte growth medium 
(SSCGM) was used to initiate a hypertrophic response in mdx cardiomyocytes, 
followed by dexamethasone treatment 24h later. Cardiomyocyte area was measured 
from images of cells positive for α-actinin immunostaining. A trial experiment was 
conducted where four 96h serum starved samples were analysed, one non-treated 
control and three different concentrations of dexamethasone treatment: at 20µg/ml, 
2µg/ml and 200ng/ml. One-tailed Student’s t-test analyses of compared samples 
showed that treating cardiomyocytes with all three concentrations of dexamethasone 
resulted in significantly reduced cardiomyocyte area (figure 5.3 and table 5.2). 
 
Comparison Levene's Test p-value Variance t-test p-value 
96h v 20µg/ml 0.05927345 Equal 0.000382483 
96h v 2µg/ml 0.000705371 Unequal 2.77107E-07 
96h v 200ng/ml 0.005331064 Unequal 4.69495E-09 
Table 5.2. Dexamethasone treatment statistical analyses results. The first column 
represents Levene’s and Student’s t-test comparisons. All samples were serum 
starved for 96h. In the column, 96h represents the non-treated control sample and 
the concentrations represent samples treated with dexamethasone. Significant t-test 
p-values<0.05 are underlined. 
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Figure 5.3. Small-scale study of dexamethasone effect on mdx cardiomyocyte 
hypertrophy. Serum starved cardiomyocytes were treated with three concentrations 
of dexamethasone from the 24h serum starvation time-point (red columns). Non-
treated control cardiomyocytes serum starved for 96h (blue column) were 
significantly larger than cells treated with dexamethasone (*** corresponds to p-
value<0.001), assessed by one-tailed Student’s t-test. Error bars represent standard 
error of the mean. 
 
Dexamethasone powder was dissolved in ethanol and the 20µg/ml treatment solution 
had a 2% (V/V) ethanol concentration. Two studies were subsequently performed 
where a separate corresponding ethanol concentration vehicle-treated control 
sample was also included in parallel with each dexamethasone-treated sample 
(figure 5.4). Although the results showed that dexamethasone-treated 
cardiomyocytes were on average smaller than 96h serum starved non-treated cells, 
the vehicle-only treated cardiomyocytes were also smaller, and at 200ng/ml 
dexamethasone / 0.02% ethanol in the first study (figure 5.4.A) vehicle-treated cells 
were even smaller than the non-treated 24h serum starvation control sample. 
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Figure 5.4. Controlled studies of dexamethasone effect on mdx cardiomyocyte 
hypertrophy. Serum starved cardiomyocytes were treated with three concentrations 
of dexamethasone (red columns) and the corresponding ethanol vehicle (dark blue 
columns) from the 24h serum starvation time-point. Non-treated control 
cardiomyocytes (light blue columns) serum starved for 96h were on average larger 
than cells treated with dexamethasone or ethanol. Error bars represent SEM. 
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5.4 Angiotensin Converting Enzyme Inhibitor Treatment 
ACE inhibitors are considered a first-line therapy to tackle DMD cardiac pathology 
(Bushby et al., 2010a). The effect of captopril – an ACE inhibitor drug – on mdx 
cardiomyocyte hypertrophy was assessed. Adding 1g of captopril to 10ml of SFCGM 
caused a drop in the stock solution pH, observed from the change in SFCGM 
colouration. In order to compensate for this change the solution was supplemented 
with 450µl of 1M sodium hydroxide (NaOH), restoring the normal pH level of SFCGM 
(figure 5.5). 
 
 
Figure 5.5. Pharmacological Compound stock solution pH. Adding captopril to serum-
free cardiomyocyte growth medium (SFCGM) changed the solution’s pH. The stock 
solution pH was adjusted with 450µl of 1M sodium hydroxide (NaOH) to bring it back 
to the physiological level of SFCGM. 
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Cardiomyocytes isolated from mdx E17.5 hearts were serum starved and treated with 
100µg/ml, 10µg/ml, 1µg/ml, 100ng/ml or 10ng/ml captopril. MRes student Elizabeth 
Roberts quantified the area of non-treated cells at 0h, 24h and 96h of serum 
starvation, along with captopril-treated cells at each of the concentrations. On 
average, 100µg/ml, 1µg/ml and 100ng/ml captopril treated cells were considerably 
smaller than the 96h non-treated control sample (figure 5.6), but only the 100µg/ml 
caused a significant reduction in cardiomyocyte area, determined by a one-tail 
Student’s t-test (p-value<0.05). This reduction resulted in the treated cardiomyocyte 
average area being non-significantly different from the 24h serum starved non-
treated control cells, assessed by the same method, taking into account 
heteroskedasticity between the samples, assessed by Levene’s test (table 5.3). 
Although there was no significant difference between the 24h control cardiomyocytes 
and 1µg/ml captopril treated cells, the difference between 96h control cells and 1 
µg/ml treated cells was also non-significant. 
 
Comparison Levene's Test p-value Variance t-test p-value 
96h v 24h 0.030863692 Unequal 0.0130 
96h v 100µg/ml 0.097869639 Equal 0.0420 
24h v 100µg/ml 0.326658334 Unequal 0.3554 
96h v 10µg/ml 0.260166933 Equal 0.3907 
24h v 10µg/ml 0.001030229 Equal 0.0130 
96h v 1µg/ml 0.147505382 Equal 0.0524 
24h v 1µg/ml 0.246194231 Equal 0.2986 
96h v 100ng/ml 0.60258218 Equal 0.1181 
96h v 10ng/ml 0.449104105 Equal 0.4121 
Table 5.3. Captopril treatment statistical analyses results. The first column represents 
Levene’s and Student’s t-test comparisons. 24h and 96h represent the non-treated 
control samples and the concentrations represent 96h serum starved samples 
treated with captopril. Significant t-test p-values<0.05 are underlined. 
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Figure 5.6. The effect of Captopril on mdx cardiomyocyte hypertrophy. Serum 
starved cardiomyocytes were treated with a range of captopril concentrations from 
the 24h serum starvation time-point (red columns). Non-treated control 
cardiomyocytes (blue columns) serum starved for 96h were significantly larger than 
cells serum starved for 24h and cells treated with 100µg/ml captopril (* corresponds 
to p-value<0.05). The average area measurements of cardiomyocytes treated with 
1µg/ml, 100ng/ml and 10ng/ml captopril in SFCGM were also smaller than the non-
treated sample, but none of these reductions in area were statistically significant (NS 
stands for non-significant), based on one-tailed Student’s t-test analysis. Error bars 
represent standard error of the mean. 
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5.5 Beta-adrenergic Receptor Blocker Treatment 
The combination treatment of cardiomyopathy with ACE inhibitors and βAR blockers 
has shown improved left ventricular function in DMD patients (Jefferies et al., 2005). 
The effect of metoprolol, a β1AR blocker, on mdx cardiomyocyte hypertrophy was 
assessed. MRes student Elizabeth Roberts serum starved cardiomyocytes with 
SFCGM for 24h, followed by metoprolol treatment at five concentrations in one 
magnitude steps from 50µg/ml to 5ng/ml. All of metoprolol treated cardiomyocytes 
were on average larger than non-treated 96h serum starved control cells. In fact, 
based on one-tailed Student’s t-test analyses the 500ng/ml, 50ng/ml and 5ng/ml 
metoprolol treatments caused a significant increase in average cardiomyocyte area 
in comparison to 96h serum starved non-treated control cells (table 5.4). 
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Figure 5.7. The effect of metoprolol on mdx cardiomyocyte hypertrophy. Serum 
starved cardiomyocytes were treated with a range of metoprolol concentrations (red 
columns) from the 24h serum starvation time-point. Non-treated control 
cardiomyocytes (blue columns) serum starved for 96h were significantly larger than 
cells serum starved for 24h (*** corresponds to p-value<0.001). The average area 
measurements of cardiomyocytes treated with 500ng/ml, 50ng/ml and 5ng/ml 
metoprolol in SFCGM were significantly larger than the non-treated 96h serum 
starved control sample (* corresponds to p-value<0.05), based on one-tailed 
Student’s t-test analysis. Error bars represent standard error of the mean. 
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Comparison Levene's Test p-value Variance t-test p-value 
96h v 24h 0.001130576 Unequal 4.44297E-05 
96h v 50µg/ml 0.864760912 Equal 0.2148 
96h v 5µg/ml 0.353772268 Equal 0.2408 
96h v 500ng/ml 0.183411251 Equal 0.0287 
96h v 50ng/ml 0.656947668 Equal 0.0187 
96h v 5ng/ml 0.918614095 Equal 0.0189 
Table 5.4. Metoprolol treatment statistical analyses results. The first column 
represents Levene’s and Student’s t-test comparisons. 24h and 96h represent the 
non-treated control samples and the concentrations represent 96h serum starved 
samples treated with metoprolol. Significant t-test p-values<0.05 are underlined. 
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Angiotensin (Ang) signalling is mediated by the mitogen-activated protein kinase 
(MAPK) and extracellular signal-regulated kinase (ERK) mediated pathways 
(Schlüter & Wenzel, 2008). The protein level of β1AR and activation of ERK pathway 
in BL/10 and mdx cardiomyocytes undergoing serum starvation were assessed by 
Western blotting with antibodies targeting β1AR and phosphorylated ERK1/2, 
respectively (figure 5.8). Protein expression patterns were similar along the serum 
starvation course in both types of cardiomyocytes, assessed by quantifying protein 
band intensities and adjusting to skeletal myosin heavy chain (MYH6) band 
intensities with ImageJ software. Phosphorylated ERK1/2 levels were lower in mdx 
cardiomyocytes in comparison to BL/10 cells at the start of serum starvation (0h). By 
48h of serum starvation the protein level of activated ERKs in mdx cardiomyocytes 
was higher and although at 72h the levels were relatively equal, by 96h there was 
again more phosphorylated ERK 1/2 in mdx cells. β1AR expression was near two-fold 
higher in BL/10 cardiomyocytes at the start of serum starvation in comparison to 
serum starved BL/10 cells and all mdx samples. In mdx cardiomyocytes an initial 
reduction in β1AR protein level in response to serum starvation by the 24h time-point 
was reversed and expression levels similar to the 0h sample were evident in the 
remaining serum starvation time course. Pearson’s chi-squared test was used to 
identify whether there was a significant difference in ERK phosphorylation or β1AR 
expression between all BL/10 and mdx samples or only serum starved (24h, 48h, 72, 
96h) BL/10 and mdx cardiomyocyte samples. In both comparisons for both proteins 
of interest the observed expression levels in mdx cardiomyocytes were significantly 
different (p-value<0.001) than BL/10 cells (table 5.5). 
 
Comparison Protein Σ (O-E)2/E DoF 𝑿2 p<0.001 H0 
All BL/10 v mdx β1AR 9634 4 18.47 Reject 
All BL/10 v mdx p-ERK 5632 4 18.47 Reject 
SS BL/10 v mdx β1AR 1029 3 16.27 Reject 
SS BL/10 v mdx p-ERK 2379 3 16.27 Reject 
Table 5.5. Protein expression and activation statistical analyses. Sample relative 
protein levels were determined and compared. BL/10 cardiomyocytes were the 
expected (E) and mdx cells the observed (O) datasets. Chi squared (𝑿2) values for p-
value<0.001 based on degrees of freedom (DoF) were used to either accept or reject 
the null hypothesis (H0) of observed values not differing from expected values. 
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Figure 5.8. ERK activation and β1AR expression in mdx cardiomyocytes. Protein 
samples from BL/10 and mdx cardiomyocytes along the serum starvation time-
course were analysed by Western blotting, with antibodies targeting beta-1 
adrenergic receptor (β1AR) and phosphorylated extracellular signal-regulated kinase 
(p-ERK1/2). Protein expression levels were normalised to skeletal myosin heavy 
chain (MYH6). 
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5.6 Sodium-hydrogen Exchanger Inhibitor Treatment 
The role of sodium-hydrogen exchanger (NHE) in cardiomyocyte hypertrophy was 
discussed in sub-section 4.8.4. It has been hypothesised that inhibiting the NHE 
channel may reduce cardiomyocyte hypertrophy by reducing the sodium gradient in 
cardiomyocytes and thus aiding the sodium-calcium exchanger (NCX) to clear 
intracellular Ca2+ ions from the sarcoplasm (Bkaily et al., 2015). KR-33028 is a potent 
compound used to inhibit NHE activity (Jung et al., 2006).  
 
The effect of KR-33028 treatment on mdx cardiomyocyte hypertrophy was assessed 
at five drug concentrations ranging from 100µM to 10nM in one order of magnitude 
increments. The compound was dissolved in polyethylene glycol (PEG) and vehicle-
only control samples treated with corresponding PEG concentrations were therefore 
also conducted for each compound concentration used. Cardiomyocytes treated with 
100µM of KR-33028 in SSCGM were significantly smaller than non-treated control 
cardiomyocytes by the 96h serum starvation time-point (figure 5.9).  
 
Although the 0.85% PEG (V/V) vehicle-treated cardiomyocytes, corresponding to the 
PEG content in 100µM KR-33028, also showed a significant reduction in mdx 
cardiomyocyte hypertrophy, there was a significant difference between the average 
area measurements of 100µM KR-33028 and 0.85% PEG treated samples. There 
was no significant difference between the no treatment control 96h serum starved 
sample and the 0.085% as well as 0.0085% PEG treated samples, but 0.00085% 
and 0.000085% PEG treatment resulted in significant cardiomyocyte area reduction. 
A significant reduction in average cardiomyocyte area was also recorded in 10nM 
KR-33028-treated cells (table 5.6). 
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Figure 5.9. The effect of KR-33028 on mdx cardiomyocyte hypertrophy. Serum 
starved cardiomyocytes were treated with a range of KR-33028 (red columns) and 
corresponding PEG vehicle concentrations (dark blue columns) from the 24h serum 
starvation time-point. Non-treated control cardiomyocytes (light blue columns) serum 
starved for 96h were significantly larger than cells serum starved for 24h, as well as 
100µM KR-33028 and 0.85% PEG-treated cells (*** corresponds to p-value<0.001). 
The average area of cardiomyocytes treated with 100µM KR-33028 was also 
significantly lower than 0.85% PEG-treated cells. One-tailed Student’s t-test and 
Levene’s test were used for statistical analyses. Error bars represent standard error 
of the mean. 
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Comparison Levene's Test p-value Variance t-test p-value 
24h v96h 6.98923E-88 Unequal 2.3479E-18 
24h v 100µM 1.08952E-20 Unequal 0.0003 
96h v 100µM 2.26175E-25 Unequal 1.3092E-84 
100µM v .85% 1.3551E-11 Unequal 5.37354E-22 
24h v .85% 8.10486E-53 Unequal 7.61135E-40 
96h v .85% 0.008976764 Unequal 3.64483E-14 
96h v 10µM 0.545493143 Equal 0.0228 
96h v .085% 0.030950756 Unequal 0.2448 
96h v 1µM 0.628426431 Equal 0.1024 
96h v .0085% 0.424205853 Equal 0.2734 
96h v 100nM 0.078347397 Equal 0.4513 
96h v 0.00085% 0.41591503 Equal 0.0481 
96h v 10nM 0.589148296 Equal 0.0138 
96h v 0.000085% 0.901567295 Equal 0.0102 
Table 5.6. KR-33028 and PEG vehicle treatment statistical analyses. The first column 
represents Levene’s and Student’s t-test comparisons. 24h and 96h represent the 
non-treated control samples and the concentrations represent 96h serum starved 
samples treated with KR-33028 in molar units and PEG in percentage values (V/V). 
Significant t-test p-values<0.05 are underlined. 
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5.7 Purinergic Receptor Inhibitor Treatment 
Purinergic receptor P2X ligand-gated ion channel 7 (P2RX7) has emerged as a novel 
target for ameliorating the DMD phenotype (Sinadinos et al., 2015). P2RX7 is an 
ATP-activated ion channel, which opens a pore on the sarcolemma upon exposure to 
extracellular ATP, allowing Ca2+ and small molecule influx to the sarcoplasm, 
consequently increasing [Ca2+]i and triggering autophagic and apoptotic cascades 
(Young et al., 2015). A potent P2RX7 inhibitor compound A804598 (Donnelly-
Roberts et al., 2009) was used to treat mdx cardiomyocytes undergoing serum 
starvation-induced hypertrophy. A804598 was dissolved in dimethyl sulfoxide 
(DMSO) and diluted in SFCGM or SSCGM. The compound was used to treat 
cardiomyocytes at seven concentrations ranging from 1µM to 1pM at one order of 
magnitude increments. DMSO treatment was also conducted to account for vehicle 
effect on cardiomyocyte hypertrophy.  
 
Two experiments were conducted where A804598 was dissolved in SFCGM and the 
highest concentration of the drug used for treatment was 1µM, containing 0.01% 
(V/V) DMSO (figure 5.10). BSc student Sophie Wright assessed mdx cardiomyocyte 
hypertrophy in these two experiments by measuring the volume of immunostained 
cells positive for α-actinin signal. In both biological replicates 1nM and 100pM 
A804598 treatment significantly reduced mdx cardiomyocyte hypertrophy. In the first 
replicate (figure 5.10 A) 10nM A804598 did not cause a significant reduction in 
cardiomyocyte area, whereas in the second replicate (figure 5.10 B) a significant 
reduction was observed in the treated sample. Furthermore, in the first biological 
replicate A804598 treated cardiomyocytes were only significantly smaller than the 
corresponding DMSO vehicle-only treated samples at the 0.00001% and 1nM 
concentrations, respectively. In the second biological replicate all three of the lowest 
A804598 concentration treated samples were also significantly smaller on average 
than the corresponding DMSO-treated vehicle control cells (table 5.7). 
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Figure 5.10. A804598 effect on mdx cardiomyocyte hypertrophy induced by SFCGM. 
Two biological replicate experiments were conducted. Volume measurements of six 
different concentrations of A804598 (red columns) treated and DMSO vehicle treated 
(dark blue columns) cardiomyocytes in the first replicate (A) and five concentrations 
in the second replicate (B) were compared to non-treated cardiomyocytes (light blue). 
In both samples 1nM and 100pM treated cells were significantly smaller than the 96h 
serum starved non-treated control cardiomyocytes (** corresponds to p-value<0.01 
and *** corresponds to p-value<0.001). In the second replicate three of the drug 
treated samples (10nM, 1nM and 100pM) were significantly smaller than the 
corresponding DMSO vehicle treated controls (0.0001%, 0.00001% 0.000001%), 
whilst only the 1nM A804598 and 0.00001% DMSO treatment comparison showed a 
significant reduction in the drug treated cells (NS stands for non-significant). One-
tailed Student’s t-test and Levene’s test were used for statistical analyses. Error bars 
represent standard error of the mean. 
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Comparison A Levene's Test p-value Variance t-test p-value 
24h v 96h 1.38596E-08 Unequal 8.03675E-08 
96h v 1µM 0.477255677 Equal 0.2825 
96h v .01% 0.137505372 Equal 0.2145 
1µM v .01% 0.354265771 Equal 0.4102 
96h v 100nM 0.480822159 Equal 0.2217 
96h v .001% 0.593109685 Equal 0.4264 
100nM v .001% 0.809172041 Equal 0.1263 
96h v 10nM 0.228692712 Equal 0.0572 
96h v .0001% 0.001512264 Unequal 0.1058 
10nM v .0001% 0.00794106 Unequal 0.3447 
96h v 1nM 0.004194548 Unequal 0.0011 
96h v .00001% 0.822602694 Equal 0.3007 
1nM v .00001% 0.00262294 Unequal 2.7136E-05 
96h v 100pM 0.003522354 Unequal 0.0044 
96h v .000001% 0.342066521 Equal 0.1070 
100pM v .000001% 0.087855495 Equal 0.1149 
96h v 10pM 0.025658596 Unequal 0.0050 
96h v .0000001% 0.014567125 Unequal 0.0821 
10pM v .0000001% 0.421222705 Equal 0.1175 
Comparison B Levene's Test p-value Variance t-test p-value 
24h v 96h 4.39809E-13 Unequal 1.71964E-22 
96h v 1µM 0.01403757 Unequal 0.3828 
96h v .01% 0.263353414 Equal 0.3415 
1µM v .01% 0.00109465 Unequal 0.4593 
96h v 100nM 0.898080185 Equal 0.2446 
96h v .001% 0.206009378 Equal 0.3600 
100nM v .001% 0.3241352 Equal 0.1714 
96h v 10nM 0.006808231 Unequal 1.00698E-06 
96h v .0001% 0.024604463 Unequal 0.3052 
10nM v .0001% 1.07016E-05 Unequal 0.0005 
96h v 1nM 0.074301449 Equal 0.0021 
96h v .00001% 0.025351859 Unequal 0.1895 
1nM v .00001% 0.51914125 Equal 0.0004 
96h v 100pM 0.443073794 Equal 0.0005 
96h v .000001% 0.564385123 Equal 0.1018 
100pM v .000001% 0.215287585 Equal 1.13739E-05 
Table 5.7. A804598 and DMSO vehicle treatment statistical analyses. The first 
column represents Levene’s and Student’s t-test comparisons. 24h and 96h 
represent the non-treated control samples and the concentrations represent 96h 
serum starved samples treated with A804598 in molar units and DMSO in 
percentage values (V/V). Significant t-test p-values<0.05 are underlined. 
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A third biological replicate of A804598 treatment was conducted where SSCGM was 
used to serum starve mdx cardiomyocytes. The drug was less soluble in SSCGM 
and required a stronger vehicle concentration in the medium (10% DMSO for 1µM 
A804598). The high vehicle concentration was toxic to the cells and cardiomyocytes 
surviving the 10% DMSO (V/V) treatment were very small in their average area, 
almost comparable to 0h serum starved control samples (figure 5.11). 10nM and 1nM 
A804598 treated cells were significantly smaller than non-treated 96h serum starved 
control cells, but the 0.01% DMSO vehicle treated cardiomyocytes were also smaller 
and unexpectedly the 0.001% DMSO treated cardiomyocytes were significantly 
larger than 96h non-treated control cells (table 5.8). 
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Figure 5.11. A804598 effect on mdx cardiomyocyte hypertrophy induced by SSCGM. 
Average area measurements of non-treated 0h, 24h and 96h serum starved control 
cardiomyocytes (light blue columns) were compared to A804598 (red columns) and 
DMSO vehicle (dark blue columns) treated cells. 1nM A804598 treated 
cardiomyocytes were significantly smaller (*** corresponds to p-value<0.001) and 
0.001% DMSO vehicle treated cells significantly larger (** corresponds to p-
value<0.01) than 96h non-treated control cardiomyocytes. One-tailed Student’s t-test 
and Levene’s test were used for statistical analyses. Error bars represent standard 
error of the mean. 
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Comparison Levene's Test p-value Variance t-test p-value 
24h v96h 3.71683E-09 Unequal 3.82646E-06 
96h v 100nM 0.947835254 Unequal 0.3612 
96h v 1% DMSO 0.421799589 Equal 0.3866 
96h v 10nM 0.045706928 Unequal 0.0002 
96h v 1nM 1.11473E-07 Unequal 2.35631E-11 
24h v 1nM 0.267579681 Equal 0.0004 
96h v 0.01% DMSO 0.361897323 Equal 0.0032 
96h v 100pM 0.402365579 Equal 0.0528 
Table 5.8. A804598 and DMSO vehicle treatment statistical analyses. The first 
column represents Levene’s and Student’s t-test comparisons. 24h and 96h 
represent the non-treated control samples and the concentrations represent 96h 
serum starved samples treated with A804598 in molar units and DMSO in 
percentage values (V/V). Significant t-test p-values<0.05 are underlined. 
 
5.8 Transducing mdx Cardiomyocytes with eGFP and µDys 
Becker muscular dystrophy (BMD) is a milder form of dystrophinopathy, mostly 
caused by large open reading frame deletions in the rod domain of the DMD gene 
(Ferreiro et al., 2009). BMD mutations have been used prototypically to derive 
smaller functional versions of dystrophin deliverable as gene therapy using viral 
vectors with restricted genetic packaging capacity (Fabb et al., 2002). The m2 micro-
dystrophin (µDys) construct, characterised in Newcastle (Jørgensen et al., 2009), 
was packaged into adeno-associated viruses (AAV) by Oliver Müller’s research 
group in Heidelberg and used to attenuate the dystrophic phenotype in mdx mouse 
hearts (Schinkel et al., 2012). These constructs were optimised from a 
cytomegalovirus (CMV) promoter to an improved CMV promoter with a myosin light 
chain (MLC) enhancer region MLC0.26 combination, packaged into AAV6 and AAV9 
in Heidelberg and shipped to Newcastle for testing their efficacy in transducing mdx 
cardiomyocytes.  
 
AAV6-CMV-eGFP and AAV6-CMV-MLC0.26-eGFP both successfully transduced 
mdx cardiomyocytes at multiplicity of infection (MOI) 100,000vg/cell (vg is a unit for 
the number of viral genomes) and expressed eGFP 72h post-transduction (panels A 
and B in figure 5.12, respectively). It was also possible to perform ICC for α-actinin 
expression on PFA-fixed cardiomyocytes serum starved for 96h and transduced at 
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the 24h serum starvation time-point with AAV6-CMV-MLC0.26-eGFP and AAV6-
CMV-MLC0.26-µDys (panels D and E in figure 5.12, respectively) to investigate 
cardiomyocyte specificity of construct expression due to the MLC0.26 enhancer 
region incorporation. Expression of eGFP was exclusively found in α-actinin-positive 
cardiomyocytes. Expression of µDys could not be detected using mouse monoclonal 
dystrophin antibody MANDRA1 or with the rabbit polyclonal dystrophin antibody 
ab15277. The latter antibody yielded punctate fluorophore signal in cells negative for 
α-actinin expression, also seen in α-actinin-negative cells in a control sample where 
the secondary fluorophore-conjugate antibody was added without the ab15277 
antibody to mdx cells not transduced with µDys (figure 5.12 panels E and F, 
respectively). 
 
Figure 5.12. Transduction of mdx cardiomyocytes with eGFP and µDys-containing 
AAV6 vectors. (A) AAV6-CMV-eGFP and (B) AAV6-CMV-MLC0.26-eGFP 
transduction resulted in eGFP signal in mdx cells isolated from E17.5 mouse embryo 
hearts 72h post-transduction, while (C) in non-transduced control cells no eGFP 
signal was detected. (D) ICC for α-actinin (in red) was performed to identify 
cardiomyocyte-specific expression of CMV-MLC0.26-driven expression of eGFP 72h 
post-transduction in cells serum starved for 96h. (E) AAV6-CMV-MLC0.26-µDys was 
used to transduce cells serum starved for 24h and ICC dual-stained at the 96h serum 
starvation time-point for α-actinin (red) and dystrophin (green). Punctate signal for 
dystrophin signal was seen in α-actinin-negative cells. (F) A similar punctate pattern 
of fluorophore signal was observed in non-transduced control primary mdx cells 
negative for α-actinin staining, also serum starved for 96h. Scale bars represent 
200µm. 
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The effect of eGFP and µDys transduction with AAV6 on mdx cardiomyocyte 
hypertrophy was determined by transducing 24h serum starved cells with AAV6-
CMV-MLC0.26-eGFP or AAV6-CMV-MLC0.26-µDys and quantifying cell area 72h 
later (figure 5.13). There was no significant difference between µDys transduced 
cardiomyocytes and non-transduced control cells serum starved with SSCGM for 
96h. Cardiomyocytes transduced with eGFP were used as a control to detect 
whether AAV6 transduction affected the mdx hypertrophic response. Area 
measurements were recorded separately for eGFP positive (n=1069) and negative 
(n=131) cells in the sample, then also combined. There was no statistical reduction or 
increase in mdx cardiomyocyte average area by AAV6 transduction with eGFP when 
the overall cardiomyocyte population and only eGFP positive cells were compared to 
96h serum starved non-transduced control cells (table 5.9). Transduction efficiency 
with AAV6-CMV-MLC0.26-eGFP at 100,000vg/ml was 89%, determined by the 
proportion of cardiomyocytes positive for eGFP signal in the population used for area 
measurements (1,069 of 1,200). 
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Figure 5.13. Effect of AAV6 Transduction on mdx cardiomyocyte hypertrophy. 
Average area measurements of non-treated 0h, 24h and 96h serum starved control 
cardiomyocytes (blue columns) were compared to cells transduced with AAV6 
vectors containing either an eGFP or a µDys construct (red columns). 24h serum 
starved cardiomyocytes were significantly smaller than 96h serum starved non-
treated cells (*** corresponds to p-value<0.001). Transduced cardiomyocytes were 
not significantly (NS) larger or smaller than non-transduced control cells serum 
starved for 96h. One-tailed Student’s t-test and Levene’s test were used for statistical 
analyses. Error bars represent standard error of the mean. 
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Comparison Levene's Test p-value Variance t-test p-value 
24h v96h 6.98923E-88 Unequal 1.9981E-143 
96h v eGFP+&- 0.093644555 Equal 0.3085 
96h v eGFP+ 0.036544958 Unequal 0.1133 
96h v µDys 0.525337377 Equal 0.0559 
eGFP+ v µDys 0.163529799 Equal 0.4261 
eGFP+&- v µDys 0.318357788 Equal 0.1783 
eGFP+&- v eGFP+ 0.697673949 Equal 0.2535 
Table 5.9. AAV6 µDys and eGFP cardiomyocyte transduction statistical analyses. 
The first column represents Levene’s and Student’s t-test comparisons. 24h and 96h 
represent the non-transduced control samples and µDys represents AAV6-CMV-
MLC0.26-µDys transduced cardiomyocytes. Cells transduced with AAV6-CMV-
MLC0.26-eGFP were analysed as either all cardiomyocytes positive and negative for 
eGFP signal combined (eGFP+&-) or only the eGFP positive cells on their own as a 
dataset (eGFP+). Significant t-test p-value<0.05 is underlined. 
 
It was not possible to detect µDys expression with ICC in mdx cardiomyocytes 
transduced with AAV6 vectors and these transduced cells displayed a hypertrophic 
response comparable to non-transduced serum starved cardiomyocytes. It was 
subsequently investigated with Western blotting whether µDys was expressed in 
AAV6 transduced cells. Cardiomyocytes from mdx mouse embryos were serum 
starved with SSCGM and transduced with AAV6-CMV-MLC0.26-µDys virus at 
100,00vg/ml. Cells were collected for protein extraction at the 0h, 24h, 72h and 96h 
non-transduced, as well as µDys-transduced 72h and 96h serum starvation time-
points. The same rabbit polyclonal antibody ab15277, which was used to detect µDys 
by ICC was also used for immunoblotting. A band was detected in the anticipated 
125kDa region for m2 µDys (Jørgensen et al., 2009) in the transduced samples at 
both 72h and 96h of serum starvation (figure 5.14), which correspond to 48h and 72h 
of transcript expression, respectively. 
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Figure 5.14. AAV6-transduced mdx cardiomyocytes express µDys protein. A band in 
the anticipated 125kDa range was detected in both 72h and 96h µDys-transduced 
samples. This band was absent in the non-transduced no virus control (NVC) 
samples at all time-points of serum starvation included in this experiment. Dysferlin 
expression was used as the loading control. 
 
Two further experiments were conducted where both AAV6-CMV-MLC0.26-µDys and 
AAV9-CMV-MLC0.26-µDys were used in separate samples to assess their effect on 
mdx cardiomyocyte hypertrophy. Primary cells from mdx E17.5 hearts were serum 
starved with SSCGM and transduced with µDys AAV6 and AAV9 vectors. ICC for α-
actinin expression was performed to measure the area of cardiomyocytes. MRes 
student Stephanie Carr performed the image analysis of µDys-transduced samples. 
Both AAV6 and AA9 µDys transduced cardiomyocytes were on average significantly 
smaller than 96h serum starved non-transduced control cardiomyocytes in both 
biological replicates (figure 5.15). On average AAV9 transduced cardiomyocytes in 
replicate A were smaller than AAV6 transduced cells, but this was not a statistically 
significant reduction in size, whilst AAV6 transduced cells in replicate B were 
significantly smaller than AAV9 transduced cardiomyocytes. Both AAV6 and AAV9 
transduced cardiomyocytes in replicate B were still significantly larger than 24h 
serum starved non-transduced control cells. However, in replicate A the AAV9 
transduced cardiomyocytes were not statistically larger than the control cells fixed at 
the start of transduction (table 5.10). 
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Figure 5.15. AAV6 and AAV9 µDys transduction reduced mdx cardiomyocyte 
hypertrophy. Average area measurements of non-treated 0h, 24h and 96h serum 
starved control cardiomyocytes (blue columns) were compared to cells transduced 
with AAV6 or AAV9 for µDys delivery (red columns). (A) In the first biological 
replicate µDys delivered by both AAV serotypes significantly attenuated the serum-
induced hypertrophic response in comparison to 96h serum starved non-transduced 
control cells (*** corresponds to p-value<0.001). AAV9 transduced cardiomyocytes 
were smaller than AAV6 transduced cells on average, but this difference was non-
significant (NS). (B) In the second biological replicate both AAV6 and AAV9-delivered 
µDys significantly diminished the serum starvation effect on mdx cardiomyocyte area. 
One-tailed Student’s t-test and Levene’s test were used for statistical analyses. Error 
bars represent standard error of the mean. 
 
Comparison A Levene's Test p-value Variance t-test p-value 
24h v 96h 6.00257E-14 Unequal 1.5606E-17 
24h v AAV6 2.99671E-05 Unequal 0.0019 
24h v AAV9 0.001861874 Unequal 0.0573 
96h v AAV6 0.001634265 Unequal 1.31011E-07 
96h v AAV9 0.000112922 Unequal 5.99851E-10 
AAV6 v AAV9 0.385821353 Equal 0.1350 
Comparison B Levene's Test p-value Variance t-test p-value 
24h v 96h 4.75866E-11 Unequal 3.07159E-26 
24h v AAV6 1.25517E-09 Unequal 0.0008 
24h v AAV9 9.3752E-10 Unequal 1.44938E-07 
96h v AAV6 0.149120859 Equal 1.05186E-10 
96h v AAV9 0.895266543 Equal 4.53942E-07 
AAV6 v AAV9 0.217540267 Equal 0.0458 
Table 5.10. Statistical analyses of AAV6 and AAV9 µDys transduced mdx 
cardiomyocytes. The first column represents Levene’s and Student’s t-test 
comparisons. 24h and 96h represent the non-transduced control samples, AAV6 
represents AAV6-CMV-MLC0.26-µDys transduced cardiomyocytes and AAV9 
represents AAV9-CMV-MLC0.26-µDys transduced cardiomyocytes. Significant t-test 
p-values<0.05 are underlined.  
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5.9 Discussion 
Cardiomyocyte size data comparison assessed in chapter 3 (figure 3.14) showed a 
strong correlation between mdx cardiomyocyte area and volume measurements. 
Therefore, all but two mdx cardiomyocyte treatment experiments were evaluated by 
area quantification. Area measurements performed with SSCGM also showed a 
greater difference between the 24h and 96h serum starvation time-points in 
comparison to SFCGM-induced hypertrophic response experiments. Therefore, the 
sensitivity of this model to detect therapeutic rescue of mdx cardiomyocyte 
hypertrophy was also improved. 
  
The effect of the seven therapies tested for their efficacy in reducing mdx 
cardiomyocyte hypertrophy is summarised in table 5.11. Out of the three groups of 
compounds currently prescribed to DMD patients to manage their cardiac pathology 
corticosteroids prednisolone and dexamethasone showed no direct effect on mdx 
cardiomyocyte hypertrophy, the β1AR antagonist metoprolol caused a significant 
escalation of serum starvation-induced hypertrophy and captopril significantly 
reduced mdx cardiomyocyte size. NHE inhibitor KR-33028 and P2RX7 inhibitor 
A804598 showed promising results of their ability to tackle the hypertrophic response 
and in preliminary studies discussed in sections 5.6 and 5.7, respectively, illustrated 
that there is potential in further exploration of their efficacy as DMD therapeutic 
compounds. AAV delivery of µDys significantly reduced mdx cardiomyocyte 
hypertrophy and therefore shows this model of hypertrophy can be used as an 
outcome measure in pre-clinical trials of DMD rescue therapies. 
 
Therapy Type of Compound/Delivery Effect on hypertrophy 
Prednisolone Corticosteroid 0 
Dexamethasone Corticosteroid 0 
Metoprolol β1-adrenergic receptor antagonist ↑ 
Captopril Angiotensin-converting enzyme inhibitor ↓ 
KR-33028 Sodium-hydrogen antiporter inhibitor ↓ 
A804598 P2X7 receptor antagonist ↓ 
µDys AAV6 and AAV9 transduction ↓ 
Table 5.11. Summary of pharmacological compound and rescue therapy trials. 
Metoprolol significantly increased, corticosteroids had no significant effect and four of 
the seven trialled therapies significantly reduced cardiomyocyte hypertrophy. 
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5.9.1 Systemic and Cellular Effect 
Although there are many retrospective studies now published on both the beneficial 
effects and negative side-effects of steroid treatment on DMD patients (Ricotti et al., 
2013; Kim et al., 2015), the specific mechanisms delaying the age at which patients 
become non-ambulant are not well characterised. Furthermore, corticosteroid 
treatment has been shown not to have a significant effect on delaying the cardiac 
pathology in DMD when administered independently from cardioprotective 
medication (Barp et al., 2015). The GCR gene Nr3c1 was not differentially expressed 
in the RNA-Seq dataset. While this indicates that receptor gene expression does not 
affect drug treatment efficacy, it does not account for receptor protein level 
differences, the baseline presence of competitor compounds for the active site, or 
receptor nuclear translocation efficiency. Results from prednisolone and 
dexamethasone treatment of mdx cardiomyocytes undergoing a hypertrophic 
response to serum starvation suggest that these corticosteroids do not have a direct 
effect on cardiomyocytes, but may be able to deliver their protective effect via other 
types of cells, both in skeletal muscle and cardiac tissue, where they have been 
shown to slow disease progression by anti-inflammatory impact (Falzarano et al., 
2015) and a novel glucocorticoid-like compound VBP15 improves membrane 
strength (Heier et al., 2013). However, the latter effect has not been reported in 
treatment with other corticosteroids and most anti-inflammatory drugs alone do not 
rescue DMD pathology, therefore corticosteroids must also protect dystrophic muscle 
via some other mechanism (Rosenberg et al., 2015). 
 
There are also stark geographical corticosteroid-of-choice differences in clinical care 
offered to DMD patients. In Germany, Italy and the US deflazacort is most frequently 
prescribed to patients at all ambulatory stages, while in the UK prednisolone is by far 
the most prevalent administered corticosteroid (Landfeldt et al., 2015). 
Dexamethasone was not featured in this publication. Its higher potency for GCR 
activation and longer in vivo half-life (Longui, 2007) may also exacerbate side-effects 
caused by steroid use in young males, which are now targeted with testosterone 
treatment trials, but there is still no consensus on whether testosterone treatment is 
beneficial to DMD patients (Wood et al., 2015). New steroid compounds, such as 
VBP15, with improved efficacy on GCR translocalisation to the nucleus and 
subsequent NFκB signal transduction inhibition similar to dexamethasone 
effectiveness, but with reduced affinity for hormonal signal transduction and 
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consequent undesirable side-effects are now under investigation and may provide 
improved DMD disease management alternatives (Reeves et al., 2013; Heier et al., 
2013). The mdx cardiomyocyte hypertrophy model could be used to compare 
treatment with novel steroid-like compounds to currently prescribed corticosteroids, 
identifying whether they exhibit a direct effect on cardiomyocytes in addition to a 
system effect. 
 
βAR blockers, such as metoprolol, are prescribed for managing cardiac 
complications of DMD pathology (Bushby et al., 2010b). Based on RNA-Seq data of 
mdx and BL/10 cardiomyocytes only the β1AR gene Adrb1 was expressed at above 
negligible levels, but was not identified as a differentially expressed gene in any of 
the serum starvation or genotype comparisons. In the mdx cardiomyocyte treatment 
study metoprolol augmented the hypertrophic response to serum starvation. Other 
studies have shown that stimulation of βARs causes cell apoptosis (Dalal et al., 
2012) (Wang et al., 2015) and inhibition of these receptors can have a 
cardioprotective effect via mitigated apoptotic signalling (Zhao et al., 2014). While the 
drug may have a protective effect systemically and when administered long-term, it 
may be that the short-term effect within this model was in fact to inhibit 
cardiomyocyte apoptosis and allow cells that had outgrown their natural size 
limitations to keep expanding rather than going through programmed cell death.  
 
Hypertrophy-stimulating tendencies in this metoprolol treatment experiment also 
supported results from a study where metoprolol and propranolol (a non-selective 
βAR inhibitor) treatment switched on the foetal gene program in rat ventricular 
cardiomyocytes (Patrizio et al., 2007). It may be that without the native tissue 
environment βAR antagonists have a damaging effect on mdx cardiomyocytes. A 
similar β1AR protein expression pattern in both BL/10 and mdx serum starved 
cardiomyocytes, identified by Western blotting (figure 5.8), also supports the 
hypothesis that βAR signalling was not responsible for the differences identified in 
cardiomyocyte size between the control and dystrophinopathy mouse models. 
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ACE inhibitors are commonly prescribed as a combination therapy with βAR to DMD 
patients (Ogata et al., 2009). However, early combinational βAR and ACE inhibitor 
treatment in vivo has not shown the same beneficial effects in mdx mice (Blain et al., 
2015). Cardiac improvement in mdx mice has been shown in a study using losartan, 
an ACE inhibitor (Spurney et al., 2011). Captopril treatment also showed significant 
reduction in mdx cardiomyocyte hypertrophy (figure 5.6), but only at the highest 
dose. The effect of ACE inhibitors is also most likely systemic, as it has been 
suggested to be mediated through vasorelaxation (Ennen et al., 2013) rather than a 
direct effect on cardiomyocytes. In RNA-Seq results discussed in the previous 
chapter, the Ang gene Agt expression was significantly upregulated in mdx 
cardiomyocytes (by 2.8-fold from 0h to 96h of serum starvation). Granted, the 
nominal transcript levels identified from HT-Seq data did show relatively low 
expression throughout the serum starvation time-course in both BL/10 and mdx 
samples, which could mean that the autocrine effect is not large enough to have 
significant effect on the hypertrophic response. Furthermore, the ACE gene Ace was 
upregulated in both BL/10 and mdx cardiomyocytes in response to serum starvation, 
which could enhance the autocrine effect of Ang expression from mdx 
cardiomyocytes. However, the AngII receptor genes Agtr1b and Agtr2 were not 
expressed at all in most mdx cardiomyocyte samples and Agtr1a was expressed at a 
very low level, based on HTSeq gene count data from RNA-Seq experiments. These 
results make it difficult to believe that the significant reducing effect of captopril 
reported in section 5.4 would replicate in future experiments. Expression patterns of 
Agt and Ace in E17.5-derived cardiomyocytes may explain why captopril showed a 
cardiomyocyte cell-level effect in the hypertrophy drug treatment trial experiment, but 
low receptor gene expression suggests the drug effect may have been artefactual. 
  
P2RX7 and angiotensin receptor type 1 (AT1R) can both activate ERK and cause a 
downstream hypertrophic response (Young et al., 2015; Schlüter & Wenzel, 2008). 
Data in figure 5.8 suggest that there is more phosphorylated ERK in mdx 
cardiomyocytes from the 48h serum starvation time-point onwards, but these findings 
also need comparison of p-ERK1/2 to the overall protein level of ERK1/2 to assess 
activation level more adequately rather than just overall protein content or 
normalising to a reference protein band. A drawback of Western blotting in this model 
is also that the total protein content can be affected by levels of the protein of interest 
in the whole heterogeneous primary cell population, whereas size measurements 
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were only done on α-actinin positive cells and therefore a homogeneous 
cardiomyocyte population. However, taking the protein levels at face value, these 
results on ERK phosphorylation may support the reason why both captopril and 
A804598 had an attenuating effect on mdx cardiomyocyte hypertrophy. Data on ERK 
activation alone does not give a conclusive account on the specific downstream 
signalling pathway that was inhibited by these compounds until drug treated 
cardiomyocyte protein lysates are compared against non-treated control cells with 
the appropriate non-activated protein control. 
 
Previously published findings of elevated P2RX7 expression in mdx skeletal muscle 
(Young et al., 2012) were not confirmed in RNA-Seq analyses of serum starved 
BL/10 and mdx cardiomyocytes, where the P2rx7 gene was not differentially 
expressed. In addition to skeletal and cardiac muscle, P2RX7s are also located on 
macrophages and mdx/P2RX7 double knockout mice have reduced inflammatory 
infiltration in skeletal muscle (Sinadinos et al., 2015). Taking into account that the 
presence of macrophages in the primary mdx cardiomyocyte population in this model 
is improbable, it is more plausible that the A804598 drug effect on P2RX7 may have 
been mediated by improved Ca2+ homeostasis. In dystrophic skeletal muscle and 
heart tissue tears in the sarcolemma can cause increased external adenosine 
triphosphate (ATP), which is able to activate P2RX7 pore formation, resulting in Ca2+ 
influx to myocytes and consequent hypertrophic signalling pathway activation (Yeung 
et al., 2006). Lack of dystrophin also results in mislocalised dystrophin glycoprotein 
complex (DGC) members (Matsumura et al., 1992). It has been suggested that 
dystrophic muscle also has impaired extracellular ATP clearance capacity due to 
mislocalised DGC member α-sarcoglycan, which is a transmembrane protein with an 
ectopic ATP hydrolase activity (Berry et al., 2000). Therefore, it is possible that 
P2RX7 inhibition with A804598 contributed towards improved Ca2+ handling in mdx 
cardiomyocytes, resulting in a diminished hypertrophic response. It will be important 
to address the discrepancies witnessed in the third biological replicate of A804598 
treatment, where SSCGM-treated mdx cardiomyocytes did not respond to the 
therapeutic compound in the same way as SFCGM-treated cells in the previous two 
replicates. This may have been caused by a difference in vehicle concentration 
required to solubilise A804598. Further repeats of therapeutic treatment will be 
required before concluding that the drug had a hypertrophy-reducing effect on mdx 
cardiomyocytes. 
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The role of NHE in DMD cardiac pathology was discussed in detail in the previous 
chapter (sub-section 4.8.4). NHE inhibitor KR-33028 was expected to have an 
[Ca2+]i-reducing effect on mdx cardiomyocytes and previous work done on a hamster 
model of muscular dystrophy supports this hypothesis (Bkaily et al., 2015). The 
results from a single biological replicate experiment conducted on serum starved mdx 
cardiomyocytes (figure 5.9) revealed that KR-33028 treatment had a significant effect 
on the hypertrophic response. However, the corresponding PEG vehicle-only treated 
sample also showed a significant effect on cardiomyocyte area. It may be necessary 
to explore alternative vehicles for preparation of the treatment compound stock 
solution in order to fully explore the potential of the drug in an in vitro setting.  
 
5.9.2 AAV µDys Rescue Therapy 
It is difficult to package the whole dystrophin gene into viral vectors due to its large 
size. A wide range of smaller constructs with deletions in the internal rod domain, 
cysteine-rich domain carboxy- or amino-terminus of the protein have been designed 
and based on their size named either mini-dystrophins (mDys) or µDys (Scott et al., 
2002). It is possible to package µDys constructs into AAV vectors and these have 
been used in several studies to restore dystrophin expression in animal model and 
more recently in human clinical trials (Fabb et al., 2002; Yue et al., 2015; Mendell et 
al., 2010). Engineering viral capsids and testing different AAV serotypes has 
improved tissue tropism of the proposed therapies (Nance & Duan, 2015). 
 
The skeletal muscle and heart-targeting tissue tropism characteristics of AAV6 and 
AAV9 have been previously documented (Hastie & Samulski, 2015). In this study a 
µDys construct, expressed under a muscle-specific CMV promoter with a MLC0.26 
enhancer region, was packaged into AAV6 and AAV9 vectors, which were 
subsequently used to transduce mdx cardiomyocytes undergoing a hypertrophic 
response to serum starvation. This AAV9 was used in preclinical in vivo mdx mouse 
studies, where it produced long-term µDys expression and arrested disease 
progression in cardiac tissue (Schinkel et al., 2012). Delivery of µDys with both AAV6 
and AAV9 vectors significantly reduced mdx cardiomyocyte hypertrophy (figure 5.15) 
and expression of the µDys protein product was detected by Western blotting (figure 
5.14). 
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Viral transduction was optimised using eGFP reporter gene delivery with an AAV6 
vector, which yielded an 89% transduction efficiency when 100,000 viral genomes 
per cell were used to deliver the construct of interest to cardiomyocytes. This did not, 
however, mean that the same transduction efficiency was reached when delivering 
µDys with the same serotype of AAV, nor was efficiency of eGFP delivery quantified 
for AAV9 transduction. Identifying an antibody that binds to µDys in ICC experiments 
will be important to quantify differences between µDys positive and negative cells in 
the same transduced sample. Alternatively, having eGFP cloned into the same 
construct as µDys would be an option, but an already challenged capacity of AAV 
vectors may mean that any further increase in the construct DNA size would result in 
no successful packaging at all. 
 
5.9.3 Summary 
Results reported in this chapter illustrated that serum starvation-induced hypertrophy 
in mdx cardiomyocytes can be reduced with a range of pharmacological compounds. 
The significant reduction in hypertrophy in response to µDys delivery with AAV6 and 
AAV9 demonstrated that this model can be used as an in vitro platform for testing 
rescue therapies. 
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Chapter 6. General Discussion and Future Directions 
 
6.1 Establishing the Cardiomyocyte Hypertrophy Model 
Duchenne Muscular Dystrophy is a severe debilitating childhood-onset disease. 
Although several therapies are in pre-clinical and early clinical trials, with one 
approved rescue therapy now conditionally available as a prescription drug for 
patients with specific mutations (Haas et al., 2015), there is still an urgent need for an 
effective and more universal therapy for all DMD patients. One hurdle for developing 
DMD therapies is that the disease affects both skeletal and cardiac muscle, which 
have subtle differences when it comes to delivering therapies to these tissues. 
Successful delivery to the whole musculature, including the heart is a challenging 
task. 
 
This thesis established a dystrophic cardiomyocyte hypertrophy model with potential 
use as an outcome measure in pre-clinical trials of therapeutic compounds for DMD. 
Cardiomyocytes isolated from embryos of the DMD mouse model (mdx) became 
hypertrophic in response to serum starvation. Control BL/10 mouse embryos were 
also serum starved, but did not show the equivalent size increase. The technique 
was used to identify potential pathways responsible for the hypertrophy seen in mdx 
cardiomyocytes by RNA-Seq analysis. Current drug therapies for managing the 
dystrophic phenotype of DMD patients, along with novel treatment compounds and 
viral vector-delivered gene therapy were trialled for their efficacy in reducing serum-
induced hypertrophy in mdx cardiomyocytes. Results showed that the hypertrophic 
response can be reversed and therefore indicate the potential for using this model in 
a pre-clinical setting for discovering and improving potential treatments for DMD. 
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6.2 Limitations of the Cardiomyocyte Hypertrophy Model and Potential 
Improvements 
The mdx mouse is a widely used model in DMD research and whilst it does not 
reflect the wide variety of mutations seen in the patient population (Bladen et al., 
2015), it is still an irreplaceable tool for conducting research into therapies. For 
instance, even with the one mutation, mdx mice are useful for testing efficacy of exon 
skipping compounds with different chemical backbones and conjugates (Gebski et 
al., 2003; Lu et al., 2003). The dystrophin and utrophin double knockout mouse 
model (dko) exhibits earlier onset of dystrophic pathology, comparable to the human 
disease, but does not reflect the genotype of DMD (Deconinck et al., 1997). It would 
be an option to investigate whether the hypertrophic response is more pronounced in 
dko mice, further improving the sensitivity of assaying cell size. 
 
Therapeutic testing was standardised to only measuring the effect of treatments at 
the 96h serum starvation end-point. There may be variability in compound effect time 
and function in terms of their ability to either arrest the hypertrophic response from 
the time of reaching peak effect or reverse the size increase process to reduction 
back to baseline. This effect could be monitored by extending the observed time-
course and analysing intermediate time-points once an optimal concentration of the 
therapeutic compound of interest has been determined. Furthermore, the long-term 
effect of compounds remains unknown in the current setting. It has been shown that 
long-term steroid treatment causes fibrosis and cardiomyopathy in mdx mouse hearts 
(Bauer et al., 2009; Sali et al., 2012). The short investigated time-frame when testing 
steroid treatment on mdx cardiomyocytes does not reveal these effects, nor does it 
mimic the compounds’ systemic contributions in vivo.  
 
The presence of other cell types in addition to cardiomyocytes may have been 
responsible for the effect of systemic-effect therapeutic compounds on mdx cell 
samples. Contaminating cell number variability between batches could also affect 
results obtained when testing such compounds. However, removing the 
contaminating population through cell sorting could also limit the model’s applications 
for therapeutic testing. In addition to the temporal and systemic effect limitations of 
the model, biological variability between batches of cardiomyocytes as a result of 
pooling hearts of embryos may also affect data replication, as observed when 
establishing the model and also when testing some of the therapeutic compounds.  
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AAV therapy follow-up is important also to investigate safety of the drug in terms of 
the insertion site, expression length and immunogenicity (Mendell et al., 2012; Nance 
& Duan, 2015). Clinical relevance of the hypertrophy model is compromised due to 
the viral delivery mechanism being simplified in culture, as opposed to living 
organisms where cardiomyocytes are less accessible. When moving from in vitro 
studies onwards it will still be necessary to conduct pre-clinical in vivo animal model 
testing. 
 
Combination therapies are now starting to emerge in DMD research. Recently it was 
shown that ibuprofen as an anti-inflammatory drug administered with nitric oxide 
donor isosorbide dinitrate can markedly improve dystrophic pathology of mdx hearts 
(Sciorati et al., 2013). Using the mdx cardiomyocyte hypertrophy model in a high-
throughput screening method could accelerate the process of identifying potential 
composite effects ahead of in vivo studies. For this to be achieved a streamlined and 
robust method for scaling up the cardiomyocyte extraction technique would be 
required, preferably with minimised variability arising from biological replicates. 
To ensure direct effect of therapeutic compounds only on cardiomyocytes, it would 
be important to purify the primary cell population by FACS. However, cardiomyocytes 
from mdx mice may be dependent on and also susceptible to hypertrophic factors 
derived from fibroblasts and other cell types in the heterogeneous primary cell culture 
population (Kamo et al., 2015). Therefore, the model may in fact be more valuable for 
investigating mechanisms of dystrophy and testing therapies in the low presence of 
other cells of cardiac origin as it provides a cell population enriched for 
cardiomyocytes, but not entirely depleted cells potentially acting as contributors to 
therapeutic effect. For these reasons further purification of the primary cell population 
may lead to undesirable outcomes in the future functions this in vitro model of 
hypertrophy may have.  
 
Despite the benefits of mixed cardiac cell type presence, it may be necessary to 
validate some key signalling gene and protein expression patterns in a purified 
cardiomyocyte population and to attempt replicating mdx cardiomyocyte hypertrophy 
in a homogeneous population before optimising this model in DMD patient 
cardiomyocytes derived from induced pluripotent stem cells (iPSC). The serum 
starvation-induced hypertrophic response may not replicate in iPSC-derived 
cardiomyocytes because of the epigenetic origin of reprogrammed cells as well as 
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variance in mechanical and current conductance properties (Lee et al., 2014; Dixit & 
Katare, 2015).  
 
Interestingly, it was recently reported that the Diablo-Xiap-Caspase 3 axis of 
mitochondrial-mediated apoptosis signalling cascade genes were upregulated in 
DMD patient iPSC-derived cardiomyocytes in comparison to healthy patient iPSC-
derived cells (Lin et al., 2015). While none of these specific genes were differentially 
expressed in the cardiomyocyte hypertrophy model RNA-Seq data, other trends of 
gene expression followed similar patterns in response to serum starvation. The 
authors stated that the purity of cardiomyocytes in their transcriptome studies was 
75%, which suggests that their dataset should bear similarities to the data discussed 
in chapter 4 of this thesis, in terms of gene regulation. However, the non-
cardiomyocytes in the iPSC population may not share the same origins or functions 
as the ones in primary mdx cardiomyocyte culture. Despite these complications that 
will need to be addressed, DMD iPSC-derived cardiomyocytes can also improve 
testing therapies in vitro by providing cells with a range of patient mutations. For 
instance, exon skipping compounds could be tested in cells that have the exact 
reading frame disruptions these drugs were designed to rescue. As further 
standardised reprogramming techniques into various types of heart cells become 
available (Xin et al., 2013), options for investigating pathways involved in DMD 
disease mechanisms and treatment methods on specific cardiac cell types in a 
dystrophic setting may provide novel treatment targets and methods. 
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6.3 RNA-Seq Data Interpretation and Validation 
Based on the discrepancies recorded in the RNA-Seq dataset validation experiments 
with qRT-PCR, it will be useful to mine the transcriptome data for identifying most 
relevant housekeeping genes within this model, analysing the dataset in a way to find 
genes with the lowest fluctuation in expression level across all the compared time-
points and genotype (Zeng et al., 2015). This may improve normalisation of gene 
expression to the most relevant housekeeping genes and therefore provide a more 
accurate gene-by-gene validation with the ΔΔCt method. 
 
The sequencing platform used to obtain RNA-Seq data did not allow identifying 
differential expression of miRNA. It is possible to perform this investigation with 
miRNA microarrays (Yang et al., 2015). However, RNA-Seq was chosen for 
cardiomyocyte transcriptome studies because it has superior sensitivity for both 
differential gene expression and alternative splicing detection (Li et al., 2015; Zhao et 
al., 2014). As a future analysis option the mixture of isoforms (MISO) (Katz et al., 
2010) or hierarchical indexing for spliced alignment of transcripts (HISAT) (Kim et al., 
2015) analysis packages can provide more robust data on potential alternative 
splicing events from RNA-Seq data to assess genotype and serum starvation effects 
in the cardiomyocyte hypertrophy model. 
 
Gene expression analysis with DeSeq2 identified differential expression of several 
foetal gene program (FGP) markers (sub-section 4.8.2). The observed trends 
showed that the embryonic origin of analysed cardiomyocytes did not mask the FGP 
expression trends identified in adult hypertrophic hearts. Despite Nfatc4 being the 
only differentially expressed FGP transcription factor, these results provide evidence 
for the strength of the mdx cardiomyocyte serum starvation technique for modelling 
dystrophic hypertrophy in the heart. 
 
Several genes discussed in this thesis express proteins that need to be further 
processed in order to perform their function in the cardiac environment. Recent 
developments in proteomics have provided information about transcriptome-to-
proteome correlation in a range of tissues, allowing translation of gene regulation 
data to corresponding effect on protein expression (Nesvizhskii, 2014; Wilhelm et al., 
2014). Furthermore, it is now also possible to identify protein activation and 
degradation profiles in given samples by phosphoproteomics (Humphrey et al., 2015) 
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and ubiquitination proteomics (Beaudette et al., 2015). Much like MISO and HISAT 
have added new functionality to transcriptome sequencing, these innovative 
proteomics techniques may provide invaluable insight to the hypertrophic pathways 
altered in mdx cardiomyocytes. 
 
6.4 Future Directions 
In the short run, it will be important to provide further evidence that in addition to 
introducing µDys with AAV vectors, a second rescue therapy already proven to be 
efficacious in pre-clinical DMD studies can also reduce serum starvation-induced 
mdx cardiomyocyte hypertrophy in this model. For instance, either the 2OMePS or 
PMO antisense oligonucleotides could be trialled for their impact on cardiomyocyte 
size. 
 
Developments in computing power along with the arrival of next generation 
sequencing and new proteomics technologies have paved the way for developing 
new methods for analysing disease mechanisms in previously unimaginable high-
throughput capacity. Performing alternative splicing and protein activation analyses 
on serum starved cardiomyocyte transcriptome and proteome data, respectively, may 
elucidate novel therapeutic targets for DMD therapy in the medium-term. 
 
In order to develop this model into a drug screening tool, it will be important to 
streamline the mouse breeding and cardiomyocyte isolation processes to provide 
faster data replication. Alternatively, to reduce biological replicate variability arising 
from differences in mouse litters, a standardised protocol for iPSC-derived 
cardiomyocyte production could provide a multi-faceted approach with improved cell 
availability and several human mutation models for identifying treatments with higher 
efficacy for patients with specific DMD gene mutations.  
 
Promising results presented in this thesis on inhibiting hypertrophy in mdx 
cardiomyocytes with P2RX7 and NHE antagonist compounds have provided 
evidence for justification of further studies into these potential therapeutic 
compounds. In the long run, it is therefore envisioned that this cardiomyocyte 
hypertrophy model may provide stepping stones for a range of therapies to be taken 
into further pre-clinical and clinical trials to ultimately provide a cure for DMD. 
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Appendix 1. Differential Gene Expression Data 
DeSeq2 was used to determine differentially expressed genes from RNA-Seq data. 
The results are presented in fold change (FC) and base 2 logarithm fold change 
(Log2FC), summarised in a table format. Expression comparisons were performed 
between BL/10 (B) and mdx (m) samples across the serum starvation time-course (0, 
24, 48, 72, 96h) and a multi-factor analysis of genotype differences across the serum 
starvation time-points (Bm2D). Significant differentially expressed genes (Benjamini-
Hochberg adjusted p-value<0.01, Log2FC +/-0.6) are highlighted on a red 
background. 
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